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Mitochondrial localisation in A549 cells (MitoTracker® Red).  
Nuclei and cytoskeleton are shown in blue and green, respectively.  
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Mitochondria are involved in the regulation of key cellular processes that determine the response of 
cells to damage. Mitochondrial fission and fusion are associated with cell cycle regulation, apoptosis, 
cellular bioenergetics and redox status, which contribute to cellular homeostasis and damage 
response. The study aimed to describe and correlate cancer cell mitochondrial features and inherent 
radiosensitivity, and to determine the effect of modulation of mitochondrial dynamics on radiation 
response using a fission inhibitor, Mdivi-1.  
Methods: Mitochondrial status in a number of cancer cell lines was characterised by assessment of 
mitochondrial morphology, respiration and membrane potential using MitoTracker® Red staining, 
respirometry and JC-1 ratiometric staining, respectively. Correlations with radiation sensitivity were 
performed. Radiation- and Mdivi-1-induced changes in mitochondrial morphology were also 
examined. Responses to various schedules of radiation and Mdivi-1 treatment were assessed using 
clonogenic survival. Microscopy was used to quantify apoptosis, micronuclei and mitotic features, 
while cell cycle dynamics were analysed using flow cytometry. 
Results: Notably, modulation of mitochondrial fission using Mdivi-1 significantly increased radiation 
response in A549 cancer cells. Mdivi-1 reduced fragmentation, increased membrane potential and 
induced cytotoxicity, cytogenetic damage, apoptosis and G2/M cell cycle arrest. However, with the 
exception of survival, sub-additive responses were consistently observed when Mdivi-1 was 
combined with radiation. Sub-lethal damage repair was unaffected by Mdivi-1. Characterisation of 
cancer cell lines revealed inherent diversity in radiation response and mitochondrial morphology, 
membrane potential and respiration, and several correlations were identified.  
Discussion and conclusions: Inhibition of mitochondrial fission was shown for the first time to 
enhance radiosensitivity in cancer cells, and to induce cytotoxicity. Mitochondrial modulators may 
therefore have therapeutic application. However, the sub-additive responses observed with Mdivi-1-
radiation interactions suggest that optimisation of treatment scheduling may be important. The 
Mdivi-1-induced mitotic arrest may, in part, be responsible for the observed radiosensitisation, as 
cells accumulate in a radiosensitive cell cycle phase. In addition, the finding that Mdivi-1 treatment 
induced micronuclei, suggested that the radiosensitisation may result from the interaction of 
cytogenetic damage induced by each agent. Overall, mitochondrial dynamics and the modulation 






The ability of cells to respond to radiation damage is a key determinant of radiotherapy outcome 
and may be influenced by mitochondrial function. A variety of factors including the extent of 
damage incurred, repair capacity, apoptosis induction and cell cycle checkpoint integrity determine 
radiation response. In addition, cell signalling and the ability to manage oxidative stress are 
important. Mitochondrial dynamics are regulated according to the conditions and needs of the cell 
and serve an integral function in cellular physiology and damage response. Therapeutic modulation 
of basic aspects of cellular function has the potential to increase radiation sensitivity of tumours and 
thereby enhance the efficacy of radiotherapy. While current radiotherapeutic strategies are partly 
effective, many tumours are resistant to treatment. It is therefore important to develop approaches 
that identify novel cellular targets and that incorporate the application of new anti-cancer agents, 
radiosensitisers and potential normal tissue radioprotectors.  
Current treatments aim to induce effects on DNA, interfere with spindle formation or target 
signalling pathways that are primarily associated with cell growth and survival. Since mitochondria 
are involved in the regulation of many cellular processes that determine the response of cells to 
damage, they may be considered rational candidates for therapeutic-targeting. Mitochondrial 
dysfunction is frequently observed in tumours and has been proposed as a factor determining 
treatment outcome1-4. In addition, a number of agents have recently been identified that disrupt 
mitochondrial function5-8. Aspects of mitochondrial function that may be targeted include apoptotic 
mechanisms9, mitochondrial metabolism10, redox status11, mitochondrial membrane homeostasis12 
and mitochondrial DNA13.  
Mitochondrial number, size, localisation and content, described collectively as mitochondrial 
dynamics, are in constant flux. These dynamic processes are often reflected in the mitochondrial 
morphology and may influence functional aspects including mitochondrial membrane potential and 
respiration. Mitochondrial morphology is largely determined by fission and fusion processes, which 
have been associated with cellular homeostasis and damage response. The net effects of fission and 
fusion contribute to many aspects of cellular function, including cell cycle regulation, apoptosis, 




Increased mitochondrial fusion has been shown to inhibit drug-induced apoptosis14-16, a process 
frequently associated with mitochondrial fission17-20. Such involvement in cell death processes 
suggests that a highly fused mitochondrial network may be protective against radiation-induced 
apoptosis. However, inhibition of fission has also been shown to induce cytotoxicity in cancer cells21-
24 and enhance the effects of certain cytotoxic agents23, 25, 26. This paradox indicates that further 
elucidation is warranted. 
In addition, functionally active mitochondria may be more efficient at inducing a stress response or 
initiating cell death processes. Furthermore, energy metabolism is frequently altered in cancer cells27 
and an increased dependence on glycolysis has been associated with radiation-resistance28-30. 
Functional and respiratory parameters of cancer cells may correlate with radiation responsiveness. 
However, the effects of inherent mitochondrial status or modulation of mitochondrial fission and 
fusion processes on radiation response have not been established. Agents that alter mitochondrial 
function, such as Metformin, have been associated with increased radiotherapy efficiency2 and thus 
are of great interest as clinical adjuncts. The current work represents a novel approach that 
elucidates and exploits mitochondrial status, and that may hold potential for significant clinical 
benefit. 
In this study, it was proposed that mitochondrial status may be associated with radiation sensitivity 
and that modulation of mitochondrial dynamics may alter radiation response in cancer cells. While 
this chapter provides a brief introduction to the thesis, the following two chapters will provide a 
review of the relevant literature and a presentation of the study hypotheses and aims, respectively. 
Experimental work is described in Chapters 4, 5 and 6. Chapter 4 describes the inherent status of 
mitochondria in relation to the intrinsic radiation responsiveness of cancer cells. Chapter 5 addresses 
the effect of modulation of mitochondrial fission, using the inhibitor Mdivi-1, on radiation response. 
Chapter 6 details the cellular effects of Mdivi-1 that may be related to altered radiosensitivity.  










Ionising radiation is an important modality in cancer therapy with more than 50 % of cancer patients 
receiving radiotherapy during their treatment31-34. Radiotherapy is unique in that it exploits both 
physical radiation dosimetric and radiobiological differentials for therapeutic advantage. However, 
further improvements and optimisation are required. While improvements in physical dose delivery 
appear to be reaching saturation, there is potential for further radiobiological improvements.  
A new and relatively un-researched area involves the role of mitochondrial dynamics in the response 
of cells to cancer therapy. Furthermore, the involvement of mitochondria in several key cellular 
processes suggests that they may be important in the modulation of radiation response. An 
understanding of the role of mitochondrial dynamics in radiation response has the potential to  
lead to the development of new treatment paradigms. 
This chapter provides an overview of the roles of mitochondria in cancer and radiation therapy. 
Radiation effects on cells and mitochondria, the role of mitochondria in response to radiation-
induced damage, mitochondrial physiology and function in tumour cells and modulation of 
mitochondrial dynamics and cancer therapy are discussed.   
2.1. Mitochondria in radiation research 
Established biological targets of radiation include chromosomal DNA, proteins and lipids. In the 
therapeutic dose range, the nucleus is considered to be a primary target although membrane 
damage may also elicit cell death signalling35, 36.  
Mitochondria may be subjected to radiation energy depositions that may influence both their 
structure and function. While the effect of radiation on mitochondria was not the focus of this  
study, discussion of potential radiation-induced mitochondrial sequelae may give insight into  






2.1.1. Could mitochondria be targets of radiation? 
Mitochondrial dysfunction incurred as a consequence of radiation may be a significant factor in the 
response of cells to therapy. An early study proposed that Abraxas grossulariata mitochondria were 
more radiosensitive than the nucleus as cytoplasmic constituents appeared to be preferentially 
damaged37. The relatively higher level of radiation-induced damage observed in mitochondrial DNA 
(mtDNA) compared to nuclear DNA, in later studies38, 39, is consistent with such a finding. More 
recent studies report changes in mitochondrial function, gene expression and ATP production 
following irradiation, which support a role for mitochondria in the response to damage40-42. 
Microbeam irradiation of cytoplasmic components, excluding irradiation of the nucleus, resulted in 
mitochondrial fragmentation, reduced respiratory chain activity and increased autophagy including 
mitophagy43, 44. 
While not all studies have found effects on mitochondria after irradiation, a large number of studies 
spanning almost 100 years have demonstrated changes37, 42-63.  Such studies have reported a range of 
structural changes to both mitochondria and cristae, as well as altered mitochondrial biogenesis 
after irradiation. Swollen mitochondria and changes in mass and number have frequently been 
described. Mitochondrial changes, including functional defects, are variable and may be apparent 
hours to days after irradiation. Overall, there appears to be significant variation in radiation-induced 
mitochondrial damage among cell and tissue types64, 65. 
Direct radiation damage to mtDNA has been reported66-68, including mtDNA point mutations55 and 
induction of the Common deletion of 4977bp69, which disrupts complex I, IV and V of the electron 
transport chain, as well as, structural changes to mtDNA (‘supercoiling formation changes’)70. 
2.2. Cellular interactions with radiation 
A complex array of biological processes form the radiation damage response, which may involve cell 
death, cell cycle regulation, DNA repair and cell signalling. It is important to understand such cellular 
interactions to identify the scope for mitochondrial involvement. 
Cellular damage after irradiation arises from both direct and indirect interactions71, 72. Indirect 
damage results from the production of free radicals mostly from interactions between radiation and 
water within the cell and is the predominant mode of action with sparsely ionising radiation.  
While the representation of direct and indirect effects is commonly illustrated using nuclear DNA, an 










Figure 2.1. Schematic representation of the direct and indirect effects 
of radiation on mitochondrial DNA (own diagram). 
Certain cellular sites will receive more-compound damage. Clustered damage, which includes the 
formation of multiple different lesions including strand breaks, base oxidation and abasic sites within 
a few helical turns of DNA, may be induced by a track of ionising radiation73, 74. Such complex lesions 
may constitute critical DNA damage that can lead to double-strand breaks75. The consequence of 
mtDNA strand breaks after irradiation on cellular integrity has not been fully investigated. 
2.2.1. Radiation targets 
DNA double-strand breaks are considered to be the primary genotoxic lesions after irradiation. In 
addition, radiation causes single strand breaks, base and sugar damage, DNA-DNA crosslinks76, 77, as 
well as cross-links with proteins and other cellular components 78, 79.  Other targets include lipids, 
membranes and metabolites, which may undergo oxidative damage. 
Aberrations, evident as changes in chromosome structure, number or morphology occur as a 
consequence of breaking and re-joining of chromosomal DNA80, 81. Chromosome aberrations result in 
unbalanced segregation of chromosomes to daughter cells or mitotic catastrophe. The interaction of 
two unrepaired DNA double strand breaks may induce serious cellular consequences, however, if 
repaired, double strand breaks may not constitute critical lesions81. Lethal chromosome aberrations 
include dicentrics, fragments, large deletions and ring chromosomes71. In contrast, cells can tolerate 




2.2.2. Cellular damage response 
DNA damage initiates a damage response process that consists of damage recognition and signalling 
(Figure 2.2). This response includes the activation of cell cycle checkpoints, as well as the initiation of 
repair mechanisms, cell death and processes that allow damage tolerance83, 84. Thus, the efficiency of 
the DNA damage response determines the fate of damaged cells. Excessive damage or ineffective 
repair may result in apoptosis or senescence85.  
Mitochondria are integral to the damage response in that they have roles in the intrinsic apoptosis 
pathway86, 87 and have been implicated in the regulation of cell cycle progression88, 89.  
Mitochondria also provide reactive oxygen species (ROS) for signalling90 and are a source of cellular 
energy that indirectly drives cellular processes91. Cell death after irradiation, while largely as a result 
of direct nuclear damage may arise partly through indirect damage from ROS generated by 
mitochondrial dysfunction following irradiation92, 93.  
 
 
Figure 2.2. Schematic representation of the DNA damage response pathway (own diagram).  





Cellular responses to radiation-induced damage are characterised by successive stages that include 
detection of the damage by sensor molecules, transduction of the signal and finally execution of the 
response (Figure 2.2). Multiple DNA damage response proteins are involved in signal transduction 
and repair85, however, only a selection of role players will be discussed here.   
After damage has occurred, cell cycle arrest may be induced to facilitate repair, the nature and 
extent of which is dependent on the cell cycle phase94, 95. In attempting mitosis, cells may succumb 
to mitotic catastrophe at division as a result of unrepaired damage. In addition, interphase death by 
apoptosis may occur96.  
2.2.3. Cell cycle arrest 
Radiation-induced cell cycle arrest is critical to allow damaged cells time for repair and to prevent 
cell division or DNA replication while damage is present97. Whereas extended cell cycle arrest may 
increase time for repair and thus enhance survival, persistent radiation-induced damage may result 
in permanent arrest and cell senescence98-100. The cell cycle position at the time of irradiation partly 
determines the checkpoint at which cells may arrest. DNA maintenance checkpoints include the G1 
and G2 checkpoints that prevent entry into S-phase and mitosis, respectively, and the intra S-phase 
checkpoint, which arrests cells that have entered S-phase (Figure 2.3). Modulation of mitochondrial 
dynamics may potentially affect cell cycle progression and thereby influence cell cycle arrest 
following irradiation. 
2.2.3.1. G1 and G2 checkpoints 
Activation of cell cycle arrest as part of the DNA damage response involves complex 
phosphorylation-dependent protein cascades that ultimately influence the individual cyclins 
responsible for cell cycle phase transition. Briefly, DNA damage activates sensor proteins, ATR and 
ATM kinases that phosphorylate Chk1 and Chk2 transducers101, 102, respectively, leading to p53 
phosphorylation and stabilisation103, 104. p53 activates p21, a cyclin-dependent kinase (Cdk) 
inhibitor105, causing repression of the cyclin E-Cdk2 complex, which is necessary for G1-S transition98, 
106. This results in a p53-dependent G1 checkpoint activation and arrest107-109. Similarly, p53 
stabilisation and inactivation of the cyclin B-Cdk1 complex, by p21 or Cdc25C inhibition101, activates 
the G2 checkpoint and prevents entry into mitosis110, 111. In addition, p53-independent arrest occurs 
via p-Chk1 and p-Chk2 leading to ubiquitination and degradation of Cdc25A112, 113, a protein involved 














Figure 2.3. Cell cycle checkpoints with potential points of mitochondrial 
involvement in cell cycle progression. 
2.2.3.2. S-phase checkpoints 
An S-M checkpoint exists that is activated in response to replication stress and prevents mitosis in 
the presence of stalled replication forks116. In addition, an intra-S phase arrest caused by DNA strand 
breaks occurs and has been observed in cells exposed to ionising radiation115, 117. Arrest is activated 
by ATM or Chk2-mediated phosphorylation of Cdc25A and requires the Mre11 recombinational 
protein in humans112, 118, 119. The ATM–MDC1–MRN–SMC1 acts as an alternative pathway120. The intra-S 
phase checkpoint slows DNA replication rather than preventing cell cycle progression completely 
and residual damage invokes a G2-checkpoint118. Additional S-phase checkpoints, mediated by the 
ATR through the RPA complex, that may be induced by replication stress or incomplete 
replication121-123 have also been distinguished from the intra-S phase arrest. 
2.2.3.3. Spindle checkpoint 
The spindle checkpoint guards the integrity of mitosis and is responsible for ensuring proper 
alignment of chromosomes prior to their separation in anaphase. It was first observed that cells in 
metaphase were prevented from entering anaphase if kinetochores were not properly positioned on 
the metaphase plate124. The presence of numerous DNA double-strand breaks during mitosis may 
elicit a strong mitotic arrest in response to lack of kinetochore attachment125.  
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The spindle assembly checkpoint, which senses spindle position and integrity, is constitutively active, 
in contrast to other cell cycle checkpoints that become activated in response to damage. High Cdk 
activity is thus maintained but requires suppression for mitotic exit126. The spindle assembly 
checkpoint regulates mitosis by inhibition of cell division cyclin 20 (Cdc20), suppression of the 
anaphase promoting complex cyclosome (APC/C) and prevention of securin- and cyclin B 
degradation for cell cycle progression127, 128. Securin is an inhibitor of separase, an enzyme required 
for cleavage of the cohesion complex that holds two sister chromatids together while cyclin B 
degradation inactivates Cdk1 allowing mitotic exit129. APC/C, an E3 ubiquitin ligase, is inhibited by 
the mitotic checkpoint complex (MCC) that includes the MAD (mitotic arrest deficient) and Bub 
(budding uninhibited by benzimidazole) proteins, Aurora B and Cdc20 among others and is associated 
with the chromatid (kinetochore) cohesion complex126, 130, 131. Prolonged mitotic arrest frequently 
results in cell death, however, Cdc20 release from the MCC132 or direct inhibition of Cdk1133 may 
occur and result in mitotic slippage126. Mitotic slippage is suggested as a mitotic cell death avoidance 
mechanism and premature mitotic exit results in polyploidy.  
2.2.4. Mitochondria and the cell cycle 
Mitochondria are important in the cell’s adaptive response to stress or damage134, 135. In particular, 
mitochondria regulate cellular ATP levels136 and indirectly modulate cell cycle progression137, 138 and 
apoptosis139. For example, in Drosophila, distinct mutations in respiratory chain complexes I and IV 
caused increased ROS and reduced ATP, respectively140, 141. ROS signalling in the mutant complex I 
clones induced activation of the G1/S checkpoint via upregulation of the cyclin E-Cdk2 inhibitor, 
Dacapo141. Reduced ATP was shown to activate AMP-activated protein kinase leading to activation of 
p53 and reduction in cyclin E with an associated G1/S arrest140. In addition, studies using respiratory 
chain inhibitors have provided evidence for a link between ATP levels and cell cycle arrest in 
malignant cells. For example, reduced ATP levels in HL-60 cells caused cell cycle arrest at both G1/S 
and G2/M142.  
As mitochondrial dysfunction was associated with cell cycle arrest, it is likely that there is some 
mitochondrial influence over cell cycle progression. Of note, the cyclin B-Cdk1 complex and 
mitochondrial matrix proteins have been shown to interact to upregulate respiration143, thus 
satisfying energy requirements for G2/M transition. Cyclical regulation of OXPHOS throughout the 
cell cycle may also influence cell cycle progression and may be controlled by mitochondrial 
dynamics. Differences in ATP levels have been observed throughout the cell cycle.  
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An increase in ATP production was shown in cells at the G1/S boundary and was associated with 
mitochondrial hyperfusion144. ATP production was reduced in S-phase and was lowest in cells in 
mitosis, which is frequently associated with mitochondrial fragmentation. Furthermore, cyclin D1, 
which is increased in S-phase, has been shown to inhibit mitochondrial function and size145 and 
repress nuclear respiratory factor 1146, which results in reduced respiratory capacity. Thus, during S-
phase and G2/M (reductive phases), cells rely mainly on glycolysis, which protects vulnerable, 
replicating DNA from damaging ROS produced by OXPHOS147, 148. In addition, mitochondrial protein 
import and mitochondrial membrane potential (ΔΨm) was lower in S-phase than in G1-phase in 
proliferating fibroblasts149. Another study, however, reported increasing ΔΨm from G1 to G2/M 
although they maintained that ΔΨm was not fully developed until mitosis150.  
Mitochondrial fission and fusion status show variation through the cell cycle (Figures 2.3 and 2.8). 
This will be described in more detail in subsequent sections that describe mechanisms of 
mitochondrial fusion and fission. 
2.2.5. Is there a mitochondrial damage-induced checkpoint? 
The concept of a mitochondrial damage checkpoint, termed a mitocheckpoint, was first proposed  
by Singh in 200492, whereby mitochondria signal changes in gene expression to repair damaged 
mitochondria. Detection of mtDNA damage is important as mitochondrial dysfunction has been 
found to lead to loss of nuclear DNA integrity after radiation exposure151-153.  
Similar to nuclear DNA damage, mtDNA damage has been shown to initiate cell cycle arrest and 
repair of mtDNA138. Drug-induced mtDNA damage was shown to result in an S-phase arrest in HeLa 
cells and was associated with an increase in Chk2 phosphorylation138. In addition, persistent mtDNA 
damage was shown to induce permanent arrest through the induction of p21154.  
G2/M checkpoint activation was suppressed in mtDNA depleted cells155, 156 indicating that damage 
signalling from mtDNA rather than the loss of mitochondrial function per se may be required for 
checkpoint induction. While mtDNA damage may influence cell cycling, other studies have reported 
that mtDNA depletion had no effect on the cell cycle157, 158.  
Cancer cells are often characterised by mitochondrial dysfunction that influences cellular 
metabolism, which may impact on the way in which cancer cells sense and respond to damage. 
However, checkpoint-related mechanisms are frequently altered in cancer cells and thus certain cell 
cycle regulatory processes may be less active or absent108, 159.  
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2.2.6. Repair of radiation-induced damage 
Radiation induces pro-survival signalling pathways that include cell cycle arrest, suppression of 
apoptosis and repair160. DNA single- and double strand breaks activate the phosphatidylinositol 3-
kinase-like protein kinases Ataxia Telangiectasia and Rad3-related protein (ATR) or ataxia 
telangiectasia mutated (ATM)161, 162, respectively. ATR is frequently involved in repair of breaks that 
result from replication stress while ATM is more important in the context of DNA damaging agents 
including ionising radiation. ATM and ATR initiate signals that are transmitted by phosphorylation, 
sumoylation and ubiqitination of a variety of transducers and effectors 85, 163.  
Phosphorylation and stabilisation of the key regulatory protein, p53103 is an important step in the 
process that allows cell cycle arrest for repair. p53 phosphorylation prevents MDM2 binding164 
thereby blocking its degradation165. In addition, the poly(ADP-ribose) polymerase (PARP) proteins, 
PARP1 and 2 are activated by single and double-strand DNA breaks, respectively, and catalyse the 
addition of poly(ADP-ribose) chains on proteins to facilitate repair166. 
Auto phosphorylation and activation of ATM is facilitated by binding of the MRN complex to double-
strand breaks with subsequent phosphorylation of chromatin-associated proteins161, 167. The histone 
H2AX, one of the first proteins marking a double-strand break, is called -H2AX when 
phosphorylated168. MDC1 amplifies H2AX phosphorylation and recruits other DNA damage response 
proteins that form foci, which can be detected by immunocytochemical staining84, 169.  
Repair of single strand DNA breaks occurs via either the nucleotide excision repair (NER) or base 
excision repair (BER) pathways that rely on copying information from a complementary template 
DNA strand83. However, more complex repair mechanisms are required for DNA double-strand 
breaks170. The two major pathways of DNA double-strand break repair are non-homologous end-
joining (NHEJ) and homologous recombination (HR). Alternative-NHEJ (alt-NHEJ) and single strand 
annealing are two further repair pathways that have been identified for double-strand break 
repair85. The choice of pathway depends on the complexity of the double-strand break, the position 
in the cell cycle and the chromatin conformation.  
HR makes use of a complementary sister chromatid for repair and is therefore only active during late 
S- and G2-phase once the DNA has been replicated171. NHEJ, which is active throughout the cell 
cycle, requires processing of the damaged ends of the strands prior to ligation. Binding of the 
Ku70/Ku80 heterodimer172 facilitates recruitment of the core NHEJ complex173 that includes, the 
XRCC4/DNA Ligase IV (X4LIG4) complex, as well as, DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) and XLF83.  
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The DNA-dependent protein kinases are important for activation of end-processing nucleases while 
the XRCC4/LIG4 complex is responsible for the ligation reaction85, 174. NHEJ represents an error-prone 
type of DNA repair as a result of DNA strand end-processing. Alt-NHEJ involves PARP proteins that 
sense DNA double-strand breaks and serves as a backup for the NHEJ pathway175. Here, the MRN 
complex is recruited in an MDC1/-H2AX-independent manner176 and LIG3/XRCC1-dependent DNA 
end ligation occurs. 
In contrast, HR relies on the sister chromatid sequence and provides a more efficient type of repair. 
The MRN complex together with CtIP initiate a resection reaction that involves EXO1 and DNA2 
nucleases and Sgs1/BLM helicase85, 177. In addition, BRCA1 in complex with CtIP can cause 
resection178. Synapsis involves homology searching and DNA strand invasion and D-loop formation 
that requires formation of the RAD51 nucleofilament179. The RPA-complex at resected ends 
facilitates binding of RAD51 and RAD52 proteins that are important for regulation of homologous 
cross-over and re-annealing of resected strands. Holliday junctions formed from cross-over events 
are resolved by the activity of GEN1 and SLX1/4 nucleases85, 179. 
2.2.7. Importance of repair in radiotherapy 
Mechanisms of repair are relevant to radiotherapy, which is often delivered using multiple fractions 
or altered dose rates. Radiotherapy generally exploits the repair differentials between tumour and 
normal tissue for therapeutic advantage. Cancer cells frequently display aberrant signalling and 
repair pathways and may thus be less repair proficient180, 181.  
In addition to sub-lethal damage, which is repaired between fractions, the post-irradiation 
conditions are important and may determine the outcome of repair of potentially lethal damage.  
It is possible that modulation of mitochondrial dynamics that influence cellular damage response 
mechanisms may conceivably affect that ability of cells to repair.  
2.2.8. Mitochondrial DNA repair 
As mentioned previously, mitochondria may influence the cell cycle to facilitate repair of mtDNA 
damage138. Such repair is necessary, particularly as mtDNA is in close proximity to the site of ROS 
production and is therefore susceptible to oxidative damage182, 183. Mitochondria have mechanisms 
for BER184, mismatch repair185 and HR186. Recognition of base damage occurs by DNA glycosylases.  
Of note, p53 has been shown to translocate to mitochondria when ROS production is increased187 
and has 3’-5’ exonuclease activity, which is able to excise oxidised bases188.  
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Double-strand break repair has been described in mitochondria after treatment with a restriction 
enzyme, ScaI, and loss of the intervening mtDNA sequence suggested NHEJ repair189. Although 
mechanisms of HR have also been described for mitochondria186, such repair may be restricted by 
limited contact between separate mtDNA molecules183, 190.   
2.2.9. Mitochondrial role in repair after irradiation 
While the role for mitochondrial dynamics in radiation repair remains to be fully elucidated, other 
aspects of mitochondrial involvement in the ability of cells to repair damage have been suggested 
from a range of different studies. For example, a recent report described the translocation of Cdk1 
to the mitochondria and subsequent increase in ATP production after irradiation. Knockdown of 
Cdk1 caused inhibition of post-irradiation repair likely as a result of inadequate ATP production191. 
Loss of a mitochondrial tumour suppressor protein, Fus1, which is regulated by oxidative stress was 
also shown to influence repair of radiation-induced damage. Fus1 knock-out in normal tissue 
resulted in premature release from cell cycle arrest, with early reduction in -H2AX in irradiated cells 
without sufficient time for repair resulting in increased radiation-induced apoptosis192.  
Mitochondrial function has been shown to be decreased in a number of radiosensitive cell lines that 
were thought to be repair deficient193. Mutations or deficiencies in mtDNA are also associated with 
reduced repair. The loss of mtDNA has been shown to downregulate HR repair protein BRCA2, 
leading to an increase in unrepaired DNA double-strand breaks and genomic instability194. Cell lines 
from ataxia telangiectasia patients, who have ATM gene mutations and associated DNA repair 
deficiency, have been observed to display mitochondrial dysfunction and oxidative stress195. Cells 
from patients with the mitochondrial diseases, Leigh syndrome and Leber’s optic atrophy, showed 
differences in gene expression related to regulation of energy and response to DNA damage from 
ionising radiation. Mutant cells showed reduced induction of repair proteins and an increased 
expression of apoptosis-related genes suggesting that mitochondrial dysfunction may limit the 
ability of cells to repair damage and preferentially induce apoptosis196. The same authors showed 
previously, that both Leigh and Leber’s cells were radiosensitive relative to normal cells with respect 
to the initial radiation damage. However, Leber’s cells were able to repair more efficiently relative to 
Leigh’s cells and ultimately displayed reduced radiation response41. Furthermore, work using Rho0 
fibroblasts, which lack mtDNA, indicated that such cells were also more radioresistant with lower 




2.2.10. Radiation-induced cell death 
Initiation and execution of the DNA damage response ultimately results in cell survival, senescence 
or death. Cell death may occur as a result of certain critical damage in the absence of cell cycle arrest 
or failure of repair mechanisms. Necrosis197, autophagy198 and apoptosis199, as well as other forms of 
programmed cell death, may be induced in response to damage. Autophagy, which is a normal 
degradation of cells to recycle cellular constituents, as well as being a form of programmed cell 
death, is relevant in the cellular radiation response and is receiving increased attention. 
Interestingly, there may be an interplay between autophagy and other types of cell death such as 
apoptosis736. 
The major form of cell death induced by radiation is mitotic cell death, which occurs as cells attempt 
division71. Cell death that is independent of mitosis, classically known as interphase death, may 
occur via apoptosis depending on the sensitivity of the cells to this mode of cell death200. In systems 
where apoptosis is the primary mode of cell death, apoptosis following irradiation has been 
described as, either early apoptosis, defined as apoptosis that occurs within 4 to 6 hours after 
irradiation and generally happens at doses below 5 Gy, or secondary apoptosis, which occurs after 
the first cell division, requires higher doses and may partly reflect reproductive cell death201, 202. In 
general, cells of haematological origin predominantly undergo early apoptosis while epithelial cells 
primarily undergo secondary apoptosis201, 203. Early and late radiation-induced apoptosis has also 
been described for high and low doses203, 204. Apoptosis in U937 cells, assessed by DNA 
fragmentation was shown to be significant only from 36 h after 5 Gy, while higher doses of 20 and  
40 Gy elicited a significant response from 6 hours. Interestingly, the S-phase cells were found to be 
the most sensitive to radiation-induced apoptosis 205. Cellular radiosensitivity has been associated 
with the induction of a high level of early apoptosis71, 206.  
Mitochondria play a central role in apoptosis induced by both the intrinsic and extrinsic pathways 
and apoptogenic factors reside in the intermembrane space. Bcl-2, Bcl-xl and Mcl1, among others, 
are anti-apoptotic proteins, able to inhibit mitochondrial outer membrane permeabilisation (MOMP) 
and are able to form heterodimers with apoptosis-initiating proteins207. Pro-apoptotic Bax and Bak, 
activated by BH3 only proteins, such as Bid, Bim, Noxa and Puma207, mediate MOMP and release of 
cytochrome C208, Smac (second mitochondria-derived activator of apoptosis)/DIABLO (direct AIP-binding 
protein with low PI) and Omi/HtrA2 (high temperature requirement protein A2) that leads to caspase 
activation through the intrinsic mechanism209. Initiator and executioner caspases exist that 
transduce a death signal and cleave diverse cellular substrates, respectively210.  
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In the cytoplasm, cytochrome C interacts with Apaf-1, to form the apoptosome that facilitates 
recruitment and activation of procaspase 9211, which then activates effector caspases 3, 6 and 7. 
Smac/DIABLO and Omi/HtrA2 function to neutralise the inhibitor of apoptosis proteins. The extrinsic 
apoptotic pathway involves binding of ligands, for example, Fas to a death receptor on the cell 
surface that activates initiator procaspase 8 leading to activation of other caspases212.  
An amplification loop exists between the extrinsic and intrinsic pathways via bid cleavage to enhance 
the apoptotic signal. In addition, release of apoptosis initiating factor and endonuclease G from the 
mitochondrial intermembrane space induces a caspase independent form of cell death that results 
in direct nuclear cleavage213.  
2.2.10.1. Mitochondrial dynamics and apoptosis 
Evasion of apoptosis has been found to be associated with mitochondrial dysfunction92 and mtDNA-
depleted cells may be resistant to cell death214. Mitochondria are therefore important in the 
induction of apoptosis. 
Mitochondrial fission, which will be described in detail later, has been shown to be associated with 
apoptosis215-217. Modulation of mitochondrial dynamics can influence MOMP through the interaction 
of DRP1, a fission protein, with Bax on the outer mitochondrial membrane218, 219. In addition, 
overexpression of fusion proteins, MFN1 and 219, and OPA1220, that reside on the outer and inner 
mitochondrial membranes, respectively, inhibit MOMP. Both DRP1221 and MFN1 and 2222 have been 
found to interact with Bax218 and OPA1 has been associated with release of cristae-bound 
cytochrome C223, 224. Thus, there appears to be a significant link between mitochondrial dynamics 
and apoptosis. Although radiation-induced apoptosis in cancer cells in culture has been well 
documented, the contribution of apoptosis to tumour cell kill in vivo varies considerably71, 201. In 
general, solid tumours are thought to be resistant to apoptosis225. Mitochondrial dysfunction in 
tumours may to some extent reflect apoptotic dysfunction.  
2.3. Determination of cellular radiosensitivity  
The response of cells to irradiation may be affected by the extent of the initial damage incurred, the 
capacity of cells to initiate a DNA damage response and repair226. Factors that determine the extent 
of critical biological damage include, the cell type227, cell cycle phase228, anti-oxidant status229 and 
possibly metabolic status, among others. Many of the factors that influence radiation response may 
be influenced by mitochondrial status and cellular bioenergetic capacity. In addition, certain physical 
factors influence cellular radiosensitivity including dose rate, fractionation and radiation quality. 
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The initial damage incurred by the cell after irradiation reflects the inherent radiosensitivity230, 231. 
While the terms radiosensitivity and radiation responsiveness are often used interchangeably, it is 
strictly-speaking important to draw a distinction between them. Radiosensitivity depends on the 
inherent sensitivity of the cells, while radiation responsiveness is dependent on the net result of 
initial damage as well as repair.  
2.3.1. In vitro radiobiological endpoints: Assays  
In the present study, certain tumour cell lines were used to assess radiobiological endpoints, as well 
as factors determining radiation response. A brief discussion of these endpoints is included below. 
Early studies suggested that cultured cells may reflect the radioresponsiveness of tumours227, 232. In 
one study, the radiosensitivity of 70 % of the 29 tumour-derived cell lines investigated was shown to 
be similar to that of normal fibroblasts233. The remaining 30 % of the cell lines from the same study 
derived from “radio-incurable” tumours, were inherently radioresistant. This suggests that tumour 
cell lines may reflect, to some extent, the inherent radioresponsiveness of a parent tumour. Intrinsic 
radiosensitivity may be a determinant of tumour cell response to radiotherapy234.  
A number of in vitro assays have been developed for quantifying the cellular effects of radiation, for 
example assessment of clonogenic cell survival, cell proliferation, genetic alterations and 
immunocytochemical markers.  
For clonogenic assays, individual cells are assessed for their ability to form colonies after irradiation. 
Cell proliferation can be assessed using colorimetric MTT (methyl-thiazolyl-tetrazolium)-type assays, which 
assess cellular metabolic activity and depend on dehydrogenase -induced reduction of tetrazolium 
salts to formazan. Alternatively, direct quantification of cellular proliferation markers, such as Ki-67 
and proliferating cell nuclear antigen can be undertaken. DNA damage may be assessed by the 
determination of -H2AX focus formation, chromosome aberrations, micronuclei and single cell gel 
electrophoresis (comet assay), amongst others. Apoptosis may be routinely assessed using a 
multitude of different techniques based on morphological or biochemical criteria. Necrosis is 
frequently assessed by the uptake of vital dyes such as trypan blue or propidium iodide, which can 
traverse compromised cell membranes. Cell cycle analysis is conducted using flow cytometry, 





2.3.1.1. Cell Survival 
The clonogenic survival assay, introduced by Puck and Marcus (1956)235, provides a measure of the 
reproductive integrity of cells after treatment and is a valuable tool for the assessment of radiation 
survival in vitro 236. This technique is suited to studying the modulation of radiation effects including 
the influence of agents that modify mitochondrial dynamics. Survival assays are considered to be 
more informative than cellular proliferation assays, which can reflect cytostatic- in addition to 
cytotoxic responses.  
The assay can be adapted for assessment of non-adherent cells, with the use of a gel matrix for 
colony formation. However, the assay requires up to 3 weeks depending on cell proliferation rate 
and relatively large numbers of cells to assess particularly toxic treatments.  
The mechanistic Linear-quadratic (LQ) model of radiation interaction is commonly used to describe 
the dose response (Figure 2.4)237-239. This relationship between survival and dose is thought to be 
determined by the interaction of two separate chromosomal breaks that may recombine to yield 
aberrations. The equation is as follows: 
S = e-(αD+βD2) 
Where S is the cell surviving fraction, D represents dose, and α and β are constants relating to the 








Figure 2.4. Graphical representation of a radiation survival curve fitted using 
the linear quadratic equation as a means to model the biological response to 
radiation. Densely ionising radiation produces a straight line while x- and -rays 




Alpha damage may result when two chromosome breaks occur simultaneously as a result of a single 
ionising track, while beta-type damage occurs when breaks are separated by time and are therefore 
amenable to repair. The initial slope of the curve is dominated by the linear alpha component while 
beta determines the quadratic component of the survival curve. The ratio of alpha to beta (α/β) 
gives the dose at which the linear and quadratic components of cell kill are equal, and defines the 
shape of the survival curve. Radiosensitivity is sometimes estimated from the initial slope of the 
radiation survival curve, determined by alpha. However, overall responsiveness, which also takes 
into account beta, is a function of the full curve. 
Other descriptors of radiation responsiveness that have been used include D10, D, SF2 and SF4.  
D10 is the dose required to give 10 % survival. The mean inactivation dose, D, represents the overall 
cellular radiation responsiveness over the whole dose range considered. This value can be estimated 
from the area under the survival curve and has been used as a measure of radiosensitivity240-243.  
The surviving fractions of cells after doses of 2 and 4 Gy, namely SF2 and SF4, are also used for 
comparison of survival. 
2.3.1.2. Micronuclei  
The cytokinesis-block micronucleus assay was developed for assessment of DNA damaging agents 
including radiation244, 245. Micronuclei are small, additional nuclei that are formed during mitosis 
(Figure 2.5). Radiation-induced chromosomal breaks or mis-alignment at metaphase and the 
resulting inadequate spindle attachment may lead to micronucleus formation. Whole or acentric 
chromosomes, or chromatid fragments may be left stranded during anaphase246, 247 and become 
bound within their own nuclear membranes. Micronuclei are either lost during cytokinesis or 






Figure 2.5. Two binucleate U937 cells each containing a single micronucleus 




The assay allows quantification of micronuclei in cells that have undergone a single division. Such 
binucleate cells can be obtained using cytochalasin B to inhibit cytoplasmic division while permitting 
nuclear division. The frequency of micronuclei for a given cell number is routinely determined as a 
measure of the DNA damaging capability of a cytotoxic agent. Alternatively, the frequency of 
binucleate cells containing micronuclei can be scored to give an indication of the proportion of cells 
expressing cytogenetic damage249-252. The OECD (Organisation for Economic Co-operation and 
Development) Guidelines for the Testing of Chemicals, in vitro Mammalian Cell Micronucleus Test253 
describe the frequency of micronucleated cells as their method of choice.  
A linear relationship has been shown to exist between radiation dose and micronuclei frequency244. 
The sensitivity of cells to radiation-induced micronuclei has been proposed to correlate with 
clonogenic survival254, 255. 
2.3.1.3. Apoptosis 
Apoptosis256 may not be a major consequence of radiation therapy in tumour cells, which 
characteristically exhibit defects in the apoptotic machinery257-259. However, it would be beneficial to 
identify agents that are able to stimulate apoptosis or modulate radiation-induced apoptosis.  
Methods to quantify apoptosis are based on the characteristic morphological and biochemical 
features associated with this type of programmed cell death. Fluorescence microscopic evaluation of 
cells undergoing apoptosis (Figure 2.6) reveals condensed chromatin (pyknosis), spherical or ovoid 
cytoplasmic fragments and cell shrinkage260. Several assays based on morphological assessment have 
been developed. Manual scoring of apoptosis that assesses the above features is a simple and 
reliable way to quantify apoptotic cells. Cells displaying such features are generally in an advanced 
stage of apoptosis260, 261. Other manual scoring methods include assays that allow discrimination 
between viable, necrotic and apoptotic cells, for example, double staining with Hoechst 33342 and 
propidium iodide (PI). While Hoechst 33342 intercalates with the DNA double helix and stains all 
cells allowing identification of apoptosis, PI is used as a vital stain to distinguish necrotic cells as a 















Figure 2.6. Representative images of apoptotic U937 cells stained with Hoechst 
33342 (present work). 100x magnification. 
A widely utilised method of apoptotic cell detection using flow cytometry combines the use of 
Annexin V and PI to effectively distinguish late and early apoptosis263, 264. Annexin V binds to 
phosphatidylserine that is exposed on the surface of cells during apoptosis264. The ability of PI to 
stain cells is dependent on membrane permeability263. Live cells and early apoptotic cells exclude PI 
and this allows them to be distinguished from necrotic cells where membranes become 
compromised263. In early apoptosis, cells are stained primarily with Annexin V but late apoptotic cells 
are stained with PI and Annexin V264. In addition, using flow cytometry, apoptosis may be detected 
by means of fragmented, hypo-diploid cells that appear as a sub-G1 peak on a DNA histogram265, 266. 
Gel electrophoresis of isolated DNA from apoptotic cells can be used to detect DNA fragmentation 
that forms a characteristic ladder pattern. Similarly, the comet assay can be performed at a single 
cell level where lysed cells are subjected to electrophoresis on a microscope slide and degraded DNA 
is visualised as a tail attached to a head consisting of intact DNA following staining with ethidium 
bromide or PI. The amount of DNA in the tail is proportional to the amount of damage induced. 
Although both necrosis and apoptosis can be detected using the comet assay, it has been shown that 
the tail moment (the product of the tail length and total DNA content) can effectively distinguish the 
two types of cell death267.  
The terminal deoxy transferase-mediated dUTP nick end labelling (TUNEL) method268, 269 exploits the 
characteristic DNA fragmentation that occurs during apoptosis to detect cell death. TUNEL uses a 
terminal transferase to label single and double-strand DNA breaks with, for example, fluorescently 







This method can distinguish early apoptotic cells as DNA breaks occur before a change in 
morphology of the cell can be detected. A similar assay, the in situ 3’-end labelling method, which 
relies on DNA polymerase I and thus only labels single-strand breaks, may be used but is less 
sensitive than TUNEL.  
Immunohistochemistry and Western blotting can be used to examine apoptosis by using antibodies 
against proteins such as caspases and the Bcl-2 family270. Apoptosis can also be quantified by 
measuring release of cytochrome C and other apoptotic factors from the mitochondria271. 
As mentioned previously, radiation may induce both early and secondary apoptosis that is dose, cell 
type and cell cycle phase dependent. The time course of apoptosis following irradiation is therefore 
an important consideration when assessing apoptosis201, 272. In addition, the differences in the 
kinetics of apoptosis in cultured cells should be considered as apoptotic cells are not eliminated by 
phagocytes in the same way as they would be in in vivo systems202. This lack of elimination of 
apoptotic cells as well as the proliferation of unaffected cells in culture may influence quantification 
of apoptosis. In general, the apoptotic index may be expected to increase initially after treatment, 
saturate, and then be reduced, as proliferation of unaffected cells occurs.  
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2.4. Mitochondrial physiology  
Mitochondria are multifaceted organelles that display a high degree of functional diversity. 
Differences in the environmental conditions and tissue of origin may dictate mitochondrial 
physiology. In addition, mitochondria derived from tumour or normal tissue may have significantly 
altered function.  
 
Discovery of mitochondria and their function 
The role of mitochondria in the generation of cellular energy in the form of ATP has been 
well established since the 1940’s. At this time, a newly developed method of tissue 
fractionation enabled Albert Claude to isolate mitochondria and determine that 
enzymes, known to be responsible for respiration (“cytochrome-linked enzymes”) 
resided in these organelles273. Although cellular structures referred to as “granules” were 
observed in the 1840’s, it is believed that mitochondria, were first recognised and 
named “bioblasts” in 1890 by Richard Altmann274. 
The popularised term “powerhouse of the cell”, coined by Philip Siekevitz in 1957275, 
encapsulated the contemporary knowledge of mitochondria and highlighted the central 
role of this organelle in cellular bioenergetics. Important research that contributed to 
this knowledge included observations by Otto Warburg. He linked mitochondria to 
cellular respiration by studying extracts of guinea-pig liver and concluded that structures 
he termed  “grana” are associated with the activity of “atmungsferment” (cytochrome C 
oxidase)274. This foundational work and his interest in the metabolism of tumours 
culminated in his belief that “the prime cause of cancer is the replacement of the 
respiration of oxygen in normal body cells by a fermentation of sugar” 276, 277. The 
observation that tumours preferentially use glycolysis even in the presence of oxygen278 
led Warburg and his contemporaries to suggest that altered metabolism was 
necessitated by a dysfunction in mitochondrial respiration278, 279. 
 
  
- Historical interest - 
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2.4.1. Altered metabolism and mitochondrial function in tumour cells 
2.4.1.1. Metabolic reprogramming as a hallmark of cancer 
2.4.1.1.1. Warburg effect 
A shift from respiration to aerobic glycolysis in tumours is a trait that is characteristic of a large 
proportion of tumours and is exploited in the field of functional imaging of tumours280, 281.  
A radioactive glucose analog 2-[I8F] fluoro-2-deoxy-D glucose (F-I8 FDG) is taken up by cells with  
a high rate of glycolysis and is used with positron emission tomography (PET) scanning to provide 
spatial information on the metabolic and biochemical activity of tissues. In combination with a 
computed tomography (CT) scan for anatomical information, a PET/CT provides a 3-D image that 
includes more precise localisation of diseased tissue than is achieved with PET scanning alone. The 
widespread use of this technique in cancer diagnostics and management attests to the prevalence  
of this alteration in tumour metabolism that has been referred to as “the Warburg effect”.   
Support for a role of upregulated glycolysis in cancer initiation or progression is highlighted by an 
emerging hallmark, “metabolic reprogramming”, described by Hanahan and Weinberg225, 282. The 
status of an emerging rather than a core hallmark results from uncertainty over whether this 
phenotype should be regarded a consequence of enhanced proliferation, as many of the genes 
involved overlap or as a fundamental change in tumour development.   
A related publication provides a review supporting the inclusion of altered metabolism as a core 
hallmark of cancer283. The primary focus of their discussion addressed the apparent paradox behind 
a shift in metabolism to increased glycolysis, a less efficient energy producing process, in cancer cells 
that are proliferating rapidly and therefore, presumably, require increased amounts of energy. They 
refer to fundamental differences in metabolism between quiescent cells and those that are 
proliferating in situations where growth factor stimulation is abundant. A shift from catabolic to 
anabolic metabolism under these conditions supports lipid, protein and nucleotide biosynthesis 
needed for cell division284, 285.  
Specifically, cellular growth requires NADPH for fatty acid and cholesterol biosynthesis, and recycled 
carbon and nitrogen for nucleic and amino acid synthesis286, 287. In addition, NADPH is important for 
modulating oxidative stress by reducing glutathione, converting H2O2 to H2O in the process, and 
preventing hydroxyl radical formation288.  
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A glycolytic phenotype may give cancer cells a survival advantage in a microenvironment 
characterised by intermittent hypoxia290, 291. Mitochondrial respiration, which regulates glycolysis  
via ATP feedback289, is often downregulated accordingly286, 291. 
2.4.1.2. Mitochondrial respiration in tumour cells 
Despite the observed dependence of tumours on glycolysis, cancer cells have been shown to be 
metabolically heterogeneous with a proportion of cells reliant on mitochondrial respiration292, 293.  
A subset of cells may exist that maintain stem cell-like characteristics and are dependent on OXPHOS 
with low basal levels of glycolysis. Such a sub-population was reportedly unable to upregulate 
glycolysis and was therefore particularly sensitive to OXPHOS-inhibiting drugs293.  
Cellular respiration involves a series of biochemical reactions culminating in ATP production. 
Glycolysis, the first stage in cellular respiration, produces ATP but also supplies pyruvate and NADH 
for pyruvate oxidation and OXPHOS, respectively. Acetyl Co-A produced by pyruvate oxidation, in the 
mitochondria, is oxidised by the citric acid cycle yielding NADH and FADH2. During OXPHOS, NADH 
and FADH2 deliver electrons to be transported by the electron transport chain (ETC), which consists 
of respiratory complexes that pump protons from the mitochondrial matrix into the intermembrane 
space to form a proton gradient. ATP generation by ATP synthase is driven by the exchange of 
protons across the inner mitochondrial membrane and oxygen acts as the final electron acceptor294.  
2.4.1.2.1. Mitochondrial function and dysfunction 
Paradoxically, it appears that cancer cells need some degree of both functional mitochondria and 
mitochondrial dysfunction for transformation and maintenance of tumour growth295. Several factors 
may account for differences in mitochondrial respiration between cancer and normal cells. 
Metabolic changes in tumour cells are frequently the result of changes in expression or regulation of 
proteins involved in respiration.  
The downregulation of OXPHOS is a common feature in cancer cells even in the context of an intact 
ETC. A particularly informative parameter of respiration, in the analysis of cancer cells, is the LEAK 
state respiration which describes mitochondrial dysfunction linked to ATP synthesis and provides a 
measure of the efficiency of electron transport. In addition, proton leak is regulated by oxidative 
stress through a feedback loop and is increased in the presence of excess ROS296-298. Cells displaying 
high proton leak, as a consequence of oxidative stress, may upregulate additional anti-oxidant 
defences, e.g. intracellular superoxide dismutase (SOD) and glutathione 299.  
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As anti-oxidant capability influences the effectiveness of radiation300-303, it may be expected  
that cells displaying increased LEAK state respiration would have increased radioresistance.  
Studies regarding the reduction of oxidative stress, and increased radioprotection, using 
mitochondrial-targeted anti-oxidants support this notion. For example, administration of ROS 
scavengers or synthesised antioxidants, were shown to reduce radiation-induced damage and 
mortality using mouse models304, 305. In a cell culture model, the use of a mitochondrial ROS 
suppressor, uncoupling protein-2 (UCP2) reduced UV-induced apoptosis in colon cancer cells306. 
Conversely, suppression of MnSOD that leads to increased ROS levels, augmented sensitivity to 
ionising radiation in colon cancer cells307.  
Alternatively, oxidative stress from reduced mitochondrial function could generate DNA damage and 
activate a DNA damage response308. Cells that are primed to detect and respond to DNA damage 
may have increased radioresistance as a result of their greater capacity to counter radiation-induced 
DNA damage. This mechanism is suggested for the radio-adaptive response where low doses of 
ionising radiation prime cells to respond more efficiently to subsequent higher doses309. Similar 
adaptations to those described above have been observed when analysing cancer stem cell 
radioresistance as they display increased antioxidant mechanisms and DNA damage response 
activation310, 311.  
2.4.1.2.2. Alterations in ATP synthase function 
ATP, among other factors, suppresses glycolysis through feedback inhibition of 
phosphofructokinase287. Reducing ATP production by downregulation of ATP synthase would 
therefore be advantageous for cell proliferation. ATP synthase inhibition by oligomycin in 
mammalian cells was also shown to reduce mitochondrially-induced apoptosis312. ATP synthase 
dysfunction thus serves to increase cellular resistance and may be responsible for increased 
resistance to radiation-induced apoptosis. 
Maintenance of ΔΨm under situations of downregulated OXPHOS, with functional ATP synthase, has 
been suggested to be a result of ATP synthase reversal where ATP is cleaved to reduce cellular ATP 
levels313, 314. Under induction of cell death, ATP synthase reversal may be a result of Bax-induced 
proton leak. The extrusion of protons from the matrix then leads to matrix alkalinity which has been 
known to cause permeability transition. This observation may explain some of the conflicting reports 
regarding an association between apoptosis and loss of ΔΨm. ATP synthase reversal would cause a 
transient increase in ΔΨm which would dissipate on opening of the permeability transition pores.  
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Inhibition or dysregulation of ATP synthase is common in tumours and results in ETC inhibition and 
increased ROS and ΔΨm295. ROS may activate hypoxia inducible factors (HIF) through HIFα 
stabilisation, which allows adaptation to oxygen-poor environments315. HIF1α increases glycolytic 
flux by increasing expression of enzymes and transporters involved in glycolysis, as well as, pyruvate 
dehydrogenase kinase (PDK) 1 that regulates PDH316. Phosphorylation inhibits PDH, an enzyme that 
catalyses the oxidative decarboxylation of pyruvate, thereby downregulating aerobic respiration. 
Upregulation of glycolysis further inhibits OXPHOS as a result of competition for phosphates and 
ADP (Crabtree effect). Increased glycolysis in tumours frequently occurs through PI3K–PTEN–AKT 
pathway activation, which increases cell surface nutrient transporters e.g. glucose. ROS can 
inactivate PTEN or activate AKT both leading to activation of the PI3K pathway311. 
2.4.1.2.3. Spare respiratory capacity 
The bioenergetic reserve capacity is the difference between maximum respiratory capacity and ATP-
linked respiration317. In cardiomyocytes exposed to oxidative stress, an initial increase in oxygen 
consumption was followed by decreased respiration as mitochondria became damaged318.  
It was proposed that assessing mitochondrial reserve function may predict cellular stress response. 
Cells with higher reserve function may have more potential to adapt to their environment319. In 
support of this finding, spare respiratory capacity has been suggested as a major determinant in 
cellular stress response and survival in neuronal320, 321, endothelial322 and memory T-cells323. 
2.4.1.2.4. mtDNA mutation 
Although mtDNA mutations have been found in cancer cells295, 324, consistent associations with 
altered respiratory function have not been determined325. Increased ROS production is both a 
consequence and inducer of mtDNA mutation, however, such increased levels are important for 
tumour growth and remain below that required for extensive damage311. Specific mtDNA haplotypes 
or single nucleotide polymorphisms (SNP) are associated with increased risk (~2-2.5 fold) for certain 
cancers2. In addition, changes to nuclear-encoded mitochondrial genes may lead to alterations in 
respiratory function. 
2.4.1.2.5. Description of respiratory parameters determined by polarographic measurements 
Reliable measurements of oxygen consumption and metabolites in cancer cells are needed326. 
Optimal protocols for assessment have only recently been developed. High resolution respirometry 
provides a simple and sensitive approach for collection of such data327.  
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Several methods have been developed for measuring energy metabolism in cultured cells using 
either permeabilised cells, isolated mitochondria or intact cells. These methods include polarography 
using O2 sensors, for example the Clarke-type O2 electrode328, O2-sensing fluorophores or fibre optic 
O2 sensors. Bioluminescent or fluorescent complementary methods that detect ATP concentrations 
or ΔΨm are also available. A summary can be found in an article by Zhang et al. (2012)329. For 
simplicity, only the oxygraph-type apparatus, a traditional method for measuring mitochondrial 
respiration, will be described, as this technique is the basis for measurements in this thesis. 
Using the oxygraph apparatus, O2 consumption is determined by recording changes in dissolved O2 
detected by a Clarke-type O2 electrode. Cells or isolated mitochondria in a physiological solution are 
stirred constantly to ensure homogeneity of the solution. The O2 facilitates the flow of electrons 
from a silver anode to a platinum cathode to create a current which is directly proportional to the O2 
concentration. The O2 consumption rate is a measure of the reduction of total O2 in the chamber.  
Respiratory states have been defined for isolated mitochondria330. State 1 respiration refers to the 
initial OXPHOS activity, state 2 and state 3 refer to respiration at depleted and saturating levels of 
ADP, respectively. State 4 is a measure of the O2 flux at rest when the added ADP is depleted and 
state 5 is respiration during anoxia or in the presence of a complex III inhibitor that abolishes 
mitochondrial respiration. A common index for mitochondrial function, the respiratory control ratio 
(RCR), is defined as the O2 consumption in state 3/state 4331. This value is highly variable as it 
depends on many factors, including the preparation of the mitochondrial isolate332.  
Respiration cannot be determined under saturating ADP conditions in intact cells and respiratory 
states specifically for evaluation in intact cells have therefore been defined327. Oxygen consumption 
for each respiratory state is determined in the presence of a mitochondrial uncoupler or inhibitor.  
A detailed description of the protocol is provided in Chapter 4.  
ROUTINE respiration can be considered equivalent to state 1 while ETS is the maximum 
mitochondrial respiratory capacity, which is similar to state 3. LEAK state respiration is similar to 
state 4 respiration, however, instead of ADP depletion, this state is induced by inhibition of ATP 
synthase by oligomycin. ROX, a measure of the non-mitochondrial respiration is equivalent to state 5 
when induced by a complex III inhibitor. RCR for intact cells, namely ETS/LEAK, is a measure of 
mitochondrial efficiency that determines the capacity for ATP generation. Flux control ratios, which 
will be described in Chapter 4, are useful indicators of mitochondrial function that allow comparison 




2.4.1.3. Mitochondrial membrane potential in cancer cells 
Functional analysis of mitochondria frequently includes both assessment of respiratory capacity and 
ΔΨm. The difference in electric potential across the inner mitochondrial membrane, or ΔΨm, is the 
result of a net positive charge created by the pumping of protons into the intermembrane space 
during electron transport.  
In general, cancer cells have been reported to display hyperpolarised mitochondria333-336, which, 
rather than representing increased mitochondrial function, is commonly associated with defective 
electron transport or ATP synthesis. For example, the hyperpolarised membrane may arise from the 
accumulation of protons in the intermembrane space as a result of ATP synthase dysfunction as 
described above 337, 338. 
Cancer cells often display increased ΔΨm in the absence of increased respiration333. Subtle 
differences in intrinsic ΔΨm have been linked to altered cellular function in cancer cells339.  
This reflects the heterogeneity in energetic status of tumour mitochondria and may be linked to 
therapeutic response340.  
A hyperpolarised ΔΨm has been associated with tumour progression282, 293, 341 and may therefore 
possibly confer a survival advantage. Neurons displaying a hyperpolarised ΔΨm were found to be 
resistant to excitotoxic injury342. Similarly, Bcl-2 overexpression, which is common in tumours and 
which was associated with elevated ΔΨm, resulted in increased survival of mouse fibrosarcoid cells 
after exposure to tumour necrosis factor343. Conversely, tumour cells with induced resistance to 
cisplatin showed increasing ΔΨm with increasing resistance344. It has been suggested that cells with 
high ΔΨm may be rationally targeted in cancer therapy345.  
2.4.1.3.1. Measurement of ΔΨm with JC-1 
The lipophilic fluorescent stain, JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide) 
can be used to determine ΔΨm in live cells346, 347. JC-1 has a broad excitation spectrum and an 
emission maximum at 590 nm. It diffuses through cell and mitochondrial membranes and, being 
cationic, accumulates in the negatively charged matrix of mitochondria with intact ΔΨm to form red 
fluorescent j-aggregates348. At lower concentrations JC-1 monomers are green and may be 
distributed throughout the cytoplasm. JC-1 is a ratiometric dye and thus the red to green (R:G) 
fluorescence ratio is an indication of ΔΨm347. In addition, the red fluorescence value (j-aggregate 
formation) as a measure of the abundance of polarised mitochondria per cell, can also be used 
independently as a measure of the functionality of the mitochondria346, 349.  
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Measurement of ΔΨm in isolation may be a poor assessment of mitochondrial function, given the 
inconsistencies between ΔΨm and mitochondrial respiration. The inclusion of specific measures of 
OXPHOS and respiratory capacity give a more holistic assessment350. For example, polarographic 
measurement of O2 consumption allows effective measurement of mitochondrial function, which 
can be analysed in conjunction with ΔΨm. 
2.4.1.4. Radiation-induced effects on mitochondrial function 
Numerous effects on mitochondrial function have been described after irradiation. The influence of 
ionising radiation on respiration includes alterations in oxygen consumption42, 63, 351, OXPHOS enzyme 
activities56, 153, 352, 353 and ATP production40, 42. Similarly, observations of altered ΔΨm57, 149, 354 and 
mitochondrial biogenesis352 including mtDNA copy number 55, 67, 355, 356 have been documented.   
Local heart irradiation in a rat model reduced ΔΨm, basal O2 consumption and LEAK state respiration 
although the RCR remained constant63. In addition, mitochondrial mass increased and a heightened 
sensitivity to swelling and mitochondrial permeability transition was observed63. Similarly, 
mitochondria in mouse hearts after 2 Gy (x-ray, 200 kV) appeared intact and healthy, however, 
functional defects, including increased ROS, decreased respiration and enhanced oxidation of 
mitochondrial proteins were observed61. Transformed small airway epithelial cells showed reduced 
O2 consumption and ATP production and increased ROS after alpha particle irradiation353. 
It has been reported that the OXPHOS complex IV was particularly sensitive to both direct irradiation 
and exposure to irradiated cell conditioned medium56. In another study by the same investigators, 
recovery from an initial decrease in respiration was associated with an increase in mitochondrial 
mass, suggesting compensatory mitochondrial biogenesis352. In A549 cells, an increase in ΔΨm 
occurred after 10 Gy irradiation and was followed by an increase in O2 consumption and ATP 
production, as well as mitochondrial biogenesis42. In addition, radiation-induced effects were 
observed in a highly radioresistant glioblastoma cell line, including increased ΔΨm and upregulated 
expression of three mitochondrially-encoded genes necessary for OXPHOS40. Similarly, an increased 
expression of mitochondrial proteins of heart cells after 3 Gy whole body irradiation of mice was 






Increased mtDNA copy number, which may also be compensatory, has been shown after irradiation 
of cells in culture353, mice355, 356 and humans67. The mtDNA common deletion (4977bp) has been 
observed after irradiation and occurred frequently in radiosensitive fibroblasts68. 
Interestingly, low dose irradiation of 10 cGy caused an increase in mitochondrial protein import 
while 4 Gy decreased mitochondrial protein import, thus altering mitochondrial function and 
indicating differential effects depending on radiation dose149. Although variable, these observations 
suggest that cellular response to radiation damage involves adaptation of mitochondrial 
functionality. 
2.4.1.5. Does inherent mitochondrial functionality influence radiosensitivity? 
The influence of mitochondrial function on radiosensitivity has been investigated using cells that 
have been depleted of mtDNA or that contain mtDNA mutations, however, the results have been 
inconclusive. Rho0 (mtDNA-depleted) cells appeared to be more radioresistant as assessed by 
clonogenic survival156, 158 and micronuclei analysis358-360. However, no difference in clonogenic 
survival was found between irradiated Rho0 cells and those containing mtDNA (Rho+)157, 358-360.  
Rho0 cells also displayed reduced apoptosis155, 158 and ΔΨm155. Rho+ cells, cells with mutant mtDNA 
and Rho0 cells had high, intermediate and low radiation sensitivity, respectively, which correlated 
with ATP level358, 359. In general, differences in cell cycle regulation were also found after mtDNA 
depletion. A decrease in the number of cells in S-phase was observed in Rho0 cells156. In addition, 
mtDNA depletion suppressed the radiation-induced G2-checkpoint activation155, 156. However, other 
studies have reported no cell cycle effects157, 158.  
The radiosensitivity of certain mouse strains has been associated with mtDNA copy number356. 
Increased sensitivity to mitochondrial permeability transition pore opening was found specifically in 
radiosensitive mouse strains and offspring from radioresistant mouse strains displayed mitochondria 
that were resistant to swelling by calcium356.  
Mitochondrial membrane hyperpolarisation has been linked to increased radiation sensitivity in 
MCF7 breast cancer cells361. In addition, irradiated immortalised human lymphocytes (10 Gy) were 
shown to undergo loss of ΔΨm after an initial hyperpolarisation and maintained a population of cells 






2.4.1.5.1. Evidence from mitochondrial diseases 
Cells from patients with mitochondrial diseases, such as Leigh’s syndrome and Leber’s optic atrophy, 
showed differences in gene expression related to regulation of energy and DNA damage response to 
ionising radiation. Such patients were shown to be hypersensitive to radiation with increased 
induction of chromosomal aberrations and a reduced mitotic index, which suggests an enhanced 
G2/M checkpoint arrest364, as well as an increased tendency towards apoptosis196.  
However, although Leigh’s cells also showed increased radiosensitivity as determined by clonogenic 
survival, Leber’s cells were more radioresistant, potentially as a result of an observed greater repair 
capacity41. In this study, Leigh’s cells were characterised by an ATP6 gene mutation and reduced ATP 
levels, which may affect repair capacity. Mutant cells showed reduced induction of repair proteins 
and an increased expression of apoptosis-related genes suggesting that mitochondrial dysfunction 
may limit the ability of cells to repair damage and preferentially induce apoptosis41, 196. Leber’s cells 





2.5. Mitochondria as dynamic organelles 
Mitochondria constantly adapt to their environment and cellular conditions through changes in 
distribution and morphology. Accordingly, cells tend to maintain a predominantly fused or 
fragmented state depending on factors such as energy requirements365-368, microenvironmental 
conditions369, 370 and cell cycle phase137, 144, 371.  
Discovery of mitochondrial dynamics 
Depictions of mitochondria as individual, oval-shaped structures, commonly found in textbooks, came 
from an inability to observe 3-D structure within 2-D electron micrographs. These images relied on thin 
sections of tissue and scientists were observing cross-sections through tubular mitochondria, which in 
reality would form part of a network of interconnected mitochondrial filaments (Figure 2.7). It is 
interesting that, despite this misconception, the name ‘mitochondria’, derived by Benda in 1898, 
accurately describes this organelle274. Derived from the two Greek words “mitos” (thread) and “chondros” 
(granule) which together describe granules forming threads, the term ‘mitochondria’ hints at the dynamic 
nature of this organelle.  
Mitochondrial dynamics includes the processes of fusion and fission of mitochondria that result in fused 
networks and fragmented structures, respectively. The concept of a dynamic organelle was later 
strengthened when Lewis and Lewis (1914)372 reported not only filaments and granules but also 
“anastomosing threads and networks”. They noted that mitochondria were constantly changing shape and 
position, and reported that granules were able to fuse together to form “rods or chains”, elongate into 
threads and networks, and then “break down into threads, rods, loops and rings” again372. Other 
observations of rod- or thread-like and branched organelle structures also suggested plasticity of 
mitochondrial morphology373-375. With the invention of the phase contrast microscope in the 1930’s376, 
phase cinematography allowed the visualisation of movement and change in living cells. Bereiter-Hahn et 
al. (1990)377 reported on numerous studies that commented on the mobility of mitochondria and their 
ability to fuse and divide including studies by Zollinger, Frederic & Chevremont, Pomerat, Lefeber & Smith, 
Gey, Tobioka & Biesele and Rose between 1950 and 1960. A defining paper by Hoffman and Avers 
(1973)378 introduced the concept of the mitochondrion as a single organelle made up of branches. 
Improved microscopy techniques and the visualisation of cellular structures using fluorescent staining and 
live cell imaging, brought new understanding of the dynamic nature of the mitochondrion52, 379-381. Rather 
than the static organelles observed in electron micrographs, mitochondria were shown to form a network 
that constantly changes shape and connectivity to meet metabolic requirements52. The processes of 
mitochondrial fusion and fission were thus established as integral to cellular physiology. 
 
- Historical interest - 
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2.5.1. Mitochondrial proteins regulating fission and fusion 
Mitochondrial homeostasis is governed by proteins that allow fragmentation (fission) and fusion of 
mitochondrial segments382, 383. A number of GTPase-containing proteins, including dynamin-related 
protein 1 (DRP1), hFis1, mitofusins (MFN) 1 and 2 and OPA1 have been identified as regulators of 
mitochondrial fission and fusion, respectively. A brief description of these proteins follows with a 







2.5.1.1. Outer membrane fusion proteins: MFN1 and 2 
Mitochondrial fusion is required to balance the ongoing opposing process of mitochondrial fission 
and is regulated by two mitofusins, MFN1 and 2382, 384-386. A fusion-related gene, fzo (“fuzzy onions”) 
was first described in Drosophila melanogaster387. The name relates to the appearance of 
mitochondrial aggregates during meiosis that form a “spherical Nebenkern” resembling an onion 
slice387 before elongating during flagellum formation. Drosophila mutants for fzo are sterile and 
showed defects in Nebenkern formation. The yeast “fzo” ortholog was shown to be similarly involved 
in mitochondrial fusion388. The fzo protein, a large GTPase, was the first of a novel family of 
transmembrane GTPases to be assigned a function387. 
Overexpression of MFN1 or 2, the human homologs of the fzo proteins, results in elongated 
mitochondria384. Complete deficiencies of either MFN1 or 2 in developing zygotes lead to embryonic 
lethality, however, there is some redundancy present, with overexpression of one mitofusin 
compensating partially for deficiency of the other389, 390. The two fusion proteins have distinct roles 
in the fusion process. MFN1 has the role of tethering two opposing mitochondrial membranes while 
MFN2 appears to be important at later steps in the fusion process and have a regulatory function20, 
391-393 (Figure 2.8). A role for MFN2 in tethering the endoplasmic reticulum (ER) to the mitochondrion 
has also been proposed394, 395. 
Figure 2.7. Fluorescence image of a 
filamentous mitochondrial network.  
A549 lung cancer cell stained with 





Figure 2.8. Schematic representation of mitochondrial fusion and fission (own illustration). 
Fragmented mitochondria become fused by mitofusins MFN1 and 2 and OPA1. Fission of 
mitochondria occurs by DRP1 and FIS1. OM = outer membrane. IM = inner membrane.  
 
Mutant MFN1 cells display spherical, fragmented mitochondria of uniform size while, in contrast, 
MFN2 mutants have mitochondria of variable size and increased diameter386, 389. MFN2 mutants also 
display alterations in mobility showing random, Brownian-type movement instead of the typical 
directed movement along microtubule tracks396, 397. Interestingly, overexpression of mitofusin 
proteins leads to mitochondrial fragmentation and clumping after an initial increase in fusion. This 
suggests a threshold level of mitofusin activity398.  
The fusion process is sensitive to mitochondrial function. Fusion of the outer membrane is 
insensitive to the metabolic status of mitochondria, however, inner membrane fusion is related to 
OXPHOS activity399, 400. Reduction in mitochondrial fusion in mammalian cells was not found to 
translate into any associated defect in respiration or the loss of mtDNA. A subset of mitochondria, 
however, displayed associated loss of ΔΨm and various authors have suggested that an intact ΔΨm 
is required for membrane fusion401-403, although this requirement may be limited to inner 





2.5.1.2. Inner membrane fusion protein: OPA1 
The mitofusins are responsible for outer membrane fusion while OPA1 (optic atrophy type 1) gene, 
the human homolog of yeast mgm1p, enables fusion of the inner membrane406, 407. OPA1 exists  
in eight different isoforms408-412 consisting of both long (l-OPA1) and short (s-OPA1) forms and 
mutations in this gene cause autosomal dominant optic atrophy413, 414.  
Cells with OPA1 insufficiency display fragmented mitochondria with loss of ΔΨm and altered  
cristae morphology. Knockdown of OPA1 using siRNA resulted in cytochrome C release and 
spontaneous apoptosis, supporting the notion that cristae remodelling is necessary for  
cytochrome C release220, 415.  
OPA1 was able to protect against apoptotic cell death even in the absence of MFN1, suggesting that 
the protective effect of OPA1 is not related to its role in fusion220. Moreover, a number of additional 
studies have suggested that mitochondrial fusion is a protective mechanism20, 416-419. It appears that 
regulation of the release of cytochrome C can be linked to mitochondrial fusion via involvement of 
ATP-synthase. The F1F0-ATP synthase has been shown to be involved in regulation of cristae 
morphology420 and Mgm1p stabilises Tim11p, a protein necessary for assembly of F1F0-ATP synthase 
subunits421.  
2.5.1.3. Fission protein: DRP1 
Dynamin-related protein 1 (DRP1) is the primary mammalian fission-related protein that was 
identified and characterised by Imoto et al. (1998)422 as being similar to the yeast vsp1p, a protein 
present in the Golgi apparatus to aid vacuolar protein sorting. DRP1 was initially described as a 
protein that affected mitochondrial distribution in mammals423. Dynamin-like proteins responsible 
for the maintenance of mitochondrial morphology and distribution have been described by a 
number of investigators, who each provided a synonym for DRP1, namely DNM1p in yeast424, 
DVLP425, DLP1 in mice426 and DYMPLE in a scleroderma patient427.  
DRP1 belongs to the dynamin superfamily, which are large GTPase proteins responsible for 
endocytosis and protein trafficking at various cellular locations428. In addition to mitochondrial 
fission, DRP1 was shown to be involved in peroxisomal division429. DRP1 is regulated through  
S-nitrosylation, ubiquitination, phosphorylation and SUMOylation430. Overexpression of DRP1 in C. 
elegans caused increased mitochondrial fission and DRP1 was shown to be responsible for outer 
membrane but not inner membrane fragmentation431.  
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Additional evidence in cultured mammalian cells showed that DRP1 can tubulate and constrict 
membranes in a similar fashion to dynamin proteins432. Mutant proteins were shown to result in 
increased fusion in Cos7 mammalian cells despite no alteration in the rate of fusion433.  
DRP1 mutation has been shown to induce senescence434. The loss of DRP1, and associated loss of 
fission, may not necessarily result in the loss of mitochondrial function, as the import of 
mitochondrial proteins has been shown to be maintained in dnm1-null yeast424. However, extended 
periods without mitochondrial division may lead to an accumulation of mutant mtDNA clones, 
eventually leading to loss of function435, 436. Mitochondrial membrane potential has been shown to 
be attenuated on DRP1 depletion24 but, in contrast, ΔΨm may also be increased437.  
2.5.1.3.1. DRP1 is associated with apoptosis 
Frank et al. (2001)15 described a novel role for dynamin proteins by implicating DRP1 in the 
regulation of cell death. They showed that staurosporine (STS)-induced DRP1-dependent fission was 
reduced in cells with mutant DRP1. The loss of ΔΨm observed during STS-induced apoptosis was also 
shown to require DRP1.  
Radiation-induced apoptosis in normal and tumour cells was similarly reduced after high doses  
(200 Gy). Mitochondria became enlarged and retained both their tubular morphology and ΔΨm, 
whereas cells with wildtype DRP1 displayed fragmented mitochondria that excluded a ΔΨm 
dependent dye15. In addition, in DRP1 mutated cells that were treated with STS, cytochrome C 
showed punctate staining, suggesting a lack of apoptotic response. In contrast, diffuse staining was 
observed in wildtype cells corresponding to the release of cytochrome C. Reduction in cytochrome C 
release with loss of DRP1 was confirmed by other investigators217, however, apoptosis was delayed 
but not completely abolished, suggesting that mitochondrial fragmentation was not necessarily 
required for apoptosis217, 438.  
DRP1, primarily a cytoplasmic protein, was shown to associate with the outer mitochondrial 
membrane after apoptosis induction at discrete foci that correspond to scission points431. Both Bax 
and Bcl2, important proteins involved in the regulation of apoptosis, have also been shown to 
interact with DRP1218, 221 suggesting a role for DRP1 in apoptosis. In addition, the involvement of Bax 
in membrane scission was suggested218 and overexpression of Bax alone was shown to induce 





A role for DRP1 in cristae remodelling to allow cytochrome C release has been proposed439. Bid or 
Bik-induced cell death that results in release of cytochrome C through the activation of Bax or Bak440, 
caused recruitment of DRP1 to the mitochondria with subsequent cristae remodelling415, 439. It is 
interesting to note that bid-induced cell death could be prevented by DRP1 knockdown438, 441.  
2.5.1.3.2. ER-DRP1 association 
There is evidence for ER and DRP1 interaction. The ER has been shown to facilitate DRP1 constriction 
of membranes at mitochondrial fragmentation scission sites442, 443 and therefore is also important in 
mitochondrial dynamics. 
Staining of the ER with Rab1, a Golgi- and ER-associated membrane protein, in conjunction with 
DRP1 staining gave a pattern of DRP1 foci interspersed with Rab1 proteins426. Other associations 
between DRP1 and the ER have been proposed and may be significant in the cellular stress 
response442, 444, given the prominent role of the ER in this regard. The release of Ca2+ from the ER, 
which may act as a signal for apoptosis, was associated with the recruitment of DRP1 to 
mitochondria17, 445.  
2.5.1.3.3. Additional fission-related proteins 
In yeast, three mitochondrial-associated proteins regulate fission, namely Dnml1, Mdv1p and Fis1p. 
Mdv1p was shown to form a complex with Dnml1446 however only Fis1p was shown to be directly 
involved in the assembly and function of DRP1 as mutant Fis1p inhibits fragmentation447.  
Structural characterisation of the first mammalian homolog, hFis1, suggested that this protein was a 
molecular adaptor for DRP1448. Although not localised to scission sites, hFis1 encompassed the 
mitochondrial outer membrane and formed a scaffold for protein-protein interactions218, 448. 
Reduced expression of hFis1 has been associated with elongated mitochondria and cellular 
senescence449-451. Decreased fission leading to increasingly fused mitochondria and interaction with 
DRP1 suggest a role for hFis1 in DRP1 recruitment452.  
When expressed in cells in culture, hFis1, was shown to induce fragmentation with associated 
cytochrome C release and apoptosis, in the absence of an increase in DRP1453. In addition, 
downregulation of hFis1 inhibited apoptosis to a greater extent than downregulation of DRP1454. 
Further, spontaneous apoptosis in HeLa cells, induced by loss of OPA1, was shown to require 
hFis1454. Additional proteins that have been associated with mitochondrial fission include Endophilin 




2.5.2. Techniques used to study mitochondrial fusion and fission dynamics 
2.5.2.1. Membrane potential-dependent dyes 
The examination of dyes that rely on differences in ΔΨm460 led to the development of useful 
fluorescent lipophilic cationic stains for assessment of mitochondrial morphology, including 
Rhodamine 123461, TMRM/TMRE (tetramethylrhodamine methyl/ethyl ester)462, DiOC6 (3,3'-
dihexyloxacarbocyanine Iodide)463 and the more photostable rosamine CMXRos stains379. As a result of 
their indirect dependence on respiration, these stains are useful for assessment of mitochondrial 
function in addition to morphology464. 
Morphological assessment of mitochondria using MitoTracker® Red, a rosamine stain, has been used 
extensively for the investigation of mitochondrial dynamics. MitoTracker® Red vital staining, which 
was used in this study, requires live cells for uptake but remains well-retained after fixation379. 
Various methods have been described for determination of the proportions of fusion and fission in a 
population of cells, for example, the identification of the proportions of cells with fused, 
intermediate or fragmented mitochondria465-467; image thresholding analysis to determine the level 
of fusion or fission221; quantification of morphology based on mitochondrial length468 and analysis of 
shifts towards either fusion or fission469.  
Such dyes are commonly used for live staining of mitochondria, however, careful handling is 
required to maintain mitochondrial integrity. Staining and imaging should be conducted at 
physiological temperature and the overall processing time should be minimised to avoid artifacts. 
Excessive exposure of cells to these dyes may damage mitochondria leading to structural and 
morphological changes such as fragmentation.  
Fluorescence imaging of live cells is useful as it allows detection of fine mitochondrial structure, 
however, excessive exposures may lead to photo-toxicity. The use of fluorophores of longer 
wavelengths or two-photon excitation microscopy may decrease photo-toxicity allowing  
continuous imaging of cells for extended periods. 
Laser scanning confocal microscopy (LSCM) is often used to obtain sharp images that display 
superior detail than obtained using conventional fluorescence microscopy. LSCM allows the 
collection of serial optical sections that are assembled into a single, clear image, which is  
particularly important for objects with a significant depth of focus. In addition, spatial  
arrangement of mitochondria can be observed using 3-D image construction.  
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In conventional microscopy for imaging mitochondria, the use of flattened, adherent cells, which 
have a narrow depth of focus, can produce good quality images. Stain- and illumination damage- 
induced artifacts can be avoided by prompt fixing of cells after staining. However, photobleaching 
remains an important factor that limits imaging time. The type of fixative used and the tonicity of 
the incubation solutions are important to maintain native mitochondrial morphology. 
Paraformaldehyde fixation has been shown to be the most reliable as glutaraldehyde fixation leads 
to shrinkage of mitochondria and methanol has a precipitatory effect on membranes470. 
2.5.2.2. Morphological analysis based on detection of mitochondrial proteins 
Mitochondria can be visualised by immunocytochemistry using labelled antibodies to mitochondrial 
membrane proteins, for example, TOM20, an outer mitochondrial membrane receptor protein. In 
addition, transfection of mitochondrially-targeted fluorescent proteins, such as DsRed2 and 
mitoGFP, has been used to label mitochondria471, 472. Labelled mitochondria can then be followed 
over multiple passages using this technique, however, the transfection rate is frequently less than  
90 % implying that a proportion of cells will not be available for microscopic evaluation. Techniques 
using stable, rather than transient expression of marker proteins are recommended due to stress-
related factors that may influence mitochondrial morphology473. 
Fluorescence recovery after photobleaching is a technique that uses fluorescent stains or labelled 
mitochondrial markers to measure mitochondrial continuity as an indication of the extent of fusion. 
The method involves localised photobleaching of an area of the mitochondria and subsequent 
observation of the re-establishment of fluorescence that would suggest movement of molecules 
from connected regions.  
2.5.3. Mitochondrial dynamics and cellular function  
The mitochondrial morphological phenotype, which reflects mitochondrial dynamics, may be a 
valuable indicator of cellular physiological status474-476. Characterisation of fusion and fission has the 
potential to provide insight into the metabolic and functional status of different cancers.  
Mitochondrial dynamics, cellular function and radiosensitivity may be interrelated. In addition to 
factors that influence intrinsic radiosensitivity generally477 differences in the response of tumours to 
therapy are known to be affected by several factors that have significant effects on mitochondrial 
status. Such factors include microenvironmental features such as hypoxia478, 479, as well as position in 




In accordance with the mitochondrion’s role to provide energy through OXPHOS, mitochondrial 
morphology is closely linked with cellular respiration484. Highly fused mitochondria generally have a 
higher OXPHOS capacity399, 475, 485 and inhibition of respiration has been shown to cause 
fragmentation of the mitochondrial network486, 487. 
In addition to respiratory function, ΔΨm, another functional measure, has been associated with 
mitochondrial morphological status. From initial studies, it was shown that electrically polarised 
mitochondrial membranes are required for mitochondrial fusion403, 488, 489, however, some authors 
suggest that the association is indirect396, 400. 
Inhibitors and uncouplers of the respiratory chain, mutations in respiratory complexes and loss of 
mtDNA have been shown to cause a loss of ΔΨm and fragmentation of the mitochondrial network474, 
490. In contrast, the use of oligomycin, also induced fragmentation, in spite of an associated increase 
in ΔΨm491, 492. This fragmentation was suggested to be a result of OPA1 inactivation by decreased 
ATP levels and shows that an intact ΔΨm alone is not sufficient to maintain mitochondrial fusion396, 
493.  Decreased ΔΨm, generally observed during apoptosis, is also associated with mitochondrial 
fragmentation18, 494. It is generally acknowledged that healthy respiring cells typically display an 
intact ΔΨm of 150-180 mV495, while cellular stress496, respiratory dysfunction497 and cell death498 
processes lead to loss of ΔΨm. Thus, measurement of ΔΨm may provide an indication of 
mitochondrial and cellular fitness. 
In general, cell death and mitosis have been associated with mitochondrial fragmentation. Cellular 
stress resistance or damage, in particular the ER-initiated cellular stress response has been linked  
to fusion. It has been observed that a shift in the balance of mitochondrial dynamics towards 
mitochondrial fusion in different cell types increases stress resistance19, 416, 434, 454. For example, 
senescent cells, which typically display networked, fused mitochondria434, 449, 450, are resistant to 
cytotoxic agents including radiation449, 499. Despite the fused state senescent cells have been shown 
to display reduced ΔΨm and reduced respiration suggesting this fusion may not be metabolically-
induced500.  
Hypoxia has been shown to enlarge tubular mitochondria in a reversible, Hif-1-independent manner 
in a range of cancer cells and normal fibroblasts419. Enlarged mitochondria maintained both 
respiratory function and ΔΨm. Apoptosis resistance observed in colon cancer cells was linked to 
MFN1 induction, suggesting that the enlarged mitochondria were a consequence of increased or 




2.5.3.1. Variation of mitochondrial fusion and fission through the cell cycle 
The cell cycle is controlled by differential expression of regulatory cyclins and the activation and 
inactivation of cyclin-dependent kinases. Mitochondria also appear to be influenced by such 
processes. Dynamic changes in mitochondrial morphology are evident during the cell cycle  
(Figure 2.9). In general, mitochondrial fusion has been associated with interphase, while fission has 
been proposed as a requirement during mitosis150, 502-504. However, filamentous mitochondria have 
been observed in all phases of the cell cycle, becoming condensed and localised to the perinuclear 
region at prophase505. 
Proteins involved in mitochondrial fusion and fission, including MFN1 and 2 and DRP1, have been 
shown to be regulated by proteins that govern cell cycle progression (Figure 2.9). Importantly, 
mitotic fission is coordinated with the cell cycle and may be considered a cell cycle checkpoint 
itself443, 503. During interphase, APC/C-Cdh1 facilitates ubiquitination of DRP1 thereby inhibiting 
mitochondrial fission. DRP1 levels rise at G1/S following inhibition of APC/C-Cdh1 by cyclin D/E 
complexes and activation of DRP1 occurs by cyclin B-Cdk1-mediated phosphorylation in mitosis.  
In contrast, MFN1 is inhibited by cyclin A/B-Cdk1 as cells prepare for mitosis.  
Besides changes in fission and fusion, relocation of mitochondria to the cell periphery prior to 
cytokinesis occurs to ensure proper segregation of mitochondria to daughter cells506. Such 
redistribution of mitochondria is supported by observations of mitochondria being excluded  









Figure 2.9. Cell cycle related changes in mitochondrial dynamics and interaction of 
fusion and fission proteins with cell cycle regulatory proteins. [From: “Fueling the Cell 
Division Cycle, Salazar-Roa and Malumbres (2017)503-used with permission]. 
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Proliferation of vascular smooth muscle cells (VSMC) was reported to be dependent on 
mitochondrial dynamics. Cell division was inhibited when mitochondrial fusion or fission was 
reduced507. Higher expression of the mitochondrial fusion protein, MFN2 and netlike mitochondria 
has been found in G0/G1 relative to S-phase144, 508, suggesting cyclical changes in mitochondrial 
dynamics. Overexpression of MFN2 caused G1 cell cycle arrest while knockdown of MFN2 caused  
S-phase arrest. The investigators suggested that MFN2 controls VSMC proliferation through 
mitochondrial remodelling.  
Normal rat kidney cells at the G1-S border were found to form a transient hyperpolarised network of 
mitochondria distinct from the mixture of fused and fragmented mitochondria that were observed 
within the individual phases137. Increased connectivity at the G1-S border may be consistent with the 
increased oxygen usage reported from early to late G1 and reflect the increased ATP requirement 
for initiation of S-phase509. However, increased mitochondrial fusion was also associated with 
increased cyclin E, a requirement for G1-S transition144. Mitochondrial fusion may therefore be 
required for such transition to provide the necessary increase in ΔΨm and upregulation of cyclin E. 
Such a hyperfused mitochondrial network, however, was found to be transient137.  
In contrast, maintaining a fused morphology prevents cell cycle progression in a manner that mimics 
the effects of cyclin E overexpression144, 510. Mitochondrial hyperfusion at the G1-S border may, 
therefore also be considered a mitochondrial checkpoint. In addition, damage-induced 
mitochondrial fragmentation may be a mechanism used to reinforce the G1/S checkpoint by 
opposing the formation of such a hyperfused state required for transition.  
Mitochondrial cycling, although related to cell cycle transition, appears to be largely an independent 
process371. Mitochondrial turnover includes biogenesis and a type of programmed organellar death, 
mitophagy371, 511. Biogenesis occurs primarily in G1502, however, morphology and content are 
modified throughout the cell cycle in response to the metabolic needs of the cell (Figure 2.10)371.  
A drastic reduction in mitochondrial content has been described following mitosis502. 
There appears to be both cellular and organellar control of fission371. From G1 to M-phase, ΔΨm was 
found to be gradually increased with a reduction in ΔΨm following division502 which may be related 
to mitosis-associated fission. Fragmentation of the mitochondrial network which occurs as a result of 
the dynamic nature of mitochondrial morphology may also act as a quality control mechanism. 
Mitochondria that are depolarised and are unable to recover their ΔΨm do not fuse with polarised 













Figure 2.10. Regulation of mitochondrial biogenesis and autophagic elimination requires cell 
cycle independent fission in addition to mitosis-associated fragmentation. [From: “Organellar 
vs cellular control of mitochondrial dynamics, Hyde B, et al. (2010)371-used with permission]. 
 
2.5.4. Mitochondrial dynamics in tumours 
Dysfunctional mitochondria and mtDNA mutations are commonly described in cancer295, 513-515, 
however few studies report on the role of fission and fusion in tumour cells. It was suggested almost 
100 years ago516 that, in general, tumour tissue contained more fragmented mitochondria while 
filaments were associated with normal tissue. In a review of recent literature, Srinivasan et al. 
(2017)1 suggested that fission was pro-tumorigenic and that inhibition of fragmentation reversed 
specific tumour properties. However, there is no consensus as to whether fission or fusion 
predominates in cancer cells. It is likely that mitochondrial dynamics is cancer type specific.  
2.5.4.1. Ultrastructural changes 
Mitochondria from cancer cells have been reported to display ultrastructural changes369, 517  
although these may reflect metabolic rather than innate differences.  
Hurthle cell and other thyroid adenomas were shown to contain abundant, irregularly-shaped 
mitochondria518-520. Oncocytic tumours of the thyroid displayed large, swollen, densely-packed 
mitochondria521. Shape, size and structural anomalies have also been described in mesotheliomas522 
and leukaemia cells, which were found to be respiration deficient523.  
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Malignant papillary cystadenoma lymphomatosum (Warthin’s tumour) displayed large, swollen, 
densely-packed mitochondria with abnormal cristae that formed concentric rings of cup-shaped 
mitochondria524. A low level of fission was reported in astrocytomas and gliomas that were found to 
display heterogeneous mitochondrial morphology, often swollen with disorganised cristae525. 
Similarly, extensive mitochondrial pleomorphism was observed in tumour-derived cell lines, where 
mitochondria were more abundant and enlarged with abnormal cristae structure520.  
2.5.4.2. Biogenesis, localisation and protein expression 
Reports describing mitochondrial dynamics in cancer also include those that assess mitochondrial 
biogenesis, localisation and expression of proteins related to fission and fusion. 
Mitochondrial dysfunction in cancer may, in certain cases, result from defective expression of 
oncogenes3. Differences in mitochondrial mass have been observed in various cancers and between 
individual tumours and regulation of mitochondrial biogenesis by c-Myc, a known oncogene, has 
been described526. Immunohistochemical staining demonstrated variable mitochondrial staining of a 
range of primary human breast cancer tissues3, 521, indicating differences in mitochondrial biogenesis 
and therefore content.  
A reduced mitochondrial content was observed in carcinomas of the liver527. In hypoxic tumours, 
activation of HIF-1 induced Mxi-1, a c-Myc repressor protein resulting in reduced mitochondrial 
biogenesis526, 528. In pancreatic cancer, expression of Ras or activation of the mitogen-activated 
protein kinase pathway results in Erk2 phosphorylation of DRP1 leading to increased fission529. 
Inhibiting DRP1 phosphorylation in this model prevented tumour growth. Besides oncogene 
expression, dysregulation of genes involved in mitochondrial function occurs in cancer.  
2.5.4.3. mtDNA copy number 
Abnormal mtDNA copy number and mutations in both mtDNA and nuclear-encoded mitochondrial 
genes have been described in cancer studies. Mutations that reduce cytochrome C oxidase activity 
have been associated with tumours of the breast, colon, pancreas and prostate324, 530-534. Similarly, 
low mtDNA copy number has been associated with cancers of the breast535, prostate536 and 





2.5.4.4. Cause or effect? 
Mitochondrial dysfunction may be either a cause or consequence of tumour development539. The 
protein kinase B (AKT) survival pathway is beneficial to cancer cells and is activated in the presence 
of mitochondrial respiration defects482. Similarly, a respiratory complex 1 deficiency promotes 
tumourigenesis through activation of the AKT pathway and induction of oxidative stress540, 541 or 
inhibition of apoptosis514. Depleted mtDNA in C2C12 cells has been shown to cause mitochondrial 
retrograde signalling and lead to cellular transformation. Cellular morphological changes that are 
characteristic of tumours were accompanied by an increase in DRP1 localisation to the mitochondria 
and decreased OPA1 expression resulting in an increase in fragmentation1. In addition, either the 
prevention of fusion or forced fusion may result in reduced respiration and O2 consumption474, 475. 
2.5.4.5. Apoptosis-related proteins 
Apoptosis-associated proteins were also found to influence mitochondrial dynamics in tumours.  
The apoptotic-resistance protein, survivin is situated in the mitochondrion and is highly expressed in 
many tumours542. In neuroblastoma cells, survivin was shown to recruit DRP1 to the mitochondria 
and induce fragmentation543. The loss of DRP1 has been associated with apoptosis in colon cancer 
cells24. Deregulated expression and phosphorylation of DRP1 and decreased MFN2 leading to 




2.5.5. Radiation-induced effects on mitochondrial morphology 
As mentioned previously, mitochondrial structural changes in response to radiation, including 
ultrastructural damage, swelling, vacuolation and fragmentation of the membranes, have been 
reported53. A large proportion of the studies, however, were conducted prior to the identification  
of specific, reliable mitochondrial morphological stains, which came into use in the 1980s.  
Many of these early descriptions of irradiated mitochondria, however, described mitochondrial 
morphological features, which likely reflect mitochondrial dynamics. For example, morphological 
changes including, longitudinal branching and the formation of clubbed ends and loops, as well as 
the observation of enlarged and giant mitochondria may indicate increased fusion544.  
More recent studies described changes in mitochondrial morphology assessed using fluorescence 
microscopy. In BJ-hTERT fibroblasts and murine mammary gland cells, progressive mitochondrial 
fragmentation occurred in a dose- and time-dependent manner after irradiation with the greatest 
fragmentation occurring 3 days post-irradiation in fibroblasts57, 60. Similarly, cytoplasmic microbeam 
irradiation using high linear energy transfer (LET) particles led to increased fission43, 44. UV-irradiation 
and irradiation using green light (0.3 J/cm2) emitted by a microscope mercury lamp, also resulted in 
fragmentation, as well as perinuclear collapse of the mitochondria219, 221, 449. Mitochondrial 
movement and DRP1 translocation to the mitochondria was also shown to be stimulated after 
irradiation57.  
Changes to mitochondria may not only be the result of direct irradiation. Evidence of a bystander 
effect comes from studies using conditioned medium from previously irradiated immortalised 
keratinocytes. An increase in mitochondrial mass and perinuclear localisation was observed 
following incubation in medium from cells irradiated with 0.5 Gy. Interestingly, these changes were 
not observed using the higher radiation dose of 5 Gy545. 
Alterations in functionality were not consistently associated with changes in morphology. Despite an 
increase in ΔΨm and ATP levels, irradiated (4 Gy) glioblastoma cells did not show an increase in 
mitochondrial mass40. Notably, changes in mitochondria after irradiation have been reported to be 
reversible60. 
In addition, upregulation of mitochondrial biogenesis42, 59 and increases in mtDNA copy number54 
after irradiation have been reported. An augmented oncocytic phenotype, characterised by increased 
mitochondrial biogenesis, and large, irregular mitochondria in patient rectal adenocarcinoma 
samples after radiochemotherapy was observed546.  
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2.5.6. Targeting mitochondria for cancer therapy 
Poor response of cancer cells to many current targeted agents has prompted the development of 
drugs that target alternate pathways8, 547. Mitochondria may provide such novel targets for cytotoxic 
therapy or modulation of other agents.  
2.5.6.1. Mitochondrial targeted agents 
The differences between tumour and normal cell mitochondria may provide an opportunity to 
increase selectivity and reduce side effects of cancer therapy. While current targeted therapies tend 
to be highly pathway-specific, diverse tumour heterogeneity may be more substantially addressed 
using therapies that target mitochondria548, 549. 
The mitocans are a class of therapeutic agents that result in destabilisation of mitochondrial function 
and can be regarded as mitochondrial poisons7. Eight distinct classes of mitocans have been 
proposed8, which include; Hexokinase II inhibitors e.g. 2-deoxyglucose10; BH3 mimetics e.g. 
gossypol9; thiol redox inhibitors e.g. arsenic trioxide or isothiocyanates, e.g. phenylethyl 
isothiocyanate11; VDAC/ANT targeting e.g. ionidamine12; ETC-targeting e.g. tamoxifen550 and α-
tocopheryl succinate (α-TOS)551; lipophilic cations targeting the mitochondrial inner membrane e.g. 
rhodamine-123552; drugs targeting the citric acid cycle e.g. dichloroacetate553 and those that target 
mtDNA e.g. vitamin K313. A number of chemotherapeutic agents have been shown to damage 
mtDNA, including cisplatin, doxorubicin and DNA damaging anthracycline derivatives.  
Certain antibiotics, such as the aminoglycosides, target bacterial ribosomes and can be regarded as 
tissue-specific mitochondrial poisons. It is thought that the cochlea is particularly sensitive to 
reduced mitochondrial function as these antibiotics can cause ototoxicity554. The similarity between 
bacteria and mitochondria (endosymbiotic theory) may partly account for the off-target effects on 
mitochondria and toxicity. Mutations in mtDNA, e.g. the 12S rRNA gene555, which increases 
structural similarity between bacteria and mitochondria, have been shown to increase susceptibility 
to aminoglycoside toxicity554, 556.  
In general, mitocans act by disrupting mitochondrial function, which leads to apoptosis8. It is 
possible that, in general, the toxicity induced by agents that target mitochondria occurs as a result  
of increased oxidative stress. This mechanism has been reported for the induction of apoptosis by  
α-TOS557 and aminoglycoside ototoxicity558, among others. Cancer cells may be specifically 
vulnerable to drugs that cause higher intrinsic levels of ROS as these cells often have elevated  
base-line ROS levels311.  
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2.5.7. Modulators of mitochondrial dynamics 
The morphological make-up of the mitochondrion is the net result of fission and fusion processes in 
the cell in response to intra- and extracellular conditions and stimuli. Mitochondrial morphology 
therefore, not only reflects the physical connectedness of the mitochondria, but is also an indication 
of cellular function. In addition, modulation of mitochondrial morphology has the potential to 
influence cellular functioning, for example, by altering bioenergetic capacity or redox status.  
Modulation of mitochondrial dynamics is a relatively new area of study and few agents have been 
identified that specifically regulate fission and fusion proteins. The inhibition of DRP1 has been 
accomplished most successfully using the mitochondrial division inhibitor, Mdivi-1559. A number of 
other inhibitors of DRP1 or mitochondrial fission have also been investigated. These include, Mdivi-1 
analogues560, 561, calcineurin562, 563, overexpression of dominant-negative (K38A) Drp1 22, 564 and P110, 
a molecule that primarily prevents the interaction between DRP1 and Fis1437.  
Indirect inhibition of mitochondrial fusion and fission has been accomplished using siRNA-mediated 
knockdown of fission and fusion proteins including DRP1, Fis1, MFN1 and 2 and OPA1. Mitochondrial 
morphology can also be altered by stress565, hypoxia566, 567 and certain respiratory inhibitors568, 
among others, which are however, non-specific and often toxic, thus limiting their application.  
2.5.7.1. Mitochondrial division inhibitor-1 (Mdivi-1) 
Mdivi-1 (3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone) is a quinazolinone compound  
(Figure 2.11), which was first described by Cassidy-Stone et al. (2008)559. This compound prevents 
polymerisation of the mitochondrial DRP1 subunits into a spiralled filament that is necessary for 
mitochondrial fragmentation. Mdivi-1 is therefore a useful tool for modulation of mitochondrial 





Figure 2.11. Chemical structure of Mdivi-1  




2.5.8. Cellular responses to Mdivi-1  
2.5.8.1. Effects on mitosis and the cell cycle  
A number of studies have identified Mdivi-1-related cell cycle effects and specific abnormalities in 
mitosis21, 144, 466, 507, 569-573. Cyclin E levels became elevated in normal NRK cells and colon cancer cells 
after short Mdivi-1 exposures with a concomitant increase in S-phase cells144. The same authors 
described mis-alignment of chromosomes during metaphase in colon cancer cells treated with 
Mdivi-1. In contrast, Mdivi-1 inhibition of mitochondrial dynamics in artery smooth muscle cells led 
to a decrease in S-phase cells and an increased G0/G1 population, possibly indicating a G1 arrest507. 
However, this study used a longer (48 h) Mdivi-1 treatment than that described above. Cells 
previously arrested in S-phase may have been released and contribute to the increase in the G1 
population. Consistent with these results, 48 h of hyperfusion induced by overexpression of DRP1 
also resulted in a decrease in cell cycle progression144. In a study by Wang et al. (2015)573, an increase 
in the G2/M population of cells after 30 µM Mdivi-1 treatment was reported for cancer cells, 
however, normal dermal fibroblasts did not display a G2/M arrest.  
Mdivi-1 prevents the inactivation of Cdk1, an important cell cycle regulatory protein, by cyclin B1 
degradation571. In association with cyclin B, Cdk1 controls the G2/M transition, allowing entry of cells 
into mitosis574, 575. Cdk1 partly facilitates this transition by upregulating mitochondrial respiration 
thereby ensuring sufficient energy for cell cycle progression143. Initiation of DNA replication, and 
therefore S-phase transition, has also been linked to Cdk1, particularly in cells lacking Cdk2576.  
Related to this, modulation of the centrosome cycle, in particular centrosome duplication576 and 
separation577, 578 and spindle formation355, have also been linked to Cdk1 activity. In addition, 
chromosome condensation and separation of chromosomes after alignment at the metaphase plate 
relies on inactivation of Cdk1579, 580. Cdk1 also regulates mitotic microtubule dynamics, which are 
related to chromosome separation581.  
2.5.8.2. Cytotoxic effects of Mdivi-1 
Direct cytotoxic effects of Mdivi-1 have been reported for both cancer and normal cells. Increased 
cell death was observed in colon cancer cells with 50 µM Mdivi-1 treatments longer than 5 hours144. 
Similarly, knockdown of DRP1 led to increased apoptosis in colon cancer cells and Mdivi-1 was 
suggested to be useful as a chemotherapeutic agent in colon cancer24. A549 lung cancer cells treated 
with Mdivi-1 showed reduced proliferation and increased apoptosis21, 23, 582.  
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Similarly, decreased survival after Mdivi-1 treatment of breast (MDA-MB-231 and MCF7) and ovarian 
cancer cells (A2780), among others, was observed25, 573, 582, 583. However, reported results for cancer 
cells are variable. For example, no Mdivi-1 toxicity was reported in HL-60 leukaemia cells584, 
however, limited effects were demonstrated in A549 lung cancer, melanoma and osteosarcoma 
cells468.  
There is some evidence of Mdivi-1-induced effects in normal cells. Mdivi-1 reduced survival of small 
airway epithelial cells using doses greater than 50 µM for 6 h or 30 µM for 12 h353. Apoptosis was 
observed in mouse embryonic fibroblasts treated with Mdivi-1469, 585. In addition, toxicity was 
induced in hippocampal and primary neurons with concentrations above 75 and 25 µM, 
respectively441. Primary myoblasts and C2C12 cells also showed increased apoptosis after Mdivi-1 
treatment22.  
There are a number of studies, however, reporting no Mdivi-1 toxicity in normal cells. The cell types 
include vascular smooth muscle cells (VSMC)586, SH-SY-5Y cells587, BV-2 cells588, rat aortic VSMC569, 
spinal cord neurons589, 590 and hESC-human embryonic stem cell-derived neurons591. Some of the 
studies used low doses (1 - 25 µM) or short Mdivi-1 exposures (15 minutes - 1 hour). However, 
minimal toxicity was demonstrated in normal dermal fibroblast cells and melanocytes, even using a 
higher dose of 50 µM468, 583.  
Additional effects of Mdivi-1 include increased function, reduced mobility and transformation 
potential in a range of models. Mdivi-1 enhanced functional recovery after traumatic brain injury in 
mice592. Reduced migration of MDA-MB-436 and -231 breast cancer cells593 and mtDNA-depleted 
C2C12 myocytes1, as well as, attenuated migration of glioblastoma cells564 was shown with Mdivi-1. 
Despite having only a minimal effect on apoptosis in normal and transformed cells, Mdivi-1 
prevented E1A+RASG12V-mediated transformation and reduced clonogenic survival, as well as,  
SV-40-mediated transformation of mouse embryonic fibroblasts469.  
2.5.9. Mdivi-1 as a modulator of cytotoxic agents 
The frequently observed association between mitochondrial fragmentation and apoptosis15, 19, 20 
suggests that inhibition of mitochondrial fission may be protective after cellular injury under certain 
circumstances. Mdivi-1 was found to prevent STS-induced apoptosis as well as Bax-dependent 




Protection by Mdivi-1 against cytotoxic challenge has been demonstrated in a number of in vitro and 
in vivo models. Mdivi-1 was found to reduce or abolish drug-induced cytotoxicity in human 
ovarian594, 595, lung596 and breast597 cancer cell lines as well as a rat astrocytoma cell line598. The 
growth of brain tumour initiating cells (BTIC) from glioblastoma patients in a mouse model was 
inhibited using Mdivi-1 and survival of mice was increased. In addition, Mdivi-1 induced apoptosis in 
BTIC cells but not in non-BTIC cells599. Non-tumorigenic cells were similarly protected against 
cytotoxic agents.  
Protection against ischaemia-reperfusion injury by Mdivi-1 has also been observed in vivo in 
mammalian heart failure models where reduced cardiotoxicity584, 600, smaller infarct size601, 602 and 
improved function603 have been described604.  
Pifithrin-μ-605 and STS-induced585 cell death were reduced by Mdivi-1 in mouse embryonic fibroblasts 
but no effect was observed on BH3-induced cell death585. Other in vivo experiments showed reduced 
pilocarpine-induced seizures606, 607 and reduced neuropathic pain608 in rats. Other systems showing 
similar responses to Mdivi-1 treatment include reduced renal tubular damage609, reduced apoptosis 
in ischaemic retina610, reduced injury from cerebral ocular occlusion and ischaemic injury611-613, 
reduced neuronal injury after acute spinal cord injury589, 614, reduced infarct size, ischaemia-
reperfusion injury and cytotoxicity in neuronal tissue441, 587, 588, 591, 615, 616. 
In contrast to the protective effects detailed above, Mdivi-1 has been shown to enhance the toxic 
effects of certain cytotoxic agents. Combining Mdivi-1 with a range of chemotherapeutic agents led 
to increased efficacy of these compounds. Exposure of breast cancer cells to the combination of 
Mdivi-1 (50 µM) and cisplatin for 2 hours reduced cell number by 70 % when compared to cisplatin 
alone582. The same investigators showed that improved efficacy of a range of chemotherapeutic 
agents was obtained using extended Mdivi-1 exposure times (20 hours)582. In addition, Mdivi-1 
exposure enhanced sensitivity to TRAIL-induced apoptosis in cancer cells23, 583 while sparing normal 
fibroblasts23. Increased loss of ΔΨm and mitochondrial permeability transition pore opening induced 
by ionomycin was observed in mouse embryonic fibroblasts after Mdivi-1 treatment26. 
2.5.9.1. Does modulation of mitochondrial dynamics affect radiation response? 
The Mdivi-1-induced effects on the cellular response to cytotoxic agents described above suggest 
that modulation of mitochondria dynamics may influence cellular response to other cytotoxic 
agents, such as radiation. Some evidence exists that directly implicates mitochondrial fission in 
radiation response.  
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Apoptosis induced by high radiation doses was shown to be significantly less in both a normal and  
a colon adenocarcinoma cell line transfected with a mutant form of DRP1 compared to wildtype 
cells15.   
Radiation-induced apoptosis is an important mechanism that contributes to cellular sensitivity to 
irradiation. The ability of Mdivi-1 to protect against drug-induced apoptosis and apoptosis induced 
by hostile environmental conditions, as described above, may suggest potential for radioprotection 
by Mdivi-1. However, protective effects have generally been observed for low doses of Mdivi-1 or 
short exposure times. At higher Mdivi-1 concentrations, toxicity was often demonstrated, 
particularly in cancer cells. Additional cytotoxic effects from Mdivi-1 may contribute to therapeutic 
efficacy. Synergistic effects of radiation with Mdivi-1 may also be possible.  
As described above, Mdivi-1 has been shown to be associated with rapid progression of cells into  
S-phase144, a more radioresistant phase of the cell cycle. In addition, as mentioned previously, 
initiation of DNA replication is associated with Cdk1 activation576 and Mdivi-1 has been reported to 
activate Cdk1571. Pre-treatment of cells with Mdivi-1 prior to irradiation may therefore be protective. 
However, diverse roles for Cdk1 and the Cdk1-cyclin B complex have been identified143, primarily 
related to progression into mitosis, a radiosensitive phase. Activation of Cdk1 leads to DRP1 
phosphorylation (and activation) inducing mitochondrial fragmentation that is characteristic of 
mitosis503, 504.  
Cyclin B-Cdk1 phosphorylation and activation of respiratory complex 1 with an accompanying 
increase in ATP production is important for cell cycle progression143. This mechanism has recently 
also been associated with radiation-induced damage repair leading to increased survival191. In 
addition, in the context of radiation-induced DNA damage, Cdk1 phosphorylates mitochondrial p53 
thus blocking apoptosis617, 618. Active Cdk1, in contrast, phosphorylates BRCA2619 and 53BP1617, 620 
inhibiting DNA damage repair during G2/M transition. These observations would suggest that  
Mdivi-1 activation of Cdk1 might sensitise cells to radiation damage by promoting cell cycle 
progression into mitosis and prevent an efficient DNA damage response although there is evidence 
that Mdivi-1 can activate ATM pathways572. However, Cdk1 is able to phosphorylate and activate 
MnSOD618, which would be expected to have a protective effect by reducing radiation-induced ROS. 
Indeed, MnSOD has been shown to enhance repair of mtDNA134, 621. Together, activation of cyclin B-




2.5.9.2. Evidence for modulation of sensitivity to radiation and other cytotoxic agents by 
modulation of mitochondrial dynamics 
Little is known about the effects of mitochondrial dynamics on radiosensitivity. The mitochondrial 
morphological status at the time of irradiation may determine either the ability of cells to resist 
initial damage or respond to damage incurred.  
Knockdown of DRP1 expression prior to irradiation of fibroblast cells was shown to reduce the 
number of ionising radiation-induced DNA double-strand breaks that persisted 3 days after 
irradiation58 and prevent radiation-induced fragmentation and loss of ΔΨm57. In addition, DRP1-
deficient cells were demonstrated to be more radioresistant than normal cells58. Similarly, 
knockdown of DRP1 was shown to decrease UV-induced apoptosis in Drosophila embryos622.  
Modulation of fusion and fission proteins has been shown to influence the response of cells to a 
range of cytotoxic agents. Many of these interactions may potentially be similar to those with 
ionising radiation. During apoptosis, Bak has been shown to have a role in regulating mitochondrial 
dynamics through interaction with the mitofusins623. Loss of Bak in normal fibroblasts reduced 
apoptosis induced by STS, cisplatin and azide. In the same study, dominant-negative DRP1 expressed 
in HeLa cells suppressed apoptosis induced by the cytotoxic treatments. It was also shown that cells 
containing fragmented mitochondria were more sensitive to MOMP and apoptosis624. 
Overexpression of mitofusins rendered HeLa cells resistant to azide and cisplatin-induced 
apoptosis19. 
Brief summation 
Mitochondria are indispensable for proper cellular functioning and have been proposed as useful 
targets for cancer therapy. Tumour mitochondria are frequently found to be different both in 
function and content, which may present an opportunity for therapeutic gain. They have important 
roles in cell cycle regulation and in the response of cells to damage, particularly in the initiation of 
apoptosis. Radiation has effects on mitochondrial function and morphology and there is evidence 
that inherent mitochondrial function may influence cellular radiosensitivity. Mitochondrial dynamics 
may have roles in many of the abovementioned processes. Mdivi-1, a mitochondrial fission inhibitor, 
can affect cellular integrity and modulate cellular response. Thus, modulation of fusion and fission 




FORMULATION OF HYPOTHESES 
 
Mitochondria are prominent role-players in an array of cellular processes including those involved in 
the response of cells to radiation. In this study, it was hypothesised that the inherent mitochondrial 
status may influence cellular radiosensitivity. In addition, we hypothesised that modulation of 
mitochondrial dynamics may have the potential to alter cellular radiosensitivity. While there is some 
evidence that mitochondrial dynamics and inherent mitochondrial status, in general, may influence 
radiation response, the relevance of fusion and fission specifically has yet to be elucidated. 
General aims 
1) To characterise and correlate the inherent radiation responsiveness and certain 
mitochondrial characteristics of a range of cancer cell lines 
 
2) To modulate mitochondrial dynamics and investigate the influence thereof on 
radiation response 
 
3) To investigate the effects of Mdivi-1 that may be associated with modulation of 
radiation response  
 
Research Questions 
3.1. Is the radiation responsiveness of cancer cells associated with 
mitochondrial morphology or function? 
We sought to determine the role of mitochondrial dynamics in the radiation responsiveness of 
cancer cells and examined correlations between mitochondrial status, including morphological  
and functional features, and inherent radiation sensitivity. It was hypothesised that the extent  
of mitochondrial fragmentation would correlate with radiation responsiveness. In addition, 





3.2. Does modulation of mitochondrial dynamics influence cellular integrity 
or response to radiation? 
Modulation of mitochondrial dynamics using an inhibitor of mitochondrial fission, Mdivi-1, was used 
to investigate the role of mitochondrial dynamics in cellular radiation response. It has been reported 
that apoptosis is associated with DRP1-mediated mitochondrial fragmentation503, 504 and mutant 
DRP1 protected cells from apoptosis induced by cytotoxic agents15. It was therefore initially 
hypothesised that increased fusion would protect cells against radiation-induced cell death.  
3.2.1. Does Mdivi-1 induce mitochondrial fusion?  
Mdivi-1 has previously been demonstrated to inhibit mitochondrial fission559 and it was 
hypothesised that Mdivi-1 would increase fusion in our cancer cell lines.  
3.2.2. Does inhibition of mitochondrial fission alter survival of cancer cells?  
Having demonstrated inhibition of fission by Mdivi-1 in the experimental model used, the 
consequences of these effects were examined. Given that disruption of mitochondrial dynamics 
affects cellular physiology, it was hypothesised that Mdivi-1 would be cytotoxic.  
3.2.3. Does inhibition of mitochondrial fission influence radiation survival of cancer cells? 
Mdivi-1 has been reported to display both protective595-597 and sensitising23, 582, 583 effects when 
combined with cytotoxic agents. It was therefore hypothesised that Mdivi-1 would similarly 
modulate radiation sensitivity.  
3.2.4. Does inhibition of mitochondrial fission influence repair of radiation-induced 
damage?  
Radiation treatment seeks to exploit differences in repair capacity between tumour and normal 
tissue. It is therefore important to establish the influence of inhibition of fission on cellular repair 
capability in the event that such approaches are applied clinically. It was hypothesised that Mdivi-1 




3.2.5. Does inhibition of mitochondrial fission influence cell cycle dynamics and/or 
radiation-induced cell cycle arrest in cancer cells?  
Given the reported cyclical nature of mitochondrial fragmentation during the cell cycle371, 503, it was 
hypothesised that Mdivi-1 would influence cell cycle dynamics in our model. Specifically, a G2/M 
arrest was hypothesised as mitochondrial fission, which is inhibited by Mdivi-1, is typically required 
for distribution of mitochondria to daughter cells during mitosis. Similarly, it was hypothesised that 
the presence of Mdivi-1 would influence the radiation-induced cell cycle arrest.  
3.3. How does Mdivi-1 alter radiation response? 
In our investigations, it was found that Mdivi-1 had cytotoxic and radiosensitising properties. Further 
investigations of Mdivi-1 effects on specific processes that may be related to radiation response 
were therefore undertaken to provide mechanistic insight. Certain processes known to be involved 
in radiation response include apoptosis, cytogenetic damage-induction and cell cycle delay and 
therefore we investigated these aspects.  
3.3.1. Does Mdivi-1 delay cells in mitosis?  
Mitochondrial fragmentation is required for mitosis and therefore prolonged inhibition of fission 
may affect cell proliferation and division. Cell cycle analysis of cells exposed to Mdivi-1 showed a 
G2/M arrest and suggested an effect of Mdivi-1 on the passage of cells through mitosis. In addition, 
misalignment of mitotic chromosomes has been reported as a consequence of Mdivi-1 treatment144. 
It was thus hypothesised that Mdivi-1 would arrest cells in mitosis.  
3.3.2. Does Mdivi-1 influence the level of mitosis after irradiation? 
Having demonstrated an Mdivi-1-induced mitotic arrest, it was hypothesised that the proportion of 
mitotic cells would be altered when Mdivi-1 was combined with radiation, which induces a G2/M 
arrest. 
3.3.3. Does Mdivi-1 cause apoptosis in cancer cells?  
It was established in initial experiments that Mdivi-1 reduced clonogenic survival. Since apoptosis 
frequently contributes to cell death after exposure to cytotoxic agents, it was hypothesised that 
Mdivi-1 would cause an increase in apoptosis.  
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3.3.4. Does Mdivi-1 modulate radiation-induced apoptosis in cancer cells? 
Mdivi-1 has been reported to modulate apoptosis induced by adverse cellular conditions and 
cytotoxic agents. It was hypothesised that Mdivi-1 would modulate radiation-induced apoptosis.  
3.3.5. Does Mdivi-1 induce cytogenetic damage? 
Chromosomal aberrations induced by Mdivi-1 have been reported in other studies466, 572, 573.  
In addition, the observation that Mdivi-1 results in a cell cycle delay and cell death suggests  
that significant damage to the cell has occurred. Thus, it was hypothesised that Mdivi-1 treatment  
would result in cytogenetic damage. 
3.3.6. Does Mdivi-1 modulate the induction of radiation-induced cytogenetic damage? 
Micronuclei induction, as a result of chromosomal breaks, is a consequence of radiation treatment. 
It was hypothesised that Mdivi-1 treatment, which was demonstrated to induce cytogenetic damage 





MITOCHONDRIAL MORPHOLOGICAL AND FUNCTIONAL STATUS  
IN CANCER CELLS AND RADIATION RESPONSE 
 
Mitochondrial dysfunction has been implicated in cancer initiation and growth and may be involved 
in therapeutic response. Radiation sensitivity is determined by an array of biological and 
environmental factors many of which are associated with mitochondrial function. 
Studies into the role of inherent mitochondrial status in radiation response are lacking and 
additional research is required. We postulated that the morphological classification of mitochondria 
according to their fragmentation status, and specific parameters of mitochondrial function are 
associated with inherent radiosensitivity.  
In this chapter, the radiation response of several cancer cell lines is correlated with mitochondrial 
morphology and functional measures of inherent mitochondrial activity, including respiration and 
mitochondrial membrane potential.  
 
4.1. Aim and objectives 
To identify potential correlations between the inherent radiation-responsiveness of selected cancer 
cell lines and their mitochondrial morphological and functional characteristics.  
The specific objectives include: 
a) To determine the inherent radiation-responsiveness of a selection of established tumour cell 
lines representing a range of different cancer types 
b) To characterise the mitochondrial morphological characteristics of a subset of these cell lines 
c) To determine the relative mitochondrial membrane potential in each of the selected cells lines 
d) To determine the inherent respiratory capability of each cell line 
e) To determine whether the inherent radiation-responsiveness of these tumour cell lines is 






4.2.1. Cancer cell lines  
A selection of available tumour cell lines, described in detail in Appendix A and listed in Table 4.1, 
were characterised according to their radiosensitivity and mitochondrial status. Cells were cultured 
in the appropriate culture medium for each cell type supplemented with 10 % fetal calf serum (FCS) 
and antibiotics (AB) and were incubated under standard culture conditions of 37C, 100 % humidity 
and 5 % CO2/95 % O2 (please see Appendix A for full details).  
 
Table 4.1. Cancer cell lines selected for characterisation of inherent radiosensitivity 
Cell Line Tumour cell type 
A549 Lung adenocarcinoma 
T47D Breast ductal carcinoma 
U937 Leukemic monocyte lymphoma 
MDA-MB-231 Breast adenocarcinoma 
DU145 Prostate carcinoma 
HeLa Cervical carcinoma 
 
4.2.2. Cellular radiation responsiveness 
4.2.2.1. Clonogenic cell survival assay 
The surviving fraction after irradiation of the adherent A549, MDA-MB-231, T47D, DU145 and HeLa 
cell lines, was assessed using the clonogenic cell survival assay235. Experimental details are provided 
in Appendix B1. The survival curves for each cell line were determined for doses ranging from 1 to  
10 Gy 60Co -radiation. Unirradiated controls were mock treated. The radiation setup is shown in 
Appendix B2. Cells were irradiated in culture medium with full build-up at a dose rate of 
approximately 1 Gy/min. At the end of the assessment period, cell survival was determined by the 
number of colonies containing more than 50 cells. At least two separate experiments were 




For the U937 suspension cell line, the clonogenic assay was modified because these cells do not 
form adherent colonies. These cells were plated into culture medium containing agarose which 
provided a semi-solid matrix for colony formation (Appendix B1.2). Colonies were assessed 
microscopically using a grid for orientation and the number of colonies, representing more than  
50 cells was determined.  
4.2.2.2. Data processing and analysis 
Data from the clonogenic assays was used to construct survival curves followed by derivation of 
certain parameters of radiation response, namely SF4, SF2, D, alpha (α) and D10, as defined in 
Chapter 2. 
 
The surviving fraction (S) was determined according to the equation, 
S = colonies counted / (cells plated x PE) 
Where plating efficiency (PE) = colonies counted/cells plated in untreated cells. 
Radiation survival curves were constructed using the GraphPad Prism software v6.05 (GraphPad 
Software, Inc. San Diego, California). Survival curves were fitted to the data according to the Linear 
Quadratic model using the equation,  
S = e-(αD+βD2) 
where D represents dose, and α and β are constants relating to the contribution of non-repairable 
and repairable damage, respectively. 
Values for SF2 and SF4 were determined from surviving fractions after 2 and 4 Gy, respectively.  
The α and D10 values were determined from the fitted curves. In addition, the mean inactivation 
dose, D, was approximated by calculating the area under the curve for the region 0-6 Gy using the 







4.2.3. Characterisation of mitochondrial morphology 
4.2.3.1. MitoTracker® Red staining protocol 
Mitochondria were stained using the fluorescent dye, MitoTracker® Red CMXRos (Molecular Probes® 
Inc., Invitrogen, Carlsbad, CA, USA) in live cells. The dye diffuses through the plasma membrane and 
accumulates in actively respiring mitochondria. MitoTracker® Red reacts with protein surface thiols 
and is maintained within mitochondria after fixation and permeabilisation of cells379, 464.  
The six cell lines described above were divided into three groups on the basis of their response to 
radiation (section 4.3.1). One cell line from each group was selected for evaluation of mitochondrial 
morphology. For analysis, cells were kept under physiological conditions before being stained with 
MitoTracker® Red and the morphology was assessed microscopically.  
The MitoTracker® Red staining protocol is detailed in Appendix C1. Briefly, cells were plated onto 
glass coverslips and incubated overnight for cells to adhere. The following day cells were stained 
with MitoTracker® Red at 37°C, washed and then either fixed for scoring or mounted immediately 
for live cell imaging using glycerol mounting medium as an antifade agent (Appendix D). Fixed cells 
were stored at 4°C until visualisation. 
Representative samples from each cell line were assessed using live cell imaging to confirm that live 
and fixed cells had comparable mitochondrial morphology (Appendix C2.1). Cells were maintained at 
37C in the appropriate culture medium before visualisation and were observed promptly within  
10 minutes of mounting. Noticeable signs of deterioration, such as swollen mitochondria, defined 
previously567 were only evident after 30 minutes. 
In addition, A549 cells were transfected with a red fluorescent protein construct to allow 
visualisation of mitochondria (CellLight® Mitochondria-RFP, BacMam 2.0; Molecular Probes Inc). To 
confirm that MitoTracker® Red did not induce obvious morphological changes, the mitochondrial 
morphologies were compared (Appendix C2.2). The transfection method was not used generally for 
mitochondrial classification in experiments due to sub-total transfection rates and dilution of the 
proportion of labelled cells with cell division. The use of MitoTracker® Red was selected as the 





4.2.3.2. Visualisation and scoring of morphological subtypes 
Microscopic visualisation of mitochondria stained with MitoTracker® Red (ex: 579 nm, em: 599 nm) 
was carried out with a BX41 Olympus fluorescence microscope (Olympus, Shinjuku-ku, Tokyo, Japan) 
using the Olympus WG (green light) filter. Samples were observed at 1000x magnification using the 
MPLAPON-Oil Plan Apochromat oil immersion objective (Olympus). A detailed description can be 
found in Appendix D.  
Mitochondrial morphology was classified using adaptations of the methods used by Margineantu  
et al. (2002)625 and Lutz et al. (2009)626. Cells were assessed manually. Criteria for classification, as 
shown in Table 4.2, were similar to those used in previously published studies.  
 




Examples described  




Thin, interconnected filaments, reticular 
Margineantu et al. 2002625; Taguchi et al. 2007504, Das 
et al. 2012627; Chen et al. 2003389; Barni et al. 1996628; 
Ishihara et al. 2006629; Park et al. 2008630; Brooks et al. 
2007623; McCarron et al. 2013565; Plecita-Hlavata et al. 
2008476; Jendrach et al. 2008631; Duvezin-Caubet et al. 
2006411; Winter et al. 2008632 
Transitional 
A combination of long filaments with a 
few short tubules  
Margineantu et al. 2002625; Ishihara et al. 2006629; 
Benard and Rossignol 2008366; Jendrach et al. 2008631; 
Duvezin-Caubet et al. 2006411; Winter et al. 2008632; Lee 
et al. 2007502 
Enlarged  
Enlarged or augmented filaments (often 
accompanied by a few oval structures) 
Das et al. 2012627;  Mattiolo et al. 2014605; Rossignol et 
al. 2004485; Plecita-Hlavata et al. 2008476; Mai et al. 
2010449; Chiche et al. 2010419 
Predominantly fragmented 
Ovoid 
Enlarged, round or oval structures Liu and Hajnocsky 2011
567; Benard et al. 2007474; Chen 
et al. 2003389; Brooks et al. 2007623; McCarron et al. 
2013565; Jendrach et al. 2008631 
Fragmented 
Short, separated tubules or small bright 
speckles 
Margineantu et al. 2002625; Chen et al. 2003418; Das et 
al. 2012627; Mattiolo et al. 2014605; Ishihara et al. 
2006629; Brooks et al. 2007623; Jendrach et al. 2008631; 
Duvezin-Caubet et al. 2006411; Winter et al. 2008632; Yu 
et al. 2005633 
 
Ultimately, cells were divided into predominantly fused and predominantly fragmented categories. 
To increase objectivity, cells were first allocated to one of the five defined descriptive morphologies. 
The filamentous, transitional and enlarged sub-groups were combined to form the predominantly 
fused category while the predominantly fragmented category included the ovoid and fragmented 
sub-groups. At least 200 cells per slide (n = 5) were scored. Representative images of the 





Figure 4.1. Representative images of the different morphological sub-groups. The lower panels 
represent contrast enhanced versions of each of the images created using Image J (NIH)634 to 
highlight differences for demonstration purposes only and were not used for scoring. A 5x5 spatial 
convolution filter was applied to enhance edges of the image followed by binarisation.  
 
4.2.4. Mitochondrial membrane potential 
4.2.4.1. JC-1 assay 
As described in Chapter 2, JC-1 is a ratiometric dye and the red to green (R:G) fluorescence ratio is  
an indication of ΔΨm347. The red fluorescence value (j-aggregate formation), may also be used 
independently as a measure of mitochondrial function346, 349. Both R:G ratio and j-aggregate 
formation were determined in experiments using fluorescence cytometry635. 
Characterisation of ΔΨm was carried out in all cell lines selected for sub-analysis (A549, T47D, 
DU145 and U937).  Comprehensive methodology can be found in Appendix C3. Briefly, exponentially 
growing cells from each cell line were stained with JC-1 dye for 15 minutes under physiological 
conditions and images of cells were captured for analysis using fluorescence microscopy (Appendix 
D). Samples were stained and imaged in suspension. A sample from each cell type was processed 
concurrently to ensure comparative staining conditions. Images were acquired using identical 





4.2.4.2. Validation of the JC-1 assay in selected cell lines 
To confirm that the JC-1 assay was able to detect differences in ΔΨm in our cells, mitochondrial 
depolarisation was induced using sodium azide, a mitochondrial inhibitor636, 637, in each cell line. 
Briefly, cells were incubated in 20 mM sodium azide (Sigma-Aldrich, St. Louis, Mo, USA) for 1 to 2 hours, 
depending on the cell line, prior to staining with JC-1. Observation and image analysis of unstained 
cells from each cell line indicated the absence of cellular autofluorescence. In addition, a sample 
from each cell line was evaluated using the trypan blue viability assay (Appendix A2.3) to confirm 
that loss of ΔΨm was not attributed to cell death. 
4.2.4.3. Visualisation of cells and image acquisition 
Prepared samples, which were kept in the dark, were imaged within 20 minutes of mounting. 
Samples were visualised using a BX41 Olympus fluorescence microscope (Olympus). The green 
fluorescence, of the monomeric JC-1 units, and the red fluorescence, of JC-1 aggregates, were 
imaged using the Olympus WB filter (max ex: 488 nm) and the Olympus WG filter (max ex: 590 nm), 
respectively (Appendix D, Table D1). Images for quantification were obtained using the UPlanFl 
40x/0.75 objective (Olympus). In addition, a subset of samples were imaged with the UPlanFl 
100x/1.30 oil immersion objective (Olympus) to document differences in JC-1 aggregate distribution 
within the mitochondria of individual cells and between cell types.  
Images for analysis of ΔΨm were captured using a Canon EOS 1000D colour camera (Canon Inc. Tokyo, 
Japan) mounted onto the microscope with a MDSLR-BX 1.38x Widefield T-mount adapter for 
Olympus BX (Martin Microscope Company, Easley, USA). Camera exposure and illumination settings 
were kept constant between images and the aperture was fixed. The exposure time was set to 0.3s 
(1/3) and the ISO setting was 400 for green fluorescence capture and 100 for red fluorescence 
imaging. The green fluorescence capture is more sensitive because of the lower intensity of the 
monomeric form of the JC-1 stain. 
Care was taken to prevent unnecessary exposure of the slide to fluorescent light prior to image 
acquisition. Once positioning and focus had been set, the image was captured immediately following 
illumination of the field to avoid bleaching. RAW image files (.CR2) were converted to "Tagged Image 





4.2.4.4. Quantification of mitochondrial membrane potential  
Quantification of the green and red fluorescence intensity was carried out by measuring the mean 
grey value per cell using the image analysis application, Image J v1.48 (NIH)634 (Appendix C3.2). All 
values were corrected for background staining by subtracting the average grey value for five random 
regions containing no cells. The fluorescence intensity for both the red and green channels was 
determined for a minimum of 200 cells per sample (n = 3). The R:G fluorescence ratio per cell was 
calculated to determine the ΔΨm spectrum for each cell line.  
4.2.5. Mitochondrial respiratory capacity 
The decrease in oxygen concentration in a closed system was used as a measure of cellular 
respiration. Differences in mitochondrial oxygen consumption can be determined by uncoupling 
OXPHOS from ATP-synthesis, depolarising the inner mitochondrial membrane and by inhibiting 
complexes of the electron transport chain with specific mitochondrial inhibitors and uncouplers.  
The relative O2 consumption rates under these conditions provide a measure of both the maximal 
and physiological function of mitochondria in a population of cells.  
4.2.5.1. High resolution respirometry 
Preparation of cells for high resolution respirometry is detailed in Appendix G. Cellular oxygen 
consumption rates were determined using the OROBOROS Oxygraph-2k for high resolution 
respirometry (OROBOROS Instruments corp. Innsbruck, Austria). Prior to data collection, the oxygen 
sensor was calibrated using solutions of known oxygen partial pressures. For experiments, 
polarographic measurements were taken of intact cells in suspension at a density of 0.8 million 
cells/ml. Cells were continuously stirred in a chamber containing 2 ml of the appropriate cell culture 
medium at 37°C. Care was taken when inserting the stopper to ensure elimination of air bubbles. 
Samples were initially aerated to approximately 200 µM oxygen at 102 kPa barometric pressure by 
allowing 2 minutes of contact with air for oxygenation under agitation. In addition, a sample from 
each cell line was evaluated using the trypan blue viability assay (Appendix A2.3) both before and 






4.2.5.2. Phosphorylation control protocol 
The phosphorylation control protocol for OXPHOS analysis provided a method for determining the 
general, ROUTINE state respiration of the cells under physiological conditions as well as specific 
parameters of mitochondrial function in each cell line. These included LEAK state respiration, which 
is a measure of O2 consumption independent of ATP synthesis; ETS uncoupled state respiration, 
which determines the maximal capacity of the mitochondria for respiration and ROX respiration 
state, which denotes the cellular O2 consumption independent of mitochondrial utilisation. 
Initial measurements of O2 flux denote ROUTINE respiration supported by exogenous substrates in 
the cell culture medium. Each subsequent respiratory state was induced by administration of either 
a mitochondrial inhibitor or uncoupler that did not require permeabilisation of cell membranes. 
Addition of an ATP-synthase inhibitor, oligomycin (1 µl; 2.5 µM), allowed determination of LEAK 
state respiration. Stabilisation of this state was restricted to 5 minutes. The subsequent, step-wise, 
titration of an uncoupler, FCCP [carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone] in 4 µl (20 µM) 
steps increased membrane depolarisation until the maximum ETS capacity was determined. Finally, 
the addition of a complex I inhibitor, rotenone (1 µl; 0.5 µM) and a complex III inhibitor, antimycin A  
(1 µl; 2.5 µM), abolished mitochondrial respiration which allowed extra-mitochondrial oxygen 
consumption (ROX) to be assessed. At each stage, respiratory flux rates were allowed to reach a 
steady state. Total O2 consumption (Rabs) for each cell line, which is comparable to oxygen 
consumption rate (OCR), was determined for seven samples while values for additional respiration 
states were determined in triplicate. 
4.2.5.3. Interpretation of respirometry measurements 
The polarographic measurements were analysed using Oroboros DatLab 4.3 v6.0.1.7 software. An 
example of a trace of O2 consumption for the A549 cell line is given in Figure 4.2. The perpendicular 
blue markers indicate the time points for addition of respiration inhibitors and uncouplers as 
described above. The red markers indicate regions of stable flux for each respiratory state measured. 
Average values for the selected regions are exported from DatLab to the Oxygraph-2k Microsoft 
Excel 2010 (Microsoft, Redmond, WA, USA) template for analysis. Mitochondrial O2 flux was corrected 









Figure 4.2. O2 flux over time for a sample of A549 cells showing the regions selected (red bars) for 
determination of O2 consumption during different respiration states. Data was sampled every 2s. 
 
4.2.6. Correlation of morphological and functional mitochondrial 
characteristics with inherent radiation responsiveness 
Potential associations between the degree of mitochondrial fragmentation, ΔΨm, cellular O2 
consumption and response to radiation were examined by correlation analysis as described in 
statistical analyses below.  
4.2.7. Statistical analyses 
GraphPad PRISM v6.05 (GraphPad software) was used for construction of graphs and for statistical 
analyses and error bars represent SEM unless otherwise indicated. Groups were considered to be 
statistically significantly different if a p-value smaller than 0.05 was determined. 
Clonogenic survival  
Parameters used to describe radiation sensitivity, namely, SF2, SF4, D, D10 and α, were correlated 
using Pearson’s correlation analysis. Linear regression analysis of correlated parameters was 
conducted using Microsoft Excel 2010 (Microsoft). 
Morphology 
The fragmentation index from morphological categorisation of the three cell lines was compared 
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JC-1 ratio and red fluorescence values were evaluated for normality using the D'Agostino-Pearson 
normality test. Histograms and scatterplots were constructed displaying the distribution of ratio and 
red and green values, respectively for comparison of untreated and azide-treated samples. The 
Kruskal-Wallis nonparametric test with Dunn’s multiple comparison’s test was used for ΔΨm 
comparisons between cell lines. The range of ΔΨm determined from the fluorescence values 
calculated for each cell line was represented using box and whisker plots. Regression analyses were 
performed for median R:G ratio and red fluorescence values. 
Respirometry 
Oxygen consumption rates and flux control ratios for each of the cell lines were compared using 
ANOVA with the Fisher’s LSD test for multiple comparisons. 
Correlation 
Radiation responsiveness and mitochondrial characteristics including morphology, ΔΨm and 
respiration were correlated using Pearson’s correlation analysis. Correlation descriptors including 
the linear correlation coefficient (r) and the coefficient of determination (r2) were determined.  
Three groups defining the linear correlation coefficient were identified: weak (r = 0.4-0.59), 




4.3.1. Inherent radiation responsiveness 
The relative response of a range of cancer cell lines to radiation treatment was investigated using 
clonogenic cell survival assays. Survival curves demonstrating the fraction of cells surviving in the 
different cell lines with each dose of radiation are shown in Figure 4.3.  
 
Figure 4.3. Radiation survival curves for six cancer cell lines fitted using the Linear 




Inherent radiation responsiveness of the cell lines was described in terms of a number of different 
measures of radiosensitivity, as summarised in Table 4.3. Cell responses represent a spectrum of 







Table 4.3. Cell survival parameters indicating indices of radiation responsiveness. The alpha  
and beta coefficients, and the R2 values are derived from the curves fitted using the LQ equation.  
 
SF2  SF4  
      






A549 0.575 ± 0.097 0.284 ± 0.057 2.941 6.2 0.181 ± 0.033 0.03 ± 0.009 0.9919 
HeLa 0.749 ± 0.067 0.239 ± 0.015 2.999 5.4 0.037 ± 0.03 0.072 ± 0.009 0.9947 
U937 0.381 ± 0.07 0.177 ± 0.047 2.307 4.4 0.212 ± 0.098 0.072 ± 0.037 0.9743 
T47D 0.488 ± 0.039 0.149 ± 0.018 2.222 4.6 0.269 ± 0.01 0.051 ± 0.004 0.9997 
DU145 0.352 ± 0.023 0.111 ± 0.005 1.954 4.1 0.485 ± 0.008 0.018 ± 0.003 0.99 
MDA- 
MB-231 0.422 ± 0.118 0.074 ± 0.032 1.759 3.6 0.367 ± 0.082 0.074 ± 0.036 0.9908 
D: The area under the curve between 0 and 6 Gy 
D10: Dose required to give a surviving fraction of 0.1 according to a best-fit curve 
Errors shown are standard deviations 
 
The clonogenic survival assays established the A549 cell line as the most resistant line examined and 
the MDA-MB-231 cell line as the most sensitive, indicated by SF4 values of 0.28 and 0.074, 
respectively. A relative change in sensitivity of approximately 1.7 times was found for these cell lines 
when comparing D10 values. As expected, SF4 correlated strongly with D (r2 = 0.946; p = 0.001) and 
relative sensitivity at D10 (r2 = 0.943; p = 0.001). SF2 values were moderately but not significantly 
correlated with SF4 (r = 0.713). Linear quadratic parameters, alpha (α) and beta (β), are included in 
Table 4.3. Low α values were observed with the more resistant A549 and HeLa cell lines, and higher 
α values were associated with increasing radiation responsiveness. Alpha values correlated strongly 
with SF2 (r = -0.849; p = 0.03) but only moderately with SF4 (r = -0.794; p = 0.06). The β values did 






4.3.2. Mitochondrial characteristics 
The six cell lines analysed for radiation response were divided into three groups representing low, 
intermediate and high radiation responsiveness. One cell line from each of these groups, namely 
A549, T47D and DU145 cells, respectively, was selected for characterisation of mitochondrial status. 
In addition, the U937 cell line was included for analysis of ΔΨm and O2 consumption but was 
excluded from morphological classification because of limitations in visualisation of the morphology 
of rounded suspension cells. 
4.3.2.1. Characterisation of mitochondrial morphology 
The range of different morphological subtypes observed for each of the three cell lines is shown in 
Figure E3 (Appendix E). Each cell line was defined in terms of their mitochondrial phenotype by 
categorising cells into two morphological groups representing predominantly fused and 
predominantly fragmented cells. A graphical representation of the mitochondrial fragmentation 









Figure 4.4. The proportion of cells displaying predominantly fragmented mitochondria 
in three cancer cell lines determined using MitoTracker® Red staining. Data are shown 
as mean ± SEM and represent 5 replicate samples. *P < 0.05. 
The A549 cell line displayed the highest level of mitochondrial fusion (60 %) while both the T47D and 
the DU145 cell lines were predominantly fragmented (> 60 %). The A549 fragmentation index was 
significantly different from that of the other cell lines (p < 0.001) while the more fragmented cell 





4.3.2.2. Mitochondrial membrane potential 
The ΔΨm of four cancer cell lines was assessed (Figure 4.5). Red:Green (R:G) ratio, as well as, red  
(j-aggregate) fluorescence values alone were analysed and compared (Figure 4.6A and B). Cell 
populations reflected similar maximum and minimum red values indicating a comparable range in 
functionality of mitochondria. In general, ΔΨm values were not considered to be normally 
distributed as determined using the D'Agostino-Pearson normality test. The median j-aggregate and 









Figure 4.5. JC-1 staining of mitochondria for ΔΨm determination (present work).  
1000x magnification. 
The U937 cells yielded the highest average ΔΨm while A549 cells yielded the lowest, with a 10-fold 
difference in median j-aggregate values and an 8-fold difference in median R:G ratio values.  
In Figure 4.6A, the R:G ratios for cell lines were found to be significantly different from each other  
(p < 0.001). However, when using j-aggregate values to quantify ΔΨm (Figure 4.6B), no significant 



















Figure 4.6. Comparison of ΔΨm measurements for cancer cell lines. A) JC-1 R:G fluorescence ratios 
and B) J-aggregate (red) fluorescence values. Box and whisker plots illustrate the median values 
obtained for each cell line as well as the interquartile range and minimum and maximum values for 
each set of data. Data represent 3 replicate samples per cell line. C) Linear regression analysis of JC-1 
R:G ratio and j-aggregate (red) values. The 95 % confidence interval is shown. 
 
JC-1 sensitivity 
The sensitivity of the JC-1 assay to detect small differences in ΔΨm was assessed using an inhibitor 
of mitochondrial respiration. Figure 4.7A shows the reduction in ΔΨm in sodium azide-treated cells 
relative to controls. All cell lines responded to sodium azide treatment, which reduces mitochondrial 
function by inhibiting complex IV of the electron transport chain. Unlike FCCP, which rapidly 
depolarises mitochondrial membranes and is commonly used as a positive control, sodium azide has 
a milder effect on ΔΨm and was used at a time and dose that did not completely dissipate the ΔΨm. 
In addition the influence of sodium azide treatment on ΔΨm for the U937 cells is illustrated in Figure 


































Figure 4.7. Modulation of ΔΨm using a respiratory inhibitor. A) Relative reduction in JC-1 R:G 
fluorescence ratios observed for each cell line after sodium azide-treatment (respective control 
values were normalised to 1). B) Shift in ΔΨm observed for U937 cells after sodium azide 
treatment. Untreated cells are represented in blue while sodium azide-treated cells are 
represented in teal. C) Histogram showing the distribution of R:G ratio values for U937 
untreated and sodium azide-treated samples. Data are shown as mean ± SEM and represent 3 
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4.3.2.3. Mitochondrial respiration 
The respiratory competence of four cancer cell lines, as estimated by cellular O2 consumption rate, 
was compared using high resolution respirometry. An oxygraph trace of O2 flux through A549 cells 
over time obtained from experiments is given as a representative example in Figure 4.8. Markers, 
shown in blue, indicate the addition of mitochondrial modulators, oligomycin, FCCP and rotenone. 
The accompanying respiration states are designated R’, L’, E’ and ROX and represent physiological, 
phosphorylation-independent, maximal O2 consumption and residual O2 consumption, respectively.  
 
Figure 4.8. Oxygraph trace showing O2 flux for a sample of A549 cells. R’, L’ and E’ indicate regions 
representing physiological, phosphorylation-independent and maximal O2 consumption. The residual 
O2 consumption (ROX) for these cells is also shown.  
 
Graphs depicting absolute values of O2 consumption are presented initially in Figure 4.9, while the 
results presented thereafter (Figure 4.10) are values normalised to the maximal O2 consumption rate 
for each cell line, namely the flux control ratios (FCRs). The former allows comparison of the overall 
O2 usage of the cells in each respiration state, namely routine, phosphorylation-independent and 
uncoupled, while the latter provided a means to compare the efficiency of the respiration between 
cell lines. 
Figure 4.9A depicts the cellular respiration rate (R’), which includes both mitochondrial and non-
mitochondrial O2 consumption, for the cell lines. The T47D and A549 cellular respiration rates  
under routine cell culture were comparable (48±6.83 and 45±2.66 (pmol/s)/106 cells, respectively) 
and were approximately 15 and 20 % lower, respectively, than the DU145 respiration rate 
(56.70±6.59 (pmol/s)/106 cells). In contrast, the cellular respiration rate of the U937 cell line 






The absolute mitochondrial O2 consumption rates for each respiration state, namely, Rabs, Labs and 
Eabs, are presented in Figure 4.9B. These values were derived from R’, L’ and E’ respectively, after 
correcting for non-mitochondrial (residual) O2 consumption (ROX). The relatively high ROX value 
(36.26±9.86 (pmol/s)/106 cells) for the DU145 cell line resulted in a lower Rabs (24.67±2.68 
(pmol/s)/106 cells) despite the high cellular respiration rate (56.70±6.59 (pmol/s)/106 cells). The 
T47D and U937 cell lines differed by more than 30 %, displaying the highest (38.21±4.8 (pmol/s)/106 
cells) and lowest (13.99±1.84 (pmol/s)/106 cells) mitochondrial O2 consumption rates, respectively. 
The absolute spare respiratory capacities (Eabs - Rabs) for each cell line were 43.7, 25.1, 34.9 and 25.66 














Figure 4.9. Absolute O2 consumption rates for four cancer cell lines. A) Cellular respiration rate 
(R’), which includes mitochondrial and non-mitochondrial O2 consumption. B) Mitochondrial 
O2 consumption rate for three respiration states, Rabs, Labs and Eabs, representing physiological, 
phosphorylation-independent and maximal respiration, respectively, and ROX values used for 
adjustment. O2 consumption rate was measured per million cells in culture medium 
[(pmol/s)/106 cells]. # = spare respiratory capacity for the A549 cell line. Data are shown as 
mean ± SEM and represent at least 3 independent experiments.  
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Comparison of the respiration states, for phosphorylation-independent, Labs and maximal ETS 
capacity, Eabs, for each of the cell lines are shown in Figure 4.9B. As observed for Rabs, the T47D cells 
(15.704±3.11 (pmol/s)/106 cells) and the U937 cells (4.36±0.53 (pmol/s)/106 cells) showed the 
greatest difference (72 %) between mitochondrial O2 consumption rates that are independent of 
ATP synthesis (Labs). A549 and DU145 Labs values were similar (12.12±1.73 and 8.86±2.45 
(pmol/s)/106 cells). The highest Eabs was determined for the A549 cell line (76.09±10.85 (pmol/s)/106 
cells) and the U937 Eabs was approximately 50 % lower (39.65±7.64 (pmol/s)/106 cells). T47D and 














Figure 4.10. Flux control ratios for comparison of respiratory parameters of four cancer cell 
lines. The ratios of absolute values, R/E, L/E and ROX/E’, represent ROUTINE, LEAK and non-
mitochondrial O2 consumption, respectively, normalised to maximal respiratory capacity for 
each cell line. The respiration related to phosphorylation (R-L = net R) and normalised to 
maximal respiratory capacity is given by (net R)/E. The respiratory control ratio (RCR = E/L) and 
the uncoupling control ratio (UCR = E/R) are reciprocal ratios that indicate mitochondrial 
efficiency and excess respiratory capacity. Data are shown as mean ± SEM and represent at 





























Calculated FCRs used to describe respiratory function relative to Eabs are presented in Figure 4.10. 
The ROUTINE control ratio (R/E) describes coupled respiration in terms of the proportion of ETS 
capacity used. The T47D cells were observed to use 60 % ETS capacity (0.61±0.02) which was at least 
20 % more than used by the other cell lines (p < 0.001). Reciprocally, the T47D had a lower UCR 
(1.65±0.05) indicating reduced excess respiratory capacity than the other cell lines. The range of 
LEAK control ratios (L/E) determined, namely, 0.11-0.25 are comparable to those reported 
previously327. The T47D cell line was shown to be significantly different from the other cell lines in 
terms of proton leak (L/E = 0.25±0.014; A549: p = 0.002, DU145: p < 0.001, U937: p < 0.001). The net 
ROUTINE respiration describes the phosphorylation-related respiration as a proportion of ETS 
capacity. The T47D cell line displayed a significantly higher net ROUTINE respiration (0.36±0.025) 
compared to the other cell lines suggesting greater ETS capacity is used for ATP generation  
(p < 0.001). The DU145 cells, as mentioned previously, consume 37 % more O2 than utilised by the 
mitochondria (ROXnorm: 0.37±0.07) compared to the other cell lines where approximately 20 % of the 
O2 consumption is non-mitochondrial (A549: p = 0.01, T47D: p = 0.016, U937: p = 0.024). 
4.3.3. Correlation analyses 
We have hypothesised that mitochondrial status is associated with intrinsic cellular radiosensitivity. 
Therefore, in this thesis, both measures of mitochondrial structure and function have been 
correlated with radiosensitivity. Tables 4.4 – 4.6 list the outcomes of the correlation analyses.  
4.3.3.1. Correlation of cellular radiation-responsiveness with mitochondrial characteristics  
The radiation response for the four cell lines, represented by SF2, SF4, D and alpha were correlated 
with the mitochondrial characteristics investigated (Table 4.4). Correlations of factors with SF4 or 
were comparable. Strong negative correlations were found between both SF4 and D, and the 
fragmentation index (r = -0.919 and -0.896, respectively), however, the relationships were not 
statistically significant. 
SF2 correlated strongly with both JC-1 ratiometric (median: r = -0.822) and j-aggregate (mean:  
r = -0.857 and median: r = -0.820) measures of mitochondrial ΔΨm however, with the small data set, 
the correlations were not significantly non-zero. None of the parameters of radiation-responsiveness 
correlated strongly with measures of respiration, however the following moderate correlations were 
observed. SF2 was positively correlated with Eabs (r = 0.771, p = 0.23) and mitochondrial respiration 
(Rabs) (r = 0.69, p = 0.31). Alpha correlated positively with cellular respiration rate (R’), which includes 
mitochondrial and non-mitochondrial O2 consumption (r = 0.650, p = 0.35).  
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Table 4.4. Correlation coefficients for measures of radiosensitivity versus mitochondrial morphology 
and function. p-values are shown in brackets. 
 
SF4 D SF2 alpha (α) 
Fragmentation index -0.919 (0.258) -0.896 (0.293) -0.665 (0.537) 0.577 (0.609) 
JC-1 R:G ratio (mean) -0.407 (0.593) -0.459 (0.541) -0.777 (0.223) 0.056 (0.944) 
JC-1 R:G ratio (median) -0.485 (0.515) -0.535 (0.465) -0.822 (0.178) 0.128 (0.872) 
JC-1 j-aggregate (mean) -0.666 (0.334) -0.700 (0.300) -0.857 (0.143) 0.227 (0.773) 
JC-1 j-aggregate (median) -0.622 (0.378) -0.655 (0.345) -0.820 (0.180) 0.159 (0.841) 
R' (cellular respiration) -0.255 (0.745) -0.217 (0.783) 0.124 (0.876) 0.650 (0.350) 
Rabs (corrected for ROX) 0.173 (0.827) 0.242 (0.758) 0.690 (0.310) 0.058 (0.942) 
Eabs (max ETS capacity) 0.492 (0.508) 0.534 (0.466) 0.771 (0.229) 0.049 (0.951) 
UCR (E/R) 0.136 (0.864) 0.062 (0.938) -0.449 (0.551) -0.034 (0.966) 
RCR (E/L) 0.017 (0.983) -0.056 (0.944) -0.551 (0.449) -0.021 (0.979) 
ROUTINE (R/E) -0.183 (0.817) -0.110 (0.890) 0.396 (0.604) -0.014 (0.986) 
(Net R)/E -0.237 (0.763) -0.165 (0.835) 0.337 (0.663) -0.010 (0.990) 
LEAK (L/E) -0.134 (0.866) -0.061 (0.939) 0.446 (0.554) -0.018 (0.982) 
Spare respiratory capacity 0.635 (0.365) 0.624 (0.376) 0.500 (0.500) -0.016 (0.984) 
 
4.3.3.2. Correlation of mitochondrial morphology, ΔΨm and respiratory parameters 
Correlations between measures of mitochondrial structure and function were subsequently 
examined (Table 4.5). Strong, positive correlations were observed between the fragmentation index 
and JC-1 j-aggregate values (mean: r = 0.926 and median: r = 0.95). The fragmentation index 
correlated negatively with Eabs (r = -0.918). These correlations were, however, not significantly  
non-zero. As reported previously in section 4.3.2.2, the four different JC-1 measures of 
mitochondrial ΔΨm (R:G ratio and j-aggregate values) were strongly correlated.  
Strong, negative correlations (r = -0.915 and -0.892) were obtained between JC-1 R:G ratio values 
and mitochondrial respiration (Rabs). In addition, the mean JC-1 R:G ratio value was positively 
correlated with RCR (r = 0.809; p = 0.19). All JC-1 measures also showed strong, negative correlation 
with Eabs (Ratio mean: r = -0.981; p = 0.019 and median: r = -0.987; p = 0.013; j-aggregate mean:  







Table 4.5. Correlation coefficients for mitochondrial morphology versus function.  
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JC-1 (j-agg) median 0.950 (0.202) 0.945 (0.055) 0.964 (0.036) 0.998 (0.002) 
 
 
R' (cellular) 0.586 (0.602) -0.721 (0.279) -0.666 (0.334) -0.543 (0.457) -0.595 (0.405) 
Rabs (corrected) 0.120 (0.924) -0.915 (0.085) -0.892 (0.108) -0.739 (0.261) -0.740 (0.260) 
Eabs (max ETS) -0.918 (0.260) -0.981 (0.019) -0.987 (0.013) -0.977 (0.023) -0.986 (0.014) 
UCR (E/R) -0.584 (0.603) 0.693 (0.307) 0.650 (0.350) 0.424 (0.576) 0.425 (0.575) 
RCR (E/L) -0.453 (0.701) 0.809 (0.191) 0.772 (0.228) 0.573 (0.427) 0.576 (0.424) 
ROUTINE (R/E) 0.608 (0.584) -0.589 (0.411) -0.545 (0.455) -0.309 (0.691) -0.304 (0.696) 
(Net R)/E 0.647 (0.552) -0.517 (0.483) -0.471 (0.529) -0.227 (0.773) -0.221 (0.779) 
LEAK (L/E) 0.567 (0.616) -0.649 (0.351) -0.608 (0.392) -0.379 (0.621) -0.376 (0.624) 
 
Table 4.6 shows the correlation analysis between various respiratory measures. A strong, significant 
correlation (r = 0.996; p = 0.004) was observed between ROUTINE respiration and ATP-coupled 
respiration (netR/E). The UCR and RCR, as inverse functions of the ROUTINE and LEAK state 
respiratory ratios, respectively, also show strong correlations (r = -0.989 and -0.970; p = 0.011 and 
0.03). Cellular respiration (R’), which includes ROX, did not correlate strongly with the other 
respiratory measures while, in contrast, strong correlations were observed with all respiratory 
measures when ROX was subtracted (Rabs). Maximal respiratory capacity (Eabs), as determined by 
complete uncoupling of respiration correlated weakly with the additional measures of respiration. 
Excess respiratory capacity (UCR) correlated strongly (r = 0.984; p = 0.016) with the measure of 
mitochondrial function, RCR, and consequently with other measures determined by LEAK or 









Table 4.6. Correlation coefficients comparing measures of cellular and mitochondrial respiration.  





























Rabs 0.673 (0.327) 
 
 


































(Net R)/E 0.423 (0.577) 0.818 (0.182) 0.343 (0.657) -0.973 (0.027) -0.919 (0.081) 0.996 (0.004)  
 
LEAK 0.513 (0.487) 0.901 (0.099) 0.491 (0.509) -0.997 (0.003) -0.970 (0.030) 0.997 (0.003) 0.987 (0.013) 
 
Overall, besides the expected, significant correlations observed between different measures of 
respiration, few strong, significant correlations were observed with other measures of mitochondrial 
function. The individual measures of ΔΨm and radiation sensitivity correlated strongly with each 
other and these correlations were found to be significant. In addition, strong, significant correlations 
were obtained between ΔΨm and maximum respiratory capacity. Although statistical significance 
was not reached for correlations with mitochondrial morphology, the strong correlation observed 
between radiation sensitivity (SF4) and the fragmentation index is notable and may be shown to be 





It was the intention of the current work to characterise the mitochondrial status of cancer cell lines 
and to determine whether such features correlated with cellular radiation sensitivity. 
4.4.1. Radiation response in the cancer cell lines 
The tumour cell lines used in this study were divided into three groups based on the relative 
radiation sensitivities determined. Parameters of radiosensitivity correlated well with each other. 
Within the range of clonogenic survival observed, cell lines were classified as exhibiting relatively 
high, intermediate or low response to radiation. SF2 values, and to a lesser extent D values, are 
commonly used to describe sensitivity of cell lines240, 242. SF2 values in the current study ranged from 
0.35 - 0.75, which reflect the middle to upper end of the range observed for tumour cell lines  
(0.08 – 0.79) in several previously reported studies40, 206, 230, 231, 638-640. This suggests that the cell lines 
selected represented a significant spectrum of radiation-responsiveness. The mean inactivation dose 
(D), in our cell lines, ranged from 1.75 to 2.99 Gy. This was comparable to a large study of 70 
fibroblast cell lines, where the sensitivity (D) ranged from 0.78 to 2.5 Gy641. Similarly, from a selection 
of previous studies, a range of 0.81 to 2.4 Gy in normal fibroblasts has been determined642. Thus, the 
radiosensitivities of our cell lines, based on SF2 values or D, are similar to published ranges for 
cancer and normal cells234.  
A representative cell line from each of the three groups identified was chosen for characterisation of 
mitochondrial morphology and function. A brief discussion of the selected cell lines is presented 
below.  
Least radioresponsive cell lines 
In this study, the A549 and HeLa cell lines were the most resistant to radiation, approximately 2-fold 
more resistant than the MDA-MB-231 cell line. Although the HeLa cell line showed greater resistance 
than the A549 cell line at low doses (up to 3 Gy), sensitivity was increased at higher doses and D 
values were similar (2.941 and 2.999, respectively). Hence, the A549 cell line was selected to 





Evidence suggests that non-small cell lung cancer cell lines are radioresistant639. The reduced 
radiation responsiveness of A549 cells is consistent with clinical observations of therapeutic 
resistance in non-small cell lung cancer that is often associated with tumour heterogeneity and 
acquired mutations643-645. Investigations into the mechanisms behind the radiation resistance of non-
small cell lung cancers have implicated, among others, dysregulation of signalling pathways646, 647, 
altered p53-related pathways648, 649 and inhibition of apoptotic mechanisms650, 651. 
Most radioresponsive cell lines 
The DU145 and MDA-MB-231 cell lines were the most responsive to radiation treatment. In addition, 
the DU145 cells had the lowest SF2 and were thus chosen to represent the group with low radiation-
responsiveness. The sensitivity displayed by our DU145 cell line is similar to that published by Love 
et al. (2003)652. It has been shown that, after irradiation, purified DNA from these cells appears 
fragmented on electrophoresis suggesting sensitivity to radiation-induced apoptosis206, 228, 653.  
Other investigators have reported variants of this cell line expressing greater resistance231, 654, 655. 
In the clinic, prostate tumours are often considered to be slow growing with low α/β ratios656, 657.  
In contrast, our DU145 cell line was fast growing and appeared to have a high α/β ratio 
(approximately 27 Gy-1). The low β-component and relatively high α-component of our DU145 
survival curve suggests that these cells may be repair-deficient or have higher intrinsic radiation 
sensitivity. DU145 cells are known to be mismatch repair deficient658 and loss of this type of repair 
has been shown to influence activation of S-phase arrest in response to radiation659, although other 
investigators report no effect on radiosensitivity660, 661. Mismatch repair deficient cells are likely to 
display a mutator phenotype suggesting that other repair pathways may be affected over time. 
Differences in radiation sensitivity may thus occur as a result. Nevertheless, the DU145 cell line used 
in the present study was useful in our context as it provided a model with low radiation-
responsiveness for correlation with mitochondrial status. 
Cell lines displaying intermediate radiation-responsiveness 
The U937 monocytic leukaemia and T47D breast cancer cell lines formed the third group with 
intermediate radiation-responsiveness. Both cell lines from this group were investigated for 
mitochondrial functional parameters. While the mitochondrial morphology of T47D cells was 
documented for correlation analysis, morphology was not quantified for the U937 cell line due to 
technical limitations of scoring morphology in suspension cells.  
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Characterisation of mitochondrial features and correlation with radiation-responsiveness 
Functional aspects of mitochondria, including the fragmentation index, ΔΨm and O2 utilisation, were 
investigated with the ultimate goal of determining the strength of correlation between these 
characteristics and the radiation-responsiveness of the four selected cell lines. Additional correlation 
analysis of individual aspects of mitochondrial functional was included for completeness.  
The parameters analysed that gave favourable correlations are highlighted in Tables 4.4 – 4.6.  
To our knowledge, no formal correlation analysis between cellular radiosensitivity and the inherent 
cellular characteristics of mitochondrial structure and function, as investigated in this study, has 
been reported previously. However, an early study using tumour tissue did correlate similar aspects 
of mitochondrial structure and function with radiosensitivity of tumour samples using isolated 
mitochondria and electron microscopy50. The investigators determined that radiosensitivity was 
associated with reduced OXPHOS and ATP production and mitochondrial content, as well as, 
mitochondria that contained fewer cristae. In addition, radiosensitive tumours showed increased 
damage to mitochondria after irradiation. Although the techniques used were different, our 
respiratory results were consistent with these findings in that the more sensitive cell lines displayed 
reduced or inefficient mitochondrial O2 consumption. 
Correlations with inherent radiation-responsiveness  
Radiation-responsiveness, as defined by SF4 or D, and the fragmentation index were negatively 
correlated (r = -0.919 and -0.896, respectively). However, the correlations, although strong, were  
not statistically significant (p = 0.26 and 0.29). SF2, however, correlated only moderately. It should 
be noted that of the three cell lines analysed for mitochondrial morphology, only the A549 cell line 
displayed a significantly different fragmentation index.  
The predominantly fused mitochondrial morphology of the A549 cell line was associated with 
reduced radiation-responsiveness. Evidence exists that supports such an association. For example, 
stress-induced mitochondrial hyperfusion has been shown to protect against apoptosis caused by 
UV-irradiation in HeLa cells and mouse embryonic fibroblasts501. Similarly, inhibition of 
mitochondrial fission was reported to be protective against apoptosis in many cases15, 365, 454 
suggesting that fusion may contribute to resistance. However, induced changes in mitochondrial 




SF4 correlated moderately with ΔΨm while, SF2, which may more closely reflect intrinsic 
radiosensitivity than SF4, was found to correlate negatively (r = approximately -0.8 for all measures 
of ΔΨm). This suggests that increased ΔΨm may be associated with enhanced radiation response. 
Alpha, another estimate of radiosensitivity, did not correlate notably with ΔΨm. Since α was 
determined from fitted survival curves with limited data points in the shoulder region, which 
determines the accuracy of fit, the uncertainty in α may account for the weak correlations observed. 
Mitochondrial function, given its association with intrinsic apoptosis, is thought to be important for 
radiation-induced cell kill. It should be noted, however, that high ΔΨm may not necessarily reflect 
increased mitochondrial function, particularly in cancer cells, where ATP synthase function is 
frequently aberrant. We have shown inverse relationships between ΔΨm and measures of 
respiratory function (Table 4.5), suggesting that a higher ΔΨm in our cancer cell lines is associated 
with poorer mitochondrial function. Thus, defining mitochondrial functionality in terms of ΔΨm 
alone may be misleading. This will be examined later in the discussion of additional correlations with 
ΔΨm. The interplay between radiation response, ΔΨm and respiration is likely to be complex in the 
context of cancer cells and it may be important to consider defining factors collectively rather than 
single determinants in isolation.  
Both SF2 and α correlated moderately with the respiratory parameters, Eabs and Rabs, and R’, 
respectively. Notably, the sensitive DU145 line had the greatest alpha, approximately twice that of 
the other lines, the smallest SF2 value and the greatest total cellular respiration (R’) of the group.   
As mentioned previously, maximal ETS capacity (Eabs) is a measure of mitochondrial O2 consumption 
in a fully uncoupled state and may be an indication of the potential of cells to respond to a cellular 
stressor such as ionising radiation. In our investigations, the more resistant A549 cells had both the 
highest Eabs and greatest spare respiratory capacity, supporting this relationship. Interestingly, the 
apoptosis-sensitive U937 cells had the lowest Eabs. Spare respiratory capacity has been shown 
previously to be an important determinant in the ability of cells to respond to stress318, 320, 322.  
Correlations were observed between measures of radiosensitivity and respiration, determined under 
ideal physiological conditions where O2 was not limited. In vivo, due to the oxygen effect, tumour 
hypoxia reduces the radiosensitivity of solid tumours. Differences in the respiration rate of tumour 
cells might be expected to influence tumour O2 concentration and influence the extent of tumour 
hypoxia, particularly when blood supply is limited.  
A positive correlation between intrinsic radiosensitivity and mitochondrial respiration (Rabs) in this in 
vitro model, despite the absence of hypoxia, may suggest that inherent respiratory function may also 
affect radiation response more directly. 
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Correlations observed between respiratory parameters and radiosensitivity may relate to oxidative 
stress, which is often evident in cancer cells as a result of mitochondrial dysfunction299, 662. Adaptive 
measures that aid cells in coping with oxidative stress include increased anti-oxidant defences663, 664 
such as upregulation of MnSOD301 or increased mitochondrial proton leak298, 306. Increased 
mitochondrial O2 consumption with higher accompanying proton leak, in our cells, may indicate up-
regulation of anti-oxidant defences. The more resistant A549 and T47D cells had a higher LEAK 
respiration (Labs) and, given the role of ROS in radiation damage, such higher LEAK respiration could 
indicate an increased ability to scavenge radiation-induced ROS and induce radiation resistance. It 
has been established that the upregulation of anti-oxidant defences protects against radiation 
damage by neutralising ROS300, 302, 303, 310.  
4.4.2. Mitochondrial morphology 
Mitochondrial fission and fusion status was assessed by categorisation of cells depending on the 
relevant predominant morphology.  
Integrity of mitochondrial morphology assessment 
Mitochondrial morphology was effectively classified using fluorescence microscopy in the three 
adherent cell lines selected for characterisation. The reliability of morphological quantitation was 
optimised by processing cells under physiological conditions and by viewing cells attached to 
coverslips to attain clear images given the shallow depth of focus. In addition, it was verified that the 
fixation process did not affect the appearance of mitochondria (Appendix C, Figure C2). Further, 
confocal microscopic images for A549 cells were found to be practically identical to images obtained 
using conventional fluorescence microscopy (Appendix C, Figure C4).  
Correlations with mitochondrial morphology  
The strong correlation between the fragmentation index and inherent radiation-responsiveness 
supported our hypothesis that increased mitochondrial fusion can protect against ionising radiation. 
The A549 cell line displayed the highest level of fusion and had the lowest radiation response.  
Increased fusion has been linked with increased electron transport capacity, which is consistent with 
the negative correlation found between the fragmentation index and the respiratory parameter, ETS 
(r = -0.918). Moderate negative correlations with O2 consumption as a proportion of maximum 
capacity (R/E and netR/E) are also in agreement, as mitochondrial fusion is generally increased to 
meet respiratory demands, leading to an increase in utilised capacity.  
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The A549 model displayed a greater proportion of cells with fused mitochondria, high respiratory 
capacity and increased resistance to radiation, however, these factors cannot be unequivocally 
linked.  
Wide variation in mitochondrial morphology was particularly evident for the A549 cell population. 
Mitochondrial morphology is dynamic, and allows constant adaptation to cellular circumstances. 
Diverse morphological features in a population of cells are also indicative of a proliferative state507. 
In addition, mitochondrial morphology varies through the cell cycle371, 503, 504 and assessment of 
morphology in an asynchronous population would likely reflect the distribution of cells in the cell 
cycle. Given the variability in radiosensitivity of cells in different phases of the cell cycle, the 
proportion of cells in each phase for the different cell lines may influence their respective 
radiosensitivity. For example, a cell line that is highly proliferating would have an increased 
proportion of cells in mitosis, a particularly radiosensitive phase. In this case, the cell line may 
display an increase in fragmentation as fission occurs in preparation for mitosis. Associations 
between morphology and radiation response may therefore partly indicate differences in cell cycle 
distribution between cell lines. In our experiments, survival, ΔΨm and respiration analyses for each 
cell line were performed in an asynchronous state. While correlation analysis of the inherent 
characteristics of the cell populations as a whole may reflect radiosensitivity, potential cell cycle 
effects cannot be discounted. 
4.4.3. Mitochondrial membrane potential 
Sensitivity of the JC-1 assay used for ΔΨm assessment 
Correlation analyses with measures of ΔΨm were carried out for the four selected cell lines.  
JC-1 is commonly used to detect relatively large differences in ΔΨm that occur during apoptosis.  
It was therefore important to show that this assay could be effectively used to detect smaller 
changes in ΔΨm. The assay effectively resolved the reduction in ΔΨm induced by non-toxic 
concentrations of sodium azide indicating that sensitivity was sufficient to detect potentially small 
differences between the cell lines.  
Subtle differences in ΔΨm amongst cells within a tumour could be demonstrated using a similar 
technique339. Of note, despite heterogeneity in ΔΨm, no differences in cell viability or growth were 
observed339. Similar variability in ΔΨm was demonstrated in our cell lines as evidenced by the wide 
range of ΔΨm values determined for individual cells.  
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While mitochondrial dyes have been shown to affect cellular metabolism by, for example,  
inhibiting ATP synthase activity665, the JC-1 stain was shown not affect respiratory control ratios at 
0.37 µg/ml349. Moreover, routine use in flow cytometry assays has demonstrated no significant 
cellular effects for concentrations up to 10 µg/ml yielding a cell viability in excess of 95 %347, 666.  
In our experiments, a concentration of 1 μg/ml JC-1 was applied and we did not observe any  
adverse effects on the cell shape or membrane integrity. 
Correlations with ΔΨm 
JC-1 ratio and j-aggregate values, were strongly correlated (r2 = 0.93; p = 0.035) with each other 
(Figure 4.6). JC-1 j-aggregate values gave greater consistency between experiments, however, the 
correlations suggest that R:G ratio values also described relative differences between cell lines well.  
ΔΨm and radiation response 
As discussed above, a strong, negative correlation between ΔΨm and intrinsic radiation-
responsiveness was demonstrated. High ΔΨm in cancer cells has been associated with both 
sensitivity and resistance to chemotherapeutic agents. For example, a study investigating the 
intrinsic ΔΨm in cells from colonic and mammary tumours showed an association between 
chemoresistance and cells with higher ΔΨm667. The investigators suggested that mtDNA mutations 
may be responsible for increased ΔΨm in certain clones and reported a common heteroplasmic 
mtDNA mutation in clones with elevated ΔΨm that was absent in those with lower ΔΨm.  
Similarly, cisplatin-resistant human adenocarcinoma and hepatoma cells displayed higher ΔΨm 
along with a reduced O2 consumption and a disordered mitochondrial morphology, when compared 
to parent cells344. A high ΔΨm, therefore, is not always associated with functional integrity in tumour 
cells, despite enabling resistance to therapy. 
ΔΨm and mitochondrial fragmentation 
Mitochondrial membrane potential correlated strongly with the fragmentation index  
(median: r = 0.95; p = 0.20) in contrast to reports that decreased ΔΨm is associated with increased 
fragmentation in normal and cancer cells569, 668, 669. Mitochondrial fusion is frequently associated with 





However, cells with fragmented mitochondria may show increased ΔΨm in the context of 
respiratory dysfunction. For example, the highly fragmented DU145 cell line has been shown to have 
aberrant mitochondrial metabolism, displaying a low affinity of complex 1 for NADH and a reliance 
on glutamate as a substrate670.  
Electrogenic transport provided by a high ΔΨm is necessary for glutamate transport into the 
mitochondrial matrix. Upregulation of proton import into the matrix, in spite of the fragmented 
state, would then be required and would be consistent with the observed correlations. The 
underlying reasons for a high ΔΨm in DU145 and U937 cells may be multifaceted. However, this 
finding is consistent with the tendency for many cancer cells to display hyperpolarised ΔΨm334. 
ΔΨm and respiration 
In keeping with the inverse relationship between ΔΨm and respiration mentioned previously, 
negative correlations were observed between ΔΨm and mitochondrial O2 consumption (Rabs).  
In the context of aberrant respiratory function, these correlations are consistent with the 
phenomenon where ΔΨm is increased as a result of ATP synthase dysfunction or reversal313, 314. 
Another explanation may be related to the “leakiness” of the mitochondrial membrane. Cells that 
have a high O2 consumption may display low ΔΨm as a result of proton leak from the 
intermembrane space. Both the A549 and T47D cells showed higher LEAK respiration (Labs) and had 
relatively low ΔΨm. UCP2, a mitochondrial membrane uncoupling protein has been shown to be 
increased in cancer cells leading to increased proton leak306, which is thought to be an adaptation to 
manage oxidative stress671-673. In one study, a similar JC-1 value to that obtained for the T47D cells 
was determined for MFN2-mutant cells that displayed uncoupling of respiration and a reduced 
RCR674.   
In contrast, the U937 respiration is relatively more efficient and less O2 consumption is attributed to 
LEAK respiration. These cells may therefore maintain a higher ΔΨm than cells with increased LEAK 
respiration despite reduced overall capacity. 
Strong, significant correlations between ΔΨm and ETS capacity (Eabs), as found in this study, are 
interesting although may be difficult to interpret. Maximal respiration was measured during 
complete uncoupling whereas ΔΨm was measured under conditions of routine respiration.  
ΔΨm has been shown to be dissipated in the presence of FCCP, a respiratory uncoupler675, 676. 
Maximal stimulation of respiration during increased ATP demand, however, would presumably 
require an intact ΔΨm.  
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In addition, the ETS capacity value, although useful for normalising mitochondrial function for 
comparison of cell lines, is dependent on mitochondrial content and ΔΨm values may therefore 
reflect differences in mtDNA copy number.  
Nevertheless, the possibility that respiratory capacity may be reflected by ΔΨm under routine 
conditions is worth considering. Deficiencies in electron transport may be reflected by low ΔΨm677, 
however, reduced ΔΨm may not necessarily indicate a deficiency in maximal respiratory 
capability678. Notably, A549 cells displayed the highest Eabs despite having a reduced ΔΨm.  
A549 cells preferentially rely on glycolysis for energy metabolism. This may be due to inhibition of 
pyruvate dehydrogenase (PDH) through dysregulation of PDH kinase679. The metabolic targeting 
agent, dichloroacetic acid, which enables PDH activation, increased OCR by 60 %, thus normalising 
glucose oxidation in these cells553, 680. Likewise, the addition of succinate, the substrate for  
complex II, to A549 cells in culture increased O2 consumption681. This potential to upregulate 
OXPHOS suggests that low ΔΨm in A549 cells may reflect the restricted use rather than lack of 
respiratory capacity.  
The mitochondrial efficiency, represented by RCR, correlated positively with ΔΨm. The leakiness of 
the membranes which, in turn, influences ΔΨm determines, in part, the efficiency of mitochondrial 
respiration. Therefore, such an association is plausible.  
The U937 cells displayed the highest RCR (9.1) while the lowest value was determined for the T47D 
cell line (4.1). Healthy, respiring cells were indicated to have RCR values of 10 or higher682. Similarly 
in a study of human fibroblasts, RCR was approximately 12674.  Several studies that included both 
normal and tumour cells have shown RCR values ranging from 3 to 10 in isolated mitochondria683. It 
would appear therefore, that the mitochondrial efficiency of U937 cells was similar to that of normal 
cells. This high efficiency was in spite of a lower mitochondrial respiration rate. In contrast, the T47D 
mitochondrial respiration rate was higher.  
T47D cells have a high LEAK state respiration which corresponds with their relatively lower ΔΨm, 
and may be responsible for their low mitochondrial efficiency. In a study comparing breast cancer 
cell lines, it was reported that T47D cells have a low mitochondrial efficiency relative to MCF7 
cells292. The increased radiation-responsiveness of the T47D cells may reflect differences in 





Correlations between respiratory parameters 
As expected, strong correlations between different measures of respiratory function were found. 
Similarly, minimal correlation of measures of mitochondrial function with maximal respiratory 
capacity (Eabs) and total cellular respiration (R’), was probable as these parameters include non-
mitochondrial respiration.  
It has been reported in a diverse group of cancer cell lines that non-mitochondrial O2 consumption  
is frequently approximately 10 %, but can vary significantly between 1 and 90 % of total O2 
consumption684. The proportion of maximal O2 consumption (ROX/E’) in each of our cell lines was 
generally higher than previously reported327. In particular, the DU145 cell line showed higher non-
mitochondrial O2 consumption than the other cell lines. Non-mitochondrial O2 consumption is 
mainly due to oxidase enzymes including NAD(P)H oxidases (NOX) and peroxidases.  
DU145 cells, that displayed the highest ROX, have been shown to have high expression of NOX 
enzymes685, 686. In addition, extracellular acidification of the culture medium has been associated 
with cell surface O2 consumption684. The DU145 cells were observed to acidify the culture medium 
more rapidly than the other cell lines, which may be related to this process. 
4.4.4. Limitations of correlation analysis 
The present work selected a subgroup of available cell lines on the basis of observed radiosensitivity. 
Thus, a limited number of cell lines was analysed, which may provide selective information that 
would need to be expanded for wider generalisation and increased statistical power. In addition, 
only three parameters of mitochondrial structure and function were investigated. It may be 
necessary to describe mitochondrial function more comprehensively. No clear associations between 
radiosensitivity and the factors investigated in this study have been described previously. The 
correlations observed were, therefore, useful to identify trends that could be elucidated in future 









Characterisation and investigation of radiation sensitivity and mitochondrial structural and 
functional features in a range of tumour cell lines has provided a complex, yet informative picture of 
cellular status and radiation response.  
• The six cell lines assessed provided a range of cellular responses to radiation.  
• Strong, negative correlations were displayed between measures of radiation-responsiveness 
and both mitochondrial morphology and ΔΨm, although the associations were not 
statistically significant. 
• Heterogeneous mitochondrial morphology and ΔΨm within and between cell populations 
was observed suggesting functional differences. The relatively high ΔΨm values overall 
support the notion that cancer cells have hyperpolarised inner mitochondrial membranes. 
• Respiratory parameters examined were similar between cell types, however, the A549 cells 
had the greatest reserve respiratory capacity and the DU145 cells had significantly higher 
non-mitochondrial O2 consumption.  
• Strong correlation of ΔΨm with respiratory capacity and RCR, an index of mitochondrial 
function, suggested that ΔΨm may reflect mitochondrial efficiency. 
 
Overall, the mitochondrial status of cancer cells may be a factor contributing to cellular radiation 
response. This work highlights the application of modern mitochondrial assessment techniques to 
examine novel aspects of the radiosensitivity of cancer cells. Future studies, that include an 





DO MITOCHONDRIAL DYNAMICS AFFECT  
CELL SURVIVAL AND RADIATION RESPONSE? 
 
Since mitochondria indirectly support many aspects of cellular damage response, including repair, 
cell cycle arrest and apoptosis, it is conceivable that mitochondrial modulation may influence 
radiation response. Changes in mitochondrial dynamics have been found to affect cellular response 
to cytotoxic agents other than radiation14, 596, 597. In addition, cellular bioenergetic and redox status, 
which are largely determined by mitochondrial function, have been shown to modulate radiation 
sensitivity300, 687, 688. Alteration of mitochondrial fission and fusion processes, which may critically 
affect mitochondrial function, may influence response to radiation. 
The mitochondrial division inhibitor, Mdivi-1, has been shown to cause increased fusion, and was 
thus used to examine the influence of modulation of such processes on radiation response and 
cytotoxicity in the current work. This chapter considers inhibition of mitochondrial fission in 
combination with radiation therapy in terms of cell survival, cell cycle arrest and repair. 
 
5.1. Aims 
1) To investigate the influence of inhibition of mitochondrial fission on cancer cell survival.  
2) To investigate the potential for inhibition of fission to modulate the radiosensitivity  
     of cancer cells. 
The specific objectives were:  
a) To demonstrate an Mdivi-1-induced shift in mitochondrial morphology and determine  
the appropriate concentrations for combination with radiation treatment.  
b) To determine the effect of Mdivi-1 treatment on clonogenic cell survival. 
c) To determine the effect of Mdivi-1 treatment on clonogenic survival after irradiation. 
d) To determine the effect of Mdivi-1 treatment on repair of radiation-induced damage. 






The A549 cell line was selected for modulation of mitochondrial dynamics using Mdivi-1 and for the 
investigation of the effect of Mdivi-1 on radiation response. This cell line was an established model 
that yields clear mitochondrial morphology and has been used extensively for testing of cytotoxic 
agents in vitro. For radiation survival assays, cells were -irradiated using a 60Co-teletherapy unit as 
described in Appendix B2. 
5.2.1. Effect of Mdivi-1 on mitochondrial dynamics  
5.2.1.1. Assessment of the Mdivi-1-induced shift in mitochondrial dynamics 
Mdivi-1 (Sigma-Aldrich) was reconstituted in DMSO to a stock concentration of 57 mM. Working 
solutions were diluted in RPMI medium supplemented with 10 % FCS and 1 % AB and maintained a 
DMSO concentration below 0.1 %. 
Categorical approach based on morphological sub-types 
Adherent A549 cells were plated at a density of 10 000 cells per cm2 onto 22 x 22 mm glass 
coverslips (Lasec) placed in 35 x 10 mm CELLSTAR® cell culture dishes (Greiner Bio-One) and incubated 
in RPMI culture medium (with FCS and AB) at 37°C for 12 h to adhere. Dilutions of Mdivi-1 were 
prepared to final concentrations of 5, 10, 20, 30, 50 and 100 µM. Samples were incubated in 1 ml of 
the respective Mdivi-1 concentration for 3 h under physiological conditions. Controls containing 
equivalent concentrations of the vehicle (DMSO) to those of experimental samples were included.  
In addition, untreated samples were included for comparison with the control samples.  
After the required treatment time, Mdivi-1-containing medium was removed and cells were washed 
once with pre-warmed RPMI medium prior to staining of mitochondria. The MitoTracker® Red 
staining protocol was outlined in section 4.2.3.1. Briefly, samples were stained with 100 nM 
MitoTracker® Red (Molecular Probes® Inc) for 15 minutes at 37°C, fixed with 4 % paraformaldehyde in 
culture medium (Appendix D2.3.1) and stored at 4°C in 1 ml PBS until assessment. 
The visualisation and quantification of morphological subtypes was described in Chapter 4.  
A minimum of 200 cells per sample (n = 11), from three separate experiments, were classified 
microscopically using the mitochondrial morphology categorisation system described previously 
(section 4.2.3.2, Table 4.2).  
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Control and untreated samples (n = 7), with and without DMSO respectively, were scored in parallel 
to confirm that the DMSO did not affect mitochondrial morphology and classification.  
Small-fragment analysis for the quantification of mitochondrial fragmentation  
Methods for quantifying mitochondrial morphology are varied and not standardised for application 
in different laboratories. Observational approaches for classifying mitochondrial morphology, as 
used above, are limited by the subjective components of assessment. In an attempt to develop a 
more objective technique for assessing induced changes in fragmentation, a method based on the 
technique of Farrand et al. (2013)689 was applied. The method involves the identification of the 
minimum number of small (< 3 µm) mitochondrial fragments in individual cells and a diagram 
illustrating the principle of the technique is shown in Appendix E1.4.   
Mdivi-1 treatment and analysis for Small-fragment analysis 
The method of Farrand et al. (2013)689 was modified to quantify mitochondrial fragmentation 
induced by Mdivi-1. The criteria for distinguishing cells based on fragment number were adapted to 
account for inherent differences in the extent of fragmentation in our cell lines.  
Cells were cultured as described previously and were treated with 30 µM Mdivi-1 for 2 h prior to 
staining (Appendix C1).  MitoTracker® Red-stained cells were divided into groups based on the 
number of small (< 3 µM) mitochondrial fragments per cell. 
Initially, 4 categories, namely, 0-5, 6-11, 12-20 and > 20 fragments were selected arbitrarily to 
determine the critical level of fragmentation required to distinguish untreated cells from Mdivi-1 
treated cells. At least 50 cells were classified per category from 3 replicate samples. The results of 
this initial experiment to establish suitable criteria are shown in Figure 5.6 in the results section.  
Further categorisation was then possible to determine the number of fragments required to detect  
a difference between groups. This pilot analysis set the criteria for subsequent experiments. 
An additional analysis of the abovementioned Mdivi-1 treated and untreated samples using a small-
fragment threshold of 40 fragments was included. At least 100 cells per group (n = 3) were analysed 
and categorised as containing either ≤ 40 or > 40 small fragments.  
Based on initial preparative experiments, Mdivi-1-induced fusion in A549 cells following a 6 h 
treatment was evaluated for both 10 and 30 µM Mdivi-1 concentrations. The cells were divided into 




5.2.2. Effect of Mdivi-1 on mitochondrial membrane potential  
Mdivi-1-induced changes in ΔΨm were investigated using A549 cells. The protocol for JC-1 staining 
was similar to that described in section 4.2.4.1 and detailed in Appendix C3. Cells were plated at a 
density of 500 000 cells/ml and were incubated in 1 ml Mdivi-1 (30 µM) for 3 h under physiological 
conditions. Control samples were mock-treated. Samples were washed twice with RPMI and 
incubated in JC-1 dye for 15 minutes at 37C. As described previously, images of cells were captured 
for quantification using fluorescence microscopy (Appendix D).  
5.2.3. Effect of Mdivi-1 on clonogenic survival  
The toxicity of Mdivi-1 in the A549 cell line was determined initially. Thereafter, the role of 
mitochondrial dynamics in radiation response was examined using Mdivi-1. 
The cytotoxicity of 0, 10, 20, 30 and 50 µM Mdivi-1 in A549 cells was assessed using the clonogenic 
cell survival assay. Analyses of cell survival with Mdivi-1 were carried out using post-plated assays, as 
detailed in Appendix B1.3. Briefly, equal numbers of cells for each concentration were seeded and 
incubated for 20 h prior to treatment. The cells were treated with Mdivi-1 for a total of 6 and 16 h, 
respectively, at 37C. After the required exposure time, the Mdivi-1 incubation medium, PBS washes 
and trypsinised cells were collected to ensure that no cells were discarded. After the appropriate 
dilutions were made, cells were plated out and incubated at 37°C for 10 days for colony formation. 
At least 5 replicate samples were included for each dose point. Stained colonies were counted 





5.2.4. Effect of Mdivi-1 on cellular radiation response 
The potential modulation of radiation response by Mdivi-1 was investigated in the A549 cells using 
two different Mdivi-1 doses, as determined from initial morphology and survival experiments. The 
lowest dose that resulted in a significant change in mitochondrial morphology was selected for initial 
experiments. Subsequent experiments explored the modulation of radiation response using Mdivi-1 
doses that showed evidence of cytotoxicity as well as a shift in mitochondrial morphology. 
5.2.4.1. Effect of Mdivi-1 on radiation survival  
Treatment with doses of Mdivi-1 that induce fusion without cytotoxicity 
The lowest Mdivi-1 dose that was shown to alter mitochondrial dynamics in A549 cells was initially 
used to investigate the modulation of radiation response. In this way, the effect of increased 
mitochondrial fusion, in the absence of toxicity, on cellular response to irradiation could be 
assessed. Clonogenic survival after Mdivi-1 treatment for 6 h either prior to or post-irradiation was 
determined.  
As mentioned, cell survival analyses with Mdivi-1 were carried out using post-plated clonogenic 
assays. Mdivi-1 and radiation treatments were applied in two different schedules that are 
represented schematically in Figure 5.1. Four experimental groups were included, namely, a control, 
5 Gy, 10 µM Mdivi-1 (6 h) and 5 Gy with Mdivi-1. Briefly, cells were either treated with 10 µM Mdivi-
1 for 6 h followed by 5 Gy irradiation (immediate plating) or irradiated and then treated with Mdivi-1 
for 6 h (delayed plating after irradiation). After the required exposure time, Mdivi-1 incubation 






Figure 5.1. Two different treatment schedules for the combination of Mdivi-1 and 5 Gy 
for examination of the effect of Mdivi-1 on radiation response. A) Mdivi-1 treatment for 






For Mdivi-1 pre-treatment, cells were irradiated in the presence of Mdivi-1 or the vehicle. Surviving 
fractions were calculated as described in section 4.2.2.2. To determine Mdivi-1 effects on radiation 
response, Mdivi-1-induced reduction in survival was taken into account by using the plating 
efficiency of cells exposed to Mdivi-1 alone. Surviving fractions were determined from 8 replicates 
collected from two separate experiments.   
Treatment with doses of Mdivi-1 that induce fusion and cytotoxicity 
Clonogenic cell survival assays were also used to examine the effects of higher doses of Mdivi-1. 
Briefly, cells were incubated in 30 µM Mdivi-1 for 6 or 16 h, prior to 5 Gy irradiation. The groups 
included, an untreated control, Mdivi-1 (30 µM), 5 Gy and 5 Gy with Mdivi-1. Cells were  
pre-incubated with Mdivi-1 for the required time, as depicted in the irradiation schedule illustrated 
in Figure 5.2. Cells were irradiated in the presence of Mdivi-1 or the vehicle and were washed before 
plating. The effects of 16 h Mdivi-1 treatment were investigated with doses of 2, 5 and 8 Gy. 
Surviving fractions were calculated as described previously for at least 10 replicate samples. Again, 




Figure 5.2. Irradiation schedules for different Mdivi-1 exposure times pre-irradiation.     
5.2.4.2. Effect of Mdivi-1 on split dose repair in A549 cells 
The effect of Mdivi-1 on sub-lethal damage repair after irradiation, was investigated using a  
split-dose experiment.  
Split-dose repair assay 
A pre-plated clonogenic assay (Appendix B1) was used to assess radiation survival after delivering 
two fractions separated by different time intervals. Cells were plated into 35 x 10 mm CELLSTAR®  
cell culture dishes (Greiner Bio-One) for a yield of at least 100 colonies after treatment. Cells were 





Cells were treated in triplicate with 30 µM Mdivi-1 or the vehicle for 1 h and then irradiated. A dose 
of 6 Gy was given in a single fraction or in two separate fractions of 3 Gy each, with up to 6 h 
between fractions, as shown in Figure 5.3. After each treatment, dishes were washed with 2 ml 
RPMI to remove Mdivi-1 and samples were incubated for colony formation. Unirradiated controls 
were mock treated. Recovery ratios were calculated by determining the ratio between the surviving 
fraction obtained for a split dose and the value obtained for 6 Gy.  
To assess any potential radio-modulating effects of Mdivi-1 exposure prior to irradiation, survival at  





Figure 5.3. Irradiation schedules for examination of the effect of Mdivi-1 on split dose repair.     
 
5.2.4.3. Effect of Mdivi-1 on the cell cycle 
The cell cycle distributions for A549 cells were assessed following treatments with combinations of 
Mdivi-1 and radiation. The groups included, an unirradiated control, Mdivi-1 (30 µM), 5 Gy and 5 Gy 
with Mdivi-1. The irradiation schedule for the combined group is depicted in Figure 5.4. Briefly, cells 
were exposed to Mdivi-1 for 1 h, irradiated with 5 Gy and incubated at 37°C for a further 5 h in 
Mdivi-1. The cells were washed and incubated for an additional time, as necessary, for collection at 
5, 12, 24, and 48 h after irradiation. The control groups were mock treated and collected at the 
respective time points.  
Flow cytometry 
The flow cytometry protocol is detailed in Appendix G. Briefly, following the required treatment and 
incubation schedules, cells were trypsinised and pelleted by centrifugation for 10 minutes and 
resuspended in 2 ml PBS supplemented with 2 % FCS. Samples were washed twice and resuspended 
in 1 ml PBS (with 2 % FCS). While vortexing, 3 ml ice cold absolute ethanol was added dropwise and 
cells were incubated at 4°C for 1 h and stored at -20°C.   
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Cells were stained 24 h prior to analysis. Samples were washed with PBS and resuspended in  
500 µl RNAse A solution (1 mg/ml). After incubation at 37°C for 30 minutes, 50 µl propidium iodide 
(500 µg/ml) was added directly to the RNAse A-containing samples to give a final concentration of  
50 µg/ml. Samples were stored in the dark at 4°C until analysis. 
Flow cytometry and cell cycle profile analysis were carried out with the assistance of the UCT Flow 
Cytometry Core Facility (IDM, UCT) using a Beckton-Dickinson (BD) FACSCalibur™ flow cytometer (BD 
Biosciences, Franklin Lakes, NJ, US) and the ModFit LT™ v3.3.11 data analysis program (Verity Software 
House, Topsham, ME, US). At the time of sample acquisition, each sample was filtered using a 5 ml 





Figure 5.4. Mdivi-1 and 5 Gy irradiation schedule for A549 cell cycle analysis.  
 
5.2.5. Statistical analyses  
GraphPad PRISM v6.05 (GraphPad software) was used for all analyses. A p-value smaller than 0.05 was 
considered statistically significant and error bars in the figures represent SEM. 
Mdivi-1-treated and control groups from the Categorical morphological analysis, and Mdivi-1-
treated and irradiated groups from clonogenic survival analyses, were compared using ANOVA and 
the Fisher’s LSD test. The Student’s T-test (two-tailed, unpaired, equal variance) was used for 
pairwise comparisons to evaluate differences between Mdivi-1-treated and control groups for  
Small-fragment and survival analyses. JC-1 ratio values, for quantification of changes in ΔΨm after 
Mdivi-1 treatment, were compared using the Mann-Whitney U nonparametric test.  
Recovery ratios determined for the split-dose repair experiment, for Mdivi-1 treated and untreated 
samples, and differences in cell cycle distributions were compared for each time-point using the 




5.3.1. Effect of Mdivi-1 on mitochondrial dynamics  
5.3.1.1. Mdivi-1-induced shift in mitochondrial morphology 
Categorical approach based on morphological sub-types 
The effect of Mdivi-1 on mitochondrial fission and fusion was determined by categorisation of 
mitochondrial morphology. The overall proportion of cells representing a predominantly fragmented 
phenotype for each concentration of Mdivi-1 was determined (Figure 5.5). The proportion of cells 
with fragmented mitochondria (fragmentation index) decreased from approximately 42 to 32 % 
following exposure to Mdivi-1 concentrations of 10 µM (p = 0.011), 30 µM (p = 0.015) or 50 µM  
(p = 0.015). The trend towards a decrease in fragmentation was also observed with 100 µM but was 
not statistically different from controls (p = 0.381). At this higher concentration, there was no 
noticeable swelling of mitochondria, which might indicate stress or cytotoxicity. In addition, 
comparison of control and untreated samples indicated that the DMSO vehicle did not have a 










Figure 5.5. Mdivi-1 induced mitochondrial fusion in A549 cells. Cells were categorised 
using MitoTracker® Red staining following Mdivi-1 treatment. Data are shown as 
mean ± SEM and represent 11 replicate samples from 3 independent experiments. 
*P < 0.05 versus vehicle. 
* * * 
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Effect of Mdivi-1 on ΔΨm 
After 3 h Mdivi-1 (30 µM) treatment, the ΔΨm as determined from the mean R:G ratio was 
significantly increased by 48 % relative to controls (p < 0.01).  
Small-fragment analysis for the quantification of mitochondrial fragmentation  
Figure 5.6A shows the effect of Mdivi-1 on the proportion of cells displaying specific numbers of 
small mitochondrial fragments, namely, 0-5, 6-11, 12-20 and > 20 fragments. The difference 
between Mdivi-1 treated and control cells was most evident in the 0-5 fragment category  
(p < 0.001), indicating an increased number of cells containing only a few small mitochondrial 
fragments for the Mdivi-1-treated group. Conversely, a decrease in the number of Mdivi-1-treated 
cells displaying a larger number (12-20) of small fragments, was observed, however this was not 
significant.  
Cumulative totals of the proportion of cells displaying up to a certain threshold fragment number are 
shown in Figure 5.6B. At a threshold number of 10 fragments (≤ 10), the Mdivi-1 treated group was 
again significantly different from untreated cells (p < 0.01). However, while there was a trend 
towards an increase in the number of cells with ≤ 20 small fragments, this disappeared when a 









Figure 5.6. A shift in mitochondrial fragmentation induced by Mdivi-1. A) Cells displaying 
specific numbers of small mitochondrial fragments for each category. B) Cumulative totals of 
cells displaying up to a certain threshold fragment number. Data are shown as mean ± SEM 








The determined threshold value of 10 fragments was then applied to the analysis of 10 and 30 µM 
Mdivi-1 treatments for 6 h. The method was unable to detect a difference from untreated cells for  
10 µM but did show an approximately 30 % change relative to controls for cells treated with 30 µM  










Figure 5.7. Small-fragment analysis of cells treated for 6 h with 10 and 30 µM Mdivi-1, 
respectively. Dark bars represent the ≤ 10 fragment sub-group while light bars represent 
cells with > 10 mitochondrial fragments per cell. Data are shown as mean ± SEM and 
represent 3 replicate samples. *P < 0.05 versus control. 
 
5.3.2. Effect of Mdivi-1 on clonogenic survival  
The cellular dose response for 6 and 16 h Mdivi-1 treatment is given in Figure 5.8. Mdivi-1 was 
cytotoxic at concentrations of 20 µM and above for 16 h treatments, with a maximum toxicity of 
approximately 65 % at 30 µM. The 6 h, 30 µM Mdivi-1 treatments induced minimal toxicity (15 %), 
however this was not significant. In addition, the 20 and 50 µM survival fractions for the 6 h 
treatments were similar to that of control samples. The 10 µM Mdivi-1 treatment did not induce a 
decrease in survival for either treatment time. Additional cell proliferation assays using 
quantification of crystal violet nuclear staining confirmed that 10 µM Mdivi-1 had no toxicity in the 













Figure 5.8. Mdivi-1-induced cytotoxicity in A549 cells was dose- and time-dependent. 
Surviving fractions were normalised to control samples. Data are shown as 
mean ± SEM and represent at least 5 replicate samples from multiple experiments.  
 
 
5.3.3. Effect of Mdivi-1 on cellular radiation response  
5.3.3.1. Treatment with doses of Mdivi-1 that induced fusion without cytotoxicity 
The effect of a low, minimally toxic dose of Mdivi-1 (10 µM) on A549 radiation responsiveness was 
investigated using clonogenic survival assays. Figure 5.9 illustrates the surviving fraction of cells 
exposed to Mdivi-1 either before or after irradiation. In these experiments, Mdivi-1 induced minimal 
toxicity, which was not significantly different from controls. No significant difference was observed 
between groups for either pre-treatment or post-treatment with 10 µM Mdivi-1. A difference in 
survival after 5 Gy between the immediate and delayed plating experiments was demonstrated  















Figure 5.9. Mdivi-1 (10 µM) treatments did not influence radiation response. Cells were pre-
treated with Mdivi-1 for 6 h then irradiated (immediate plating) or irradiated and then treated 
with Mdivi-1 for 6 h (delayed plating). Data are shown as mean ± SEM and represent 8 replicate 
samples from 2 independent experiments. *P < 0.05 versus 5 Gy + 6 h vehicle. The right-hand 






5.3.3.2. Treatment with Mdivi-1 doses that induce fusion and cytotoxicity 
The effect of 30 µM Mdivi-1 (6 h) in combination with 5 Gy was assessed and the survival shown in 
Figure 5.10. The combined effect of Mdivi-1 and radiation did not significantly reduce survival 
compared to irradiation alone (0.13 versus 0.10, p = 0.17). The presence of Mdivi-1 also did not 
influence radiation efficacy as surviving fractions were equal when corrected for Mdivi-1 toxicity. 








Figure 5.10. Short exposure (6 h) to 30 µM Mdivi-1 did not influence the A549 radiation response. 
Data are shown as mean ± SEM and represent 10 replicate samples from 3 independent 
experiments. The bar labelled ‘5 Gy (Mdivi-1)’ represents the survival after irradiation corrected for 
Mdivi-1 toxicity. 
 
As reported, treatment of cells with 30 µM Mdivi-1 for 16 h reduced survival by approximately 60 %. 
Moreover, radiation cell kill and radiation efficacy were enhanced with the addition of Mdivi-1 
(Figure 5.11). Mdivi-1 when added to 5 Gy resulted in a 5-fold (80 %) decrease in survival relative to 
radiation alone (p < 0.001). Notably, as shown in the right-hand bar, Mdivi-1 sensitised cells to 5 Gy 













Figure 5.11. Extended exposure (16 h) to Mdivi-1 enhanced the A549 radiation 
response. The effect of Mdivi-1 on radiation response corrected for Mdivi-1 toxicity is 
shown on the right. Data are shown as mean ± SEM and represent 10 replicate samples 
from 3 independent experiments. *P < 0.05 versus 5 Gy. 
 
Modulation of radiation response by Mdivi-1 is also shown in Figure 5.12. Mdivi-1 significantly 
reduced survival by 40 % (p < 0.001) and 25 % (p < 0.001) for 5 and 8 Gy, respectively. Mdivi-1 did 









Figure 5.12. Mdivi-1 modulates the radiation response of A549 cells. Cells were pre-
treated with Mdivi-1 for 16 h followed by irradiation. Data are shown as mean ± SEM 








5.3.3.3. Effect of Mdivi-1 on split dose repair  
The split dose repair experiment compared the survival after two separate 3 Gy fractions separated 
by up to 6 h in the presence and absence of Mdivi-1. Figure 5.13 shows the influence of Mdivi-1 on 
repair of radiation-induced sub-lethal damage. Recovery ratios for samples irradiated alone or in the 
presence of Mdivi-1, plotted against the time between fractions, are compared. Significant repair 
was demonstrated when time was allowed between fractions in both the presence and absence of 








Figure 5.13. Mdivi-1 did not influence radiation-induced damage repair. Recovery ratios 
indicate the surviving fractions after a split dose relative to surviving fractions obtained 
using a single fraction. Data are shown as mean ± SEM and represent 3 replicate samples. 
5.3.3.4. Effect of Mdivi-1 on the cell cycle  
The effect of Mdivi-1 treatment on the A549 cell cycle was investigated using flow cytometry. In 
addition, Mdivi-1 treatment was combined with 5 Gy irradiation to determine the potential for 
Mdivi-1 to modulate cell cycle distributions (Figures 5.14 and 5.15).  
As illustrated in Figure 5.15, after Mdivi-1 treatment (6 h), a 10 % increase in the proportion of cells 
in S-phase (p = 0.01) was observed with a parallel reduction in the proportion of cells in G1  
(p = 0.01) relative to controls. After a further 6 h incubation without Mdivi-1, an 80 % increase in the 
proportion of cells in G2/M (p < 0.01) was observed and a 20 % decrease in the proportion of cells in 
S-phase (p < 0.01) relative to controls. At longer times, cycle distributions for Mdivi-1 treated cells 
were similar to those of controls, however the S-phase population showed a 10 % increase at 24 h, 
relative to controls with a concomitant decrease in G1 cells.  
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Figure 5.14. Representative cell cycle profiles for cells treated with Mdivi-1, 5 Gy or Mdivi-1 and 5 Gy. 
Indicated times represent time after irradiation. Cells were treated with Mdivi-1 for 6 h (1 h prior to 
irradiation followed by 5 h post-irradiation). Replicate data is presented in Figure 5.15. 
 
At 5 h after irradiation with 5 Gy, a similar increase in S-phase cells (p = 0.02) and decrease in G1 
cells (p = 0.04) to that observed with Mdivi-1 treatment was noted. A radiation-induced G2/M arrest 
was observed at 12 h post-irradiation (p < 0.001) relative to control samples, as shown by an 
approximately 6-fold increase in the proportion of cells in G2/M with a concomitant 70 % decrease 
in the proportion of cells in G1-phase (p < 0.001). At 24 h post-irradiation, the G2/M proportion was 
still increased 3-fold relative to the control samples. The proportion of cells in S-phase was, however, 
reduced by 70 %. An increase in the proportion of cells in G1-phase was evident at both  





Figure 5.15. Alterations in A549 cell cycle dynamics were demonstrated following Mdivi-1 treatment 
alone and in combination with irradiation. Cells were treated with Mdivi-1 for 6 h (1 h prior to 
irradiation followed by 5 h post-irradiation). Time after irradiation is indicated. Data are shown as 
mean ± SEM and represent 3 replicate samples. 
 
For the combined treatment, the cell cycle distributions at 6 and 12 h were comparatively similar  
to that observed with both the Mdivi-1 and 5 Gy individual treatments. At 6 h, a more pronounced 
increase in S-phase cells and a 50 % decrease in G2/M cells (p < 0.01) compared to control samples 
was observed.  
The combined treatment of cells with Mdivi-1 and 5 Gy enhanced the radiation-induced G2/M cell 
cycle arrest at 12 h, as seen by a decrease in the proportion of cells in G1-phase (p < 0.001) and a 
slightly increased proportion of cells in S- and G2-phases relative to irradiation alone (Figure 5.15).  
At 24 h, the S-phase population was decreased relative to 5 Gy alone while the other phases showed 
similar proportions of cells relative to that of 5 Gy. The cell cycle distributions at 48 h were similar to 
that after 5 Gy alone. Cell cycle distributions were normalised to account for slight variations over 








Mitochondrial fusion may occur as a consequence of cellular stress690, 691 and has been shown to 
guard against radiation-induced mitotic catastrophe466 and cell death including UV-induced 
apoptosis501. Chapter 4 described the correlations between measures of mitochondrial morphology 
and function, and cellular radiosensitivity. Although inherent radiosensitivity did not specifically 
correlate with any single measure of mitochondrial activity in the cell lines analysed, it is possible 
that modulation of mitochondrial fission and fusion processes may influence the response of cells to 
radiation. 
The mitochondrial division inhibitor, Mdivi-1, has previously been shown to have protective effects 
against several toxic conditions including exposure to cytotoxic drugs. Thus, we initially hypothesised 
that inhibition of mitochondrial fission using Mdivi-1 would reduce cellular response to radiation. 
However, since mitochondrial dynamics have a crucial physiological role, it was thought that Mdivi-1 
may also induce cytotoxic effects. Evidence that modulation of mitochondrial dynamics can 
influence the response of tumour cells to radiation would demonstrate a proof of principle that may 
hold clinical utility.  
In the present study, treatments leading to mitochondrial changes that could be easily controlled or 
were rapidly reversible were preferred. Mdivi-1 treatment forms such an approach as it induces 
transient mitochondrial protein inhibition. Embryonic lethality389, 390 is frequently observed when 
fusion or fission is abolished with the use of gene knock-out models suggesting that complete loss of 
these processes is incompatible with life.  
Other protein modification tools, such as dominant negative mutants and RNA knockdown, e.g. 
siRNA, of relevant proteins are commonly used in similar experiments. However, such approaches 
typically have longer-lasting and more extreme effects on the cells than are expected with Mdivi-1 
and may confound investigations into modulation of radiation response. For example, DRP1 
knockdown was shown to alter OPA1 expression and induce apoptosis, possibly by affecting cristae 
structure 24, 692. In addition, prolonged DRP1 depletion may inhibit cell proliferation possibly through 
mitochondrial dysfunction435. The use of Mdivi-1 has the advantage that investigations can be 
carried out in an otherwise physiological setting thereby avoiding indirect effects associated with 
protein depletion. In addition, Mdivi-1 effects are rapid and can be assessed immediately allowing it 




5.4.1. Effect of Mdivi-1 on mitochondrial dynamics in A549 cells  
The A549 cell line displayed diverse mitochondrial morphological characteristics that could be 
readily quantified to assess induced alterations in mitochondrial fission and fusion. In addition, this 
cell line had a relatively high spare respiratory capacity that may suggest that it would be amenable 
to modulation of mitochondrial function.  
Mdivi-1-induced fusion 
Cassidy-Stone et al. (2008)559 first described Mdivi-1-induced fusion. Mdivi-1 has been shown to 
increase mitochondrial length and connectivity599, 609, 694-696 as a result of inhibition of fission 
processes. In addition, alterations in mitochondrial electrical continuity, sometimes referred to as 
functional fusion, has also been used to demonstrate Mdivi-1-induced effects on mitochondria21, 507.  
Morphological assessment of fusion 
In the current work, A549 cells were shown to be responsive to Mdivi-1 treatment using Categorical 
morphology assessment. A significant increase in the proportion of cells displaying fused 
mitochondria was demonstrated for Mdivi-1 concentrations of 10 to 100 µM, although the increase 
was only statistically significant up to 50 µM. This shift in mitochondrial dynamics was detectable 
despite the modest level of inherent fragmentation of approximately 40 % (Figure 5.5).  
Mdivi-1-induced changes in ΔΨm 
In addition to the morphological demonstration of fusion, Mdivi-1 was also shown to induce an 
increase in ΔΨm. The higher ΔΨm was consistent with the shift towards fusion as DRP1-induced 
fragmentation has frequently been shown to result in loss of ΔΨm437, 441, 449, 697. 
High Mdivi-1 doses may affect the net detectable fusion 
Compared to lower Mdivi-1 concentrations, the 100 µM concentration may have been expected to 
induce even higher levels of fusion. However, the level of fragmentation was found to be reduced 
compared to lower concentrations. A dose-dependent increase in fusion has been reported 
previously in COS cells in vitro, which expressed increased net-like or perinuclear mitochondria after 
exposure to concentrations of Mdivi-1 as high as 200 µM559. However, owing to a high background 
fragmentation index (90 %) in COS cells, higher Mdivi-1 doses may have been required to induce 
comparable levels of fusion to that observed in our experiments.  
114 
 
While this may be an explanation for observing increased fusion with higher doses of Mdivi-1, 
because of differences in the criteria for categorisation of cells, the experiments cannot be 
compared directly.  
As indicated previously, mitochondrial fusion may result from modulation of proteins involved in 
mitochondrial dynamics, such as DRP1, or as a direct consequence of cellular stress. While there  
was no direct morphological evidence of cellular stress in the present experiments, e.g. swollen 
mitochondria, stress-induced fusion may be relevant at higher concentrations of Mdivi-1 that induce 
cytotoxicity. Any mitochondrial fragmentation associated with cytotoxicity or cell death processes 
may oppose Mdivi-1-induced fusion, and possibly account for the smaller change observed with the 
100 µM concentration.  
DRP1-independent mitochondrial fragmentation may occur in cells that are primed for death585, 698.  
It is possible that the fission associated with cell death and that associated with maintenance of 
mitochondrial dynamics are distinct processes likely to be governed by their own respective 
pathways468.  
A study involving the rescue of induced fission in neuronal cells determined 10 µM Mdivi-1 to be the 
optimum concentration for preventing fragmentation in these cells. However, a concentration of 30 
µM resulted in the formation of ‘donuts’, which may be interpreted as fragmentation and be related 
to toxicity in these cells699. In addition, they reported fragmentation induced by both a fusion and a 
fission protein, which showed distinct morphological and qualitative differences. Thus at high 
concentrations, it is possible that alternative fragmentation processes may counteract Mdivi-1-
induced fusion. 
Small-fragment analysis of fusion 
The Mdivi-1-induced increase in fusion was demonstrated using both Categorical and Small-
fragment analysis of mitochondrial morphology. A statistically significant change in fragmentation, 
given by the number of cells containing ≤ 10 small mitochondrial fragments, was observed in cells 
treated with 30 µM Mdivi-1. Small-fragment analysis was found to provide a more objective and 
simpler measure of fragmentation than the Categorical method. These two methods quantify unique 






Small-fragment analysis using 10 µM Mdivi-1 did not induce a detectable change in fragmentation, 
as had been shown using the Categorical method. Variations in the Mdivi-1 exposure times prior to 
fragmentation analysis using the two methods may account for the differences in results for the 
lower concentration. It is possible that an early decrease in fragmentation demonstrated at 3 h for 
the Categorical method was transient and may not have been detectable at 6 h, when Small-
fragment analysis was performed. In addition, the Small-fragment analysis may be dependent on the 
small-fragment threshold value selected. Lower concentrations of Mdivi-1 may be less effective in 
preventing fission resulting in fewer cells with mitochondrial fragment number corresponding to the 
10-fragment threshold.  
Although induced fusion following Mdivi-1 treatment has been frequently reported, some studies 
have failed to show a net change in mitochondrial dynamics468, 700. As observed in this study, the lack 
of a consistent detectable change with 10 µM Mdivi-1 may have been related to the concentration, 
exposure time or the choice of quantification method. It is possible that although fusion may be 
occurring it may not be evident as altered fragmentation status. 
Notably, Mdivi-1 has been shown to affect TRAIL-induced apoptosis despite a lack of change in net 
fusion468. Thus, modulation of survival may still be possible in the absence of demonstrable  
Mdivi-1-induced fusion. Alternatively, such modulation, if fusion is not being induced, may partly  
be due to potential off-target effects. Certain DRP1-independent effects have been observed  
using Mdivi-1701 and may play a role independently of mitochondrial dynamics. Overall, a large 
number of studies report Mdivi-1-induced changes in mitochondrial dynamics as a significant 
mechanism of action. 
Evaluation of fragmentation assessment methods 
The Small-fragment analysis method is based on the identification of the proportion of cells 
expressing a defined number of small (< 3 µm) mitochondrial fragments that may allow distinction 
between treated and untreated groups. This is a simple and relatively fast method that relies on the 
determination of cells expressing a small number of mitochondrial fragments improving the 
precision of the count. Ease of assessment and improved objectivity may render the Small-fragment 
method more precise than the Categorical method.  
The threshold fragment number for the investigation of Mdivi-1 effects was determined by selecting 
multiple ranges of fragment numbers (Figure 5.6). The ≤ 10 small-fragment sub-group was 
determined to be the most suitable sub-group for distinguishing between the treated and untreated 
cells on the basis of statistical significance and proportion of relevant cells.  
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Both the ≤ 10 and the ≤ 5 small-fragment sub-groups showed statistical significance, however the 
latter category represented only a small proportion of cells and therefore would be expected to be 
less accurate.  
While the induction of fusion was apparent for Mdivi-1 treatment, a limitation of Small-fragment 
analysis may be that certain treatments may not necessarily induce an increased number of 
fragments of the size evaluated. Therefore, it is important that the fragment size be defined when 
applying this method for specific treatment modalities. 
In contrast to other observational approaches, a shift in mitochondrial dynamics indicated with 
Small-fragment analysis, does not necessarily describe the predominant mitochondrial morphology 
of the cells. For example, a cell that typically displays predominantly fused mitochondria may, in 
addition, have a large number of small fragments. Using Small-fragment analysis, this cell would be 
classified as fragmented, which intuitively may seem incorrect. The inconsistency with a descriptive 
classification of cells would suggest that the method may not be suited for assessing the inherent 
mitochondrial morphology of cells. However, it can be argued that assessing the change in the 
number of small mitochondrial fragments may be of particular value when determining a response 
to treatment, as it allows quantification of the process instead of relying on the predominant 
morphological phenotype. 
It has been observed that smaller mitochondrial fragments are more likely to fuse while long, 
complex filaments are more likely to fragment702. Changes in these processes may therefore be 
noted by quantification of a change in the number of small mitochondrial fragments, as applied in 
Small-fragment analysis. Taking into account the dynamic nature of fusion and fission, this 
classification of cells, although not intuitively descriptive, has the potential to reveal shifts in the 
dynamic process, as demonstrated in this study. In addition, the Small-fragment analysis should be 
applicable regardless of the inherent fusion status of the cell population because it depends on a 
constantly evaluable sub-population of cells.  
It is uncertain which of the two methods of analysis is more sensitive to detect a change in 
fragmentation status. However, it is suggested that the Categorical method is more suited to 
estimation of the inherent mitochondrial morphology of a population of cells while the Small-
fragment analysis is more suited to detecting a change in mitochondrial dynamics in the context  





Other techniques for assessment of fusion processes 
In addition to the morphological assessment of mitochondria, techniques to demonstrate effects on 
fusion and fission proteins such as DRP1 have been developed. These include Western blotting588, 590, 
613, 696 and immunocytochemistry611, 699, 700, 703 for total or phosphorylated DRP1 and often include 
assessment of DRP1 translocation by determination of the mitochondrial and cytosolic DRP1 content 
separately. There is generally a good correlation between the changes observed at the protein level 
and the effects on mitochondrial dynamics; however very few studies have used both approaches 
and the evidence for correlation is therefore limited. 
5.4.2. Mdivi-1-induced cytotoxicity  
As eluded to above, manipulation of mitochondrial dynamics may have negative consequences  
for the cell. The effect of Mdivi-1 on cell survival was therefore determined in addition to the 
investigation of a potential role for modulation of mitochondrial dynamics in radiation response.  
A range of Mdivi-1 concentrations and exposure times were selected based on a demonstrated 
decrease in mitochondrial fragmentation. 
Effects of Mdivi-1 on survival were dose- and time-dependent. A549 cells exposed to Mdivi-1 for 6 h 
displayed minimal cytotoxicity however, 16 h exposures and concentrations of 20 µM and above 
were cytotoxic (Figure 5.8). Several studies have determined that Mdivi-1 has cytotoxic effects in 
normal441, 469, 573, 585 and cancer cell lines21, 23, 144, 573, 582, 583. The level of toxicity displayed in our 
experiments was similar to that demonstrated by others. Typically, concentrations of 20-50 µM were 
able to induce toxicity with exposures of 16 h and longer. Toxicity from Mdivi-1 exposures longer 
than 5 h has been reported144, however, other studies showed only modest decreases in cell viability 
with exposures up to 24 h, even with concentrations up to 50 µM23, 468. Such treatment, that also 
showed no net change in mitochondrial dynamics, induced only minimal effects on apoptosis and 
survival in lung cancer, melanoma and osteosarcoma cells468.  
Similar to our results concerning cell death, Rehman et al. (2012)21 showed increased apoptosis  
after 30 µM Mdivi-1 exposure for 16 h. Moreover, similar toxicity to that observed in our A549 cell 
line, approximately 30 %, was demonstrated in ovarian cancer cells following a 16 h treatment with 
50 µM Mdivi-1583. Concentrations above 25 and 75 µM were found to be toxic to normal neurons 
and immortalised hippocampal cells, respectively441. In general, Mdivi-1 concentrations of less than 
20 µM or short exposure times have not resulted in toxicity569, 584, 586, 588, 589, which is consistent with 
our findings.  
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5.4.3. Effect of Mdivi-1 on cellular response to radiation 
Mdivi-1-induced fusion has previously been shown to modulate response to cytotoxic agents other 
than radiation. Overall, the literature suggests that low Mdivi-1 concentrations and short exposure 
times either do not influence cell survival or have a protective effect when used in combination with 
cytotoxic agents. In contrast, higher Mdivi-1 concentrations and longer exposure times result in 
toxicity, particularly in cancer cells and sensitise cells to cytotoxic therapy. It was hypothesised that 
Mdivi-1 may modulate radiation response. Two different doses of Mdivi-1 that induced similar levels 
of fusion but displayed disparate toxicities were combined with radiation. 
Significant radiation enhancement by Mdivi-1 
Mdivi-1 (30 µM) significantly enhanced radiation sensitivity after 16 h exposure augmenting 
radiation-induced cell death up to 40 % after 5 Gy (Figure 5.12). Overall, the dose modification factor 
at 0.1 survival was estimated to be 1.17. Such Mdivi-1 exposures induced notable cytotoxicity alone, 
representing a 60 % reduction in survival.  
Potential mechanisms for sensitisation include effects on repair, differences in initial cellular  
damage induction, cell cycle distribution changes and altered cell death processes among others. 
Investigations into the possible mechanisms involved are outlined in Chapter 6.  
In contrast to the Mdivi-1-induced radiosensitising effect demonstrated, one of the few studies 
reporting the effects of Mdivi-1 on radiation response showed that Mdivi-1 prevented radiation-
induced fission and reduced the mitotic catastrophe in normal mouse embryonic fibroblasts, 
suggesting a protective effect. Similarly, use of DRP1 knock-out models resulted in an increase in 
radiation survival relative to wildtype cells466. Other studies combining Mdivi-1 and radiation 
investigated an effect on mitochondrial status. Mitochondrial fission caused by localised cytoplasmic 
microbeam irradiation using alpha particles was reduced by Mdivi-1 treatment although respiratory 
dysfunction could not be prevented43.  
A similar decrease in fission was observed in DRP1 knockdown lymphoma models after UV-
irradiation. In these cells, Bax translocation was reduced and cell viability was increased221 
suggesting a role for DRP1 in UV-induced cell death. 
The 10 µM Mdivi-1 dose, although shown to induce fusion, did not influence radiation survival. 
Consistent with our findings, the 10 µM Mdivi-1 concentration was previously shown to be the 




A requirement for the initial investigations was to select the lowest dose (time- and concentration-
dependent) that induced a change in mitochondrial morphology without significant toxicity. In this 
way, any potential effect on radiation response by Mdivi-1 activity could be related to its effect on 
mitochondrial dynamics specifically rather than as a consequence of cytotoxic effects. Notably, the 
10 µM Mdivi-1 concentration did not show a change in fragmentation based on Small-fragment 
analysis. Therefore, it is possible that the lack of a change in radiosensitivity may be associated with 
a lack of change in fragmentation status. As fragmentation in this assay is defined by the proportion 
of cells displaying more than a threshold number of small mitochondrial fragments as opposed to 
those appearing to be predominantly fragmented, the number of small mitochondrial fragments 
available for modulation may be important with respect to radiosensitivity. 
However, no change in radiation survival was observed for a 6 h exposure to 30 µM Mdivi-1 either 
pre- or post-irradiation. This suggests that increased fusion, either at the time of irradiation or for a 
critical time afterwards, does not influence cellular radiation response. Despite the immediate post-
irradiation period being an important time for damage repair, exposures to Mdivi-1 during this 
period failed to modulate radiation survival.  
No apparent effect of Mdivi-1 on PLD or SLD repair 
Studies investigating the effect of Mdivi-1 on repair of radiation-induced damage are lacking. As 
expected, as a result of PLD repair, the radiation survival in the post-irradiation treatment schedule 
was considerably greater than that of the pre-irradiation schedule. Mdivi-1 did not affect PLD repair 
as evidenced by no difference in radiation survival with delayed plating.  
To our knowledge, the influence of Mdivi-1 on PLD repair has not been reported previously. 
However, PLD repair has been found to be influenced by other modulators of mitochondrial 
function. For example, reduced mitochondrial ROS from the application of a mitochondrially-
targeted antioxidant showed enhanced PLD repair following irradiation704. 
The influence of Mdivi-1 on the repair of radiation-induced sub-lethal damage was investigated 
using a split dose repair experiment. A549 repair capability has been suggested to be partly 
responsible for the resistance of these cells to radiation in addition to overexpression of MDM2, 
which results in reduced p53 expression648. Split dose repair appeared to saturate within an hour 
after irradiation in our cells and was unaffected by the presence of Mdivi-1. Consistent with our 
results, it has been shown that DRP1 inhibition does not appear to influence repair of radiation-
induced DNA damage as no difference in residual -H2AX levels after 10 Gy was observed when 
comparing wildtype and DRP1 knock-out cells466. 
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Since repair inhibition has been shown at 22C in A549 cells705, split-dose repair experiments were 
performed at 37C. Potentially confounding factors, including repopulation and re-assortment of 
cells in the cell cycle that may occur when cells are incubated at 37C, can be considered negligible 
given that repair was largely complete within 1 h.  
Inefficient repair of radiation-induced damage may have potentially contributed to the 
radiosensitising effect of Mdivi-1 described above. Although not specifically investigated, the 16 h 
Mdivi-1 pre-treatment, which resulted in radiosensitisation, may have had a residual effect on 
cellular repair capability. 
Effect of Mdivi-1 on radiation-induced cell cycle arrest 
Mdivi-1 has been shown to induce changes in cell cycle distribution507, 569-572, 582 and DRP1 knock-
down caused a G2/M arrest88. Mdivi-1 may partly exert its effects through induced alterations in  
cell cycle dynamics. This is relevant to radiation since radiosensitivity varies in the cell cycle. 
As expected, radiation induced a significant G2/M arrest in the A549 cells. Mdivi-1 also induced a 
similar, but less pronounced increase in G2/M cells at this time-point. This may represent an Mdivi-1 
-induced cell cycle arrest at G2/M or could be a result of the passage of a cohort of S-phase cells into 
G2/M. Since Mdivi-1 initially induced a slight increase in the proportion of cells in S-phase, a later 
increase in G2/M may simply be the result of recruitment of cells into S-phase from G0/G1 and 
partial synchronisation. The slight S-phase increase observed at 24 h is also consistent with such a 
cohort.  
Mdivi-1 appeared to increase the radiation-induced G2/M arrest, however, partial synchronisation 
of S-phase cells may also have increased the proportion of G2/M cells. The reduced proportion of G1 
cells at 12 h for the irradiated Mdivi-1 treated samples compared with radiation alone may indicate 
an extended G2/M arrest. Such an augmented G2/M arrest may potentially be a result of increased 
damage incurred with the addition of Mdivi-1.  
DNA damage is the primary stimulus for radiation-induced cell cycle arrest and there is some 
evidence that Mdivi-1-induced arrest may be initiated by similar lesions. Longer exposure times and 
lower concentrations than used here induced an increase in micronuclei573 however, Mdivi-1 
treatment did not lead to increased -H2AX582, suggesting that direct double-strand breaks may not 




An alternative mechanism, namely DNA replication stress, manifested as an activation of Chk1 has 
been proposed572. In addition, DRP1 knock-down caused aberrant centrosome amplification leading 
to abnormal spindle attachment573. The resultant misalignment of chromosomes, which was also 
observed with Mdivi-1 treatment by other investigators independently144, 466, initiated cell cycle 
arrest as a consequence of activation of checkpoint proteins or changes in cyclin levels.  
It is relevant to mention here that Mdivi-1 caused a small increase in the number of mitotic cells 
after 6 h exposure and these results will be presented in Chapter 6. If this arrest is sustained or 
amplified after removal of Mdivi-1 (6 h treatment), it may account for the increased G2/M 
proportion observed at 12 h. This suggests that residual effects persist after Mdivi-1 removal.  
An increase in the S-phase proportion without a significant increase in G2/M cells, however, was 
demonstrated in our experiments following 6 h Mdivi-1 treatment. As a result of potential partial 
synchronisation, an increase in G2/M may be attributed to the passage of this S-phase cohort. 
Previous reports, which are consistent with the above findings, link Mdivi-1 effects with cyclin 
activity. A report indicated that exposure of cells to Mdivi-1 upregulates cyclin E levels resulting  
in an increase in the number of cells in S-phase144. In our study, a similar increase in the S-phase 
population was noted 5 h after irradiation and this could represent a transient S-phase block.  
This type of arrest is thought to be initiated to prevent replication of damaged DNA113, 118, 122.  
Overall, we showed that Mdivi-1 alone is capable of causing a G2/M arrest after only a few hours 
exposure. In addition, we found strengthening of the radiation-induced G2/M arrest when Mdivi-1 






• Mdivi-1 treatment caused a decrease in mitochondrial fragmentation at a range of 
concentrations, as determined using the Categorical method. Small-fragment analysis 
supported the finding of increased fusion at higher concentrations. 
• Mdivi-1 reduced cell survival. However, toxicity was dependent on concentration and 
exposure time. A 16 h Mdivi-1 (30 µM) treatment was significantly toxic. 
• Mdivi-1 enhanced cell kill when combined with radiation. 
• Mdivi-1 significantly radiosensitised A549 lung cancer cells.  
• Mdivi-1 did not alter the cellular radiation response after short treatments.  
• Despite the observed change in mitochondrial dynamics, 10 µM Mdivi-1 did not influence 
radiosensitivity with 6 h Mdivi-1 treatment pre- or post-irradiation.  
•  Mdivi-1 did not influence sub-lethal damage repair or potentially-lethal damage repair.  
• Mdivi-1 induced a significant G2/M cell cycle arrest several hours after exposure and 
extended the radiation-induced G2/M arrest.  
Overall, Mdivi-1 caused mitochondrial fusion and cellular toxicity, and was demonstrated to be  
an effective modulator of cell cycle dynamics and radiation sensitivity. However, Mdivi-1 did not 
influence the repair of radiation-induced damage. From these results, it would appear that fission-
inhibitors such as Mdivi-1 represent a novel class of agents that may have potential use as 






MDIVI-1-INDUCED EFFECTS ON  
CELL PROLIFERATION AND SURVIVAL 
 
In Chapter 5, it was demonstrated that the mitochondrial division inhibitor Mdivi-1, could, in 
addition to influencing radiation response, induce mitochondrial fusion, cytotoxicity and alter cell 
cycle dynamics. While certain mechanistic aspects were considered previously, it is the intention in 
this chapter to provide further analysis of the effects of Mdivi-1 on certain cellular processes that 
may contribute to a mechanistic understanding of how Mdivi-1 modulates radiation response. 
Processes examined included cell death using clonogenic survival and apoptosis assays, cytogenetic 
damage induction and cell cycle progression. 
When assessing the effect of an agent on radiation response, a number of modulatory processes  
can be considered. Factors related to mitochondrial function may be important. The activation and 
efficiency of cell death mechanisms, including apoptosis, affects radiation response. Also, cellular 
ability to initiate a damage response leading to recognition of damage and repair determines the 
amount of residual cytogenetic damage. Cell cycle arrest facilitates repair of damage and may be 
influenced by mitochondrial dynamics.  
In addition to the reported effects of Mdivi-1, it was noted in previous experiments that Mdivi-1 
caused detachment of cells. Hence, detached and residual cells were investigated independently  
as this may have had mechanistic implications. The effect of Mdivi-1 on the cell cycle was 
established using flow cytometry to document cell cycle phase and morphological criteria to quantify 
mitoses and metaphases. Histone immunocytochemistry was used to confirm G2/M status. In 
addition, the ability of Mdivi-1 to induce cytogenetic damage was investigated using the cytokinesis 
block micronucleus assay.  
Investigations of Mdivi-1 effects were conducted in two cell models, which have different substrate-
adherence dependence and susceptibility to apoptosis. Although similar end-points were assessed 







To investigate Mdivi-1-induced cellular effects that may be related to the observed modulation of 
radiation response, specifically: 
a) To determine the fate of cells that remain adherent or become detached after Mdivi-1-
treatment and the contribution of these populations to radiation survival 
b) To elucidate the effect of Mdivi-1 treatment on the cell cycle  
c) To determine whether Mdivi-1 induces cytogenetic damage and/or modulates radiation-
induced cytogenetic damage 
d) To determine the level of Mdivi-1-induced apoptosis and the influence of Mdivi-1 on 
radiation-induced apoptosis  
6.2. Methods 
6.2.1. Effects of Mdivi-1 on A549 lung cancer cells 
6.2.1.1. Viability of detached Mdivi-1-treated cells  
Clonogenic survival of cells detached during Mdivi-1 treatment was assessed independently of  
the adherent cell population. In addition, the contribution of this population of cells to the 
radiosensitising effect of Mdivi-1, described in Chapter 5, was examined. 
Survival of adherent and detached A549 cells after treatment with Mdivi-1 and radiation  
The adherent and detached cells from the same sample were assayed separately to determine the 
contribution of each to the decreased cell survival following Mdivi-1 treatment.  
Experimental groups included the untreated control, Mdivi-1 (30 µM), 5 Gy and 5 Gy with Mdivi-1. 
For each of these groups, an unseparated sample was assessed. In addition, a replicate sample for 
each of the Mdivi-1-containing groups was included for assessment of the adherent and detached 
cells separately. Clonogenic survival for each group was assessed using a post-plated experiment, 
similar to that described previously (Appendix B1.4).  
Briefly, cells were seeded and treated the following day with Mdivi-1 or the vehicle for 16 h followed 
by irradiation as required. Control samples were mock-treated. Detached cells were separated from 
adherent cells by collecting the culture- and rinse-medium containing loose cells.  
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The adherent cells were collected by trypsinisation. For the samples where the adherent and 
detached cells were to be separated, the dishes were examined after washing to ensure that all 
detached cells had been collected. Clonogenicity was assessed as described previously. In addition, 
the total number of cells in each sample was calculated to determine the proportion of adherent to 
detached cells. 
6.2.1.2. Effects of Mdivi-1 on the cell cycle 
The proportion of cells in mitosis after Mdivi-1 treatment 
The mitotic index, i.e. the proportion of cells in mitosis, of Mdivi-1-treated cells and control  
samples, was determined using two different methods. Firstly, the mitotic index was estimated by 
microscopic quantification of cells displaying the typical condensed chromatin morphology using 
Hoechst 33342 staining (Figure 6.1). Secondly, DAPI staining of metaphase spreads and associated 
morphological criteria were used to identify cells arrested in metaphase, specifically.  
Mitotic cells, which displayed typical condensed chromatin and finger-like extensions706 were 
quantified manually using fluorescence microscopy (Appendix D). A 400x magnification and the blue 
(WB) fluorescence filter was used for visualisation of the Hoechst 33342 (1 µg/ml in PBS) stained 
chromatin. At least 500 cells were assessed per slide. Interphase cells were distinguished from 






Figure 6.1. A549 cells stained with Hoechst 33342. 400x magnification. Typical mitotic 
and interphase cells are labelled.  
The A549 mitotic index was investigated at 6, 16, 24 and 48 h after Mdivi-1 treatment. Cells were 
plated at the required density in 35 x 10 mm CELLSTAR® cell culture dishes (Greiner Bio-One) to obtain 
approximately 500 000 cells at collection. Samples were incubated overnight for the cells to adhere. 
The medium was replaced with 2 ml RPMI (FCS and AB) containing Mdivi-1 or the vehicle and 







Cells were trypsinised and the medium and PBS washes were collected in 12 ml CELLSTAR® cell 
culture tubes (Greiner Bio-One) together with the trypsinised cells. After centrifugation at 100 RCF for 
10 minutes, cells were stained with 500 µl Hoechst 33342 (1 µg/ml in PBS). Samples were incubated 
for 15 minutes at 37°C and the Hoechst-containing PBS was replaced with 500 µl paraformaldehyde 
fixative (Appendix D2.3). After a 20 minute incubation at room temperature, cells were stored in PBS 
at 4°C protected from light.  
Metaphase analysis of Mdivi-1-treated cells 
The experimental groups and Mdivi-1 treatment schedules described in the previous section  
were used for metaphase analysis. After the required treatment time, cells were trypsinised and  
collected as described previously. Each sample was washed once with 5 ml RPMI (FCS and AB).  
After centrifugation at 100 RCF for 10 minutes the supernatant was replaced with 4 ml mildly 
hypotonic, pre-warmed 75 mM KCl (Sigma-Aldrich) and cells were incubated at 37°C for  
10 minutes to induce swelling. The KCl was removed following centrifugation and 4 ml of ice-cold 
fixative solution A (methanol:acetic acid:Ringer’s solution as described in Appendix D2.3) was  
added dropwise to the cell pellet while vortexing. The samples were incubated on ice at 4°C for  
24 h and then thoroughly mixed by vortexing. After a 15 minute centrifugation at 200 RCF, cells  
were resuspended in 4 ml of ice-cold fixative solution B (methanol:acetic acid as described in 
Appendix D2.3). This step was repeated twice and samples stored at -20°C.  
Samples were evaluated using fluorescence microscopy and were prepared by drying 40 µl of the 
cell sample on a 76 x 26 mm glass slide (Lasec) for 30 minutes. Cells were stained with VECTASHIELD 
Antifade Mounting Medium with DAPI (Vector Laboratories Inc., Burlingame, CA, USA) and mounted 
with a 22 x 22 mm glass coverslips (Lasec). Metaphase chromosomes were manually assessed using 
fluorescence microscopy (WB filter; Appendix D) at 400x magnification and images were captured at 
1000x magnification by means of the Moticam Pro Monochrome Scientific CCD camera (Motic) as 
described previously.  
Immunocytochemical assessment of mitotic cells after Mdivi-1 treatment 
The increased mitotic index observed in A549 cells treated with Mdivi-1 was confirmed using 
immunohistochemical detection of Histone-3, which is phosphorylated in mitosis707. Cells were 
seeded at a density of 20 000 cells/ml into 35 x 10 mm CELLSTAR® cell culture dishes (Greiner Bio-One) 
containing 22 x 22 mm glass coverslips. The treatment groups included an untreated control, Mdivi-1 




In addition, two experimental control samples, namely, an autofluorescence control (no antibody) 
and a secondary antibody control (no primary antibody), were included to control for non-specific 
fluorescence. The cells were incubated at 37°C overnight to allow adherence to the coverslips. The 
incubation medium was replaced with RPMI (FCS and AB) containing Mdivi-1, Nocodazole or the 
vehicle. Samples were incubated for 16 h at 37°C. The medium was collected from each plate and 
processed separately as Mdivi-1 treatment was shown to cause cells to detach.  
The detached cells were collected by centrifugation at 200 RCF for 10 minutes and fixed with 500 µl 
paraformaldehyde in PBS (4 %). After a wash with 500 µl PBS, the cells were incubated in 200 µl 
permeabilisation buffer (0.2 % Triton X-100 in PBS) for 10 minutes. The permeabilisation buffer was 
replaced with 200 µl blocking buffer (2 % BSA, 0.1 % Triton X-100 in PBS, Sigma-Aldrich) and the cells 
were incubated at room temperature for 45 minutes. After centrifugation to remove the excess 
blocking buffer, cells were incubated in 200 µl of the primary anti-phospho-Histone-H3 [pSer10] 
antibody (1/500 dilution, Sigma-Aldrich) for 12 h at 4°C. Samples were washed with 500 µl PBS, then 
incubated with 50 µl of secondary antibody (anti-rabbit IgG FITC conjugate, Sigma-Aldrich) at room 
temperature for 1 h and stored at 4°C in PBS.  
A similar protocol was used for cells attached to coverslips except that the volume of most solutions 
was increased to 1 ml to facilitate adequate flooding of coverslips. Antibody solutions were applied 
in 500 µl volumes. No centrifugation steps were required and an additional wash was included 
between each step. Adherent cells on coverslips and cell suspensions were mounted on glass slides 
and samples were visualised using fluorescence microscopy as described previously (Appendix D). 
Cell cycle analysis by flow cytometry 
Samples were collected after 6, 16, 24 and 48 h exposure to 50 µM Mdivi-1 or the vehicle. In 
addition, samples were collected 6, 12, 18, 24, 48 and 72 h after 5 Gy. The protocol for preparation 
of cells for flow cytometric analysis is detailed in Appendix G. Briefly, samples were collected by 
trypsinisation after the appropriate exposure, washed and fixed with 70 % ethanol (Sigma-Aldrich). 
The samples were stored at -20oC. Twenty four hours prior to analysis, cells were treated with RNAse 
A solution (1 mg/ml) and stained with propidium iodide (500 µg/ml). Sample acquisition and analysis 
of cell cycle profiles were carried out at the UCT Flow Cytometry Core Facility (IDM) using a BD 
FACSCalibur™ flow cytometer (BD Biosciences) and the ModFit LT™ v3.3.11 data analysis program 




6.2.1.3. Assessment of Mdivi-1-induced cell death  
Mdivi-1-induced apoptosis 
Development of apoptosis was quantified after treatment with 30 and 50 µM Mdivi-1 
concentrations. The apoptotic index (proportion of apoptotic cells relative to the total cell 
population) was evaluated after 6, 16, 24, 48 and 72 h of Mdivi-1 treatment.  
Cells were seeded into 48-well CELLSTAR® multi-well culture plates (Greiner Bio-One) at a density of 
50 000 cells/ml. Cells were incubated at 37°C overnight to adhere to the plastic. The RPMI incubation 
medium was replaced with medium containing either Mdivi-1 or the vehicle and cells were 
incubated for the required time. Cells were then collected by trypsinisation, stained with Hoechst 
33342 (1 µg/ml in PBS) and assessed as described previously.  
Apoptosis was quantified manually by fluorescence microscopy (Appendix D1) using morphological 
criteria. Cells containing densely-stained, rounded nuclear fragments as a result of condensation and 
fragmentation of the nucleus 260, 261 were considered apoptotic (Figure 2.6). Cellular blebbing 
observed under light microscopy was used for additional confirmation of apoptosis. A 400x 
magnification and the blue (WB) filter were used for visualisation of apoptotic nuclei. A minimum of 
500 cells were scored per slide. At least 3 replicate samples were included for each group. 
Mdivi-1 and radiation-induced apoptosis  
Cells were irradiated with 5 Gy after 16 h Mdivi-1 treatment, washed and incubated for 30 h post-
irradiation to allow sufficient time for apoptotic development. The experimental groups included a 
control, Mdivi-1, 5 Gy and Mdivi-1 with 5 Gy. Cells were plated at a density of 100 000 cells per cm2 
in 35 x 10 mm CELLSTAR® cell culture dishes (Greiner Bio-One) and incubated overnight at 37°C in RPMI 
medium (FCS and AB) prior to treatment. Cells were treated with Mdivi-1 or the vehicle for  
16 h. The treatment medium and two 2 ml RPMI washes were collected in 12 ml CELLSTAR® cell 
culture tubes (Greiner Bio-One). The samples were centrifuged at 100 RCF for 10 minutes, washed and 
returned to their respective dishes. Cells were irradiated or mock-treated and incubated for a 
further 30 h. Samples were trypsinised and processed for assessment of the apoptotic index as 
described previously. In a separate experiment, apoptosis induced by a combination of radiation and 





6.2.1.4. Effects of Mdivi-1 on radiation-induced cytogenetic damage  
Micronucleus assay  
The effect of Mdivi-1 on radiation-induced cytogenetic damage was determined using the 
micronucleus assay. The experimental groups included a control, Mdivi-1, 5 Gy irradiated and  
Mdivi-1 with 5 Gy. Cells were seeded at a density of 50 000 cells/ml in 35 x 10 mm CELLSTAR® cell 
culture dishes (Greiner Bio-One) and incubated at 37C overnight to allow cells to adhere. The RPMI 
incubation medium (FCS and AB) was replaced with medium containing either Mdivi-1 or the vehicle 
and cells were incubated at 37°C for 16 h. Relevant samples were irradiated and the control samples 
were mock-treated. The incubation medium was collected into 12 ml CELLSTAR® cell culture tubes 
(Greiner Bio-One), centrifuged at 100 RCF for 15 minutes and washed twice with 3 ml RPMI medium. 
Each plate containing adherent cells was washed 3 times with 2 ml RPMI and the washes were 
collected. After centrifugation, detached cells were resuspended in 2 ml RPMI and transferred back 
to their original dishes. A volume of 40 µl of cytochalasin B solution was added to each sample, 
yielding a final concentration of 2 µg/ml. Cells were incubated at 37°C for a further 24 h to allow 
nuclear division and then trypsinised and collected as described previously. Cells were fixed using 
the methanol-acetic acid fixation technique described in section 6.2.1.2. Samples were stored at  
-20°C until required.  
For microscopic evaluation 30 µl of sample was applied to a 76 x 26 mm glass slide (Lasec) and 
allowed to dry. The cells were then stained with acridine orange solution (BDH Laboratory supplies). 
Slides were dipped into 10 µg/ml acridine orange solution for 1 minute, rinsed in ddH2O and dipped 
in 0.004 M Gurr phosphate buffer, pH: 6.8 (BDH Laboratory supplies) for 1 minute. Coverslips were 
mounted with 50 µl of Gurr phosphate buffer. 
Micronuclei were assessed in binucleate cells (Figure 2.5). The criteria for identification of 
micronuclei included: a rounded and smooth appearance; similar shape, colour and texture as the 
other nuclei; less than 1/3 the diameter of the other nuclei with no overlap249, 708.  
Binucleates containing distinct nuclear membranes and complete division of cell nuclei were 
included, while cells with nuclei displaying cytoplasmic bridges were excluded709. Micronuclei were 
distinguished from extruded nuclear material or nuclear blebbing. At least 500 cells were evaluated 





6.2.1.5. Effects of radiation on Mdivi-1 inhibition of mitochondrial fission 
Small-fragment analysis, as described in Chapter 5, section 5.2.1.1 was used to determine a 
fragmentation index based on the number of small mitochondrial fragments observed in each cell 
after treatment with radiation and Mdivi-1. Groups included a control, Mdivi-1 (30 µM), 5 Gy and 
Mdivi-1 with 5 Gy. Cells were plated as described previously and incubated in Mdivi-1 or the vehicle 
for 1 h. The relevant samples were irradiated as described and incubated for 5 h in Mdivi-1 or the 
vehicle. Unirradiated control samples were mock treated. Samples were stained with MitoTracker® 
Red, fixed and assessed microscopically as described. Cells were classified using a threshold value of 
10 small mitochondrial fragments. 
6.2.2. Mdivi-1 effects in U937 monocytic leukaemia cells 
6.2.2.1. The effects of Mdivi-1 on the cell cycle 
The proportion of cells in mitosis after Mdivi-1 treatment 
Initially, the mitotic index for U937 cells was determined following 5, 24, 48 and 72 h of Mdivi-1 
treatment. In addition, this end-point was determined in irradiated samples with or without Mdivi-1 
for the corresponding exposure times. Experimental procedures were as described for A549 cells 
above. However, there was no requirement for cells to adhere overnight or be trypsinised as  
U937 cells were grown in suspension. To assess the effect of Mdivi-1 removal on the mitotic index,  
similar experiments were conducted in which a single Mdivi-1 exposure time of 24 h was used. 
Mitoses were assessed at times up to 72 h after Mdivi-1 removal. 
Metaphase analysis of Mdivi-1-treated cells 
The experimental procedure for metaphase analysis for U937 cells was as described for the A549 
cells above. However, a shorter KCl incubation time of 5 minutes was required. Longer incubation 
times were found to induce rupturing of U937 cells.  
Microscope slides were prepared as described previously for metaphase analysis and cells were 
stained with VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories). Metaphases 
were quantified using the MSearch module (Metafer-based metaphase finder-pattern recognition 
algorithm) v4.0 on the Metasystems Metafer high performance slide-scanning platform (Metasystems 
Group Inc., Watertown, MA) equipped with a Zeiss Axioskop 2 fluorescence microscope (Carl Zeiss, 
Göttingen, Germany).  
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Two replicate slides were included for control and Mdivi-1 samples and a minimum of 5000 cells 
were analysed per slide. Prior to acquisition of experimental data, a user-trained classifier on the 
Metafer was applied and the capacity of the module to identify metaphases was verified manually.  
6.2.2.2. Assessment of Mdivi-1 induced cell death  
Mdivi-1-induced apoptosis  
The experimental procedure for apoptosis analysis was similar to that described previously. The 
method was adapted by resuspending the U937 cells in Mdivi-1 or the vehicle prior to seeding into 
48-well CELLSTAR® multi-well culture plates (Greiner Bio-One). After the required treatment times, 
cells were collected and the wells were rinsed once with 500 µl of RPMI to ensure that all cells were 
collected. Mdivi-1 exposure times ranged from 5 to 48 h. Hoechst 33342 (1 µg/ml in PBS) staining 
and evaluation of samples was as described previously. At least three replicate samples were 
included for analysis.  
In addition to the assessment of apoptosis after selected incubation times in Mdivi-1, cells were 
analysed using a 24 h Mdivi-1 exposure followed by an additional incubation period in Mdivi-1-free 
medium of up to 96 h to allow time for development of apoptosis. 
Mdivi-1-induced modulation of radiation-induced apoptosis  
Radiation-induced apoptosis in U937 cells at high doses (20 Gy) generally occurs within a few hours 
while lower doses (5 Gy) result in delayed apoptosis that is expressed following release of the G2/M 
arrest and is frequently associated with mitosis204. We initially investigated the modulation of 
radiation-induced apoptosis in U937 cells at high doses of 20 and 30 Gy. The 20 Gy samples were 
analysed at 5 and 24 h while 30 Gy samples were analysed from 5 to 48 h. At least three replicates 
were included for analysis. The experimental groups included, controls, irradiated, Mdivi-1 and 
irradiated with Mdivi-1. Relevant samples were irradiated in a 4 ml volume in 12 ml CELLSTAR® cell 
culture tubes (Greiner Bio-One) placed horizontally with full build-up. Mdivi-1 or the vehicle was 
added immediately following irradiation and cells were then seeded into 35 x 10 mm CELLSTAR® cell 
culture dishes (Greiner Bio-One) and incubated at 37°C for the selected treatment times.  
The modulation of radiation-induced apoptosis was subsequently investigated with a lower radiation 
dose of 3 Gy for comparison with doses closer to the therapeutic range. Sample groups included an 
untreated control, Mdivi-1, 3 Gy and 3 Gy with Mdivi-1. The Mdivi-1 exposure times were from 5 up 
to 72 h. Experimental procedures were as described in previous sections.  
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Modulation of radiation-induced apoptosis following delayed addition of Mdivi-1 
The following experiment investigated the effect of Mdivi-1 on radiation-induced apoptosis when  
an interval between irradiation and the application of Mdivi-1 was incorporated. The previously 
described apoptosis assay was modified by delaying addition of Mdivi-1 by 6, 24 or 48 h after 
irradiation. Cells were exposed to Mdivi-1 for 24 and 48 h according to the schedules shown in 









Figure 6.2. Irradiation schedules for investigation of the effect of Mdivi-1 on radiation-induced 
apoptosis with an interval between 3 Gy and the application of Mdivi-1 in U937 cells. Cells were 
incubated in Mdivi-1 for either 24 or 48 h, following intervals of 6, 24 or 48 h, respectively. 
 
6.2.2.3. Effect of Mdivi-1 treatment on radiation-induced cytogenetic damage 
Micronucleus assay  
The U937 cells were seeded at a density of 60 000 cells/ml in 60 x 15 mm CELLSTAR® cell culture 
dishes (Greiner Bio-One) and were incubated at 37°C in RPMI (with FCS and AB) containing either 
Mdivi-1 (10 µM) or the vehicle for 24 h. Samples were collected after the required incubation time, 
centrifuged at 100 RCF and washed once with 5 ml RPMI. Cells were resuspended in 4 ml RPMI  
(FCS and AB) and irradiated or mock-treated. A volume of 80 µl cytochalasin B solution was added to 
each sample yielding a final concentration of 2 µg/ml. Cells were transferred to cell culture dishes 
(Greiner Bio-One) and incubated at 37°C for a further 24 h to allow nuclear division. Cells were fixed, 









6.2.3. Statistical analyses 
GraphPad PRISM v6.05 (GraphPad software) was used for statistical analyses and construction of 
graphs for the experiments detailed above. Groups were considered to be statistically significantly 
different if a p-value smaller than 0.05 was achieved and error bars represent SEM. 
In evaluations of survival, the mitotic and apoptotic indices, and micronuclei frequency, the two-
tailed Student’s T-test was used for pairwise comparisons to evaluate differences between treated 
and untreated groups. ANOVA and the Fisher’s LSD test was used for multiple comparisons. 





6.3.1. Effects of Mdivi-1 in A549 cells 
6.3.1.1. Viability of detached Mdivi-1-treated cells 
Differential survival of adherent and detached cells after Mdivi-1 treatment  
Mdivi-1 treatment for 16 or 24 h resulted in the accumulation of rounded and detached cells  
(Figure 6.3). The absolute survival of cells after 30 µM Mdivi-1 treatment for 16 h was confirmed  
to be approximately 30 % (Figure 6.4), demonstrating reproducibility of the results reported in  
Chapter 5 (Figure 5.11). The proportion of cells that detached with Mdivi-1 treatment represented, 
on average, 28 % of the total cell number. Survival of adherent cells was approximately 25 % higher 
than that of the unseparated population (the total cell complement), while that of the detached cells 
was approximately 60 % lower (p < 0.001). In addition, the detached cells had a 73 % lower survival 











          
Figure 6.3. Accumulation of rounded and detached A549 cells following Mdivi-1 














Figure 6.4. Differential clonogenic survival after Mdivi-1 treatment for 16 h in the adherent 
and detached A549 cell populations compared to the total cell complement. Data are 
shown as mean ± SEM and represent 4 replicate samples from 2 independent experiments.  
Differential modulation of radiation response by Mdivi-1 in adherent and detached cells 
The effects of Mdivi-1 and radiation for the unseparated, the detached and the adherent cell 
populations were compared (Figure 6.5A-C). The radiosensitising effect of Mdivi-1, as reported in 
Chapter 5, was confirmed and is shown in Figure 6.5A. Survival after irradiation alone or combined 
with Mdivi-1 was 10 and 1 %, respectively. When the surviving fraction was corrected for Mdivi-1 
toxicity, radiation survival was 3 %, indicating significant radiosensitisation (p < 0.001).  
In addition, the adherent and detached cell populations of equivalent groups were assessed 
separately for Mdivi-1-induced radiosensitisation. When Mdivi-1 was combined with 5 Gy, similar 
qualitative differences in survival between the total, adherent and detached cell populations were 
found (Figures 6.5B and C), as was observed for Mdivi-1 treatment alone (Figure 6.3). When the 
effects of 5 Gy in addition to Mdivi-1 were assessed, 65 % higher survival was observed in the 
adherent cell population than in the total population while the detached cells showed a 79 % lower 
survival (Figure 6.5B).  
Figure 6.5C presents the surviving fractions after 5 Gy for the same groups corrected for Mdivi-1 
toxicity. The radiosensitivity of the detached cells was significantly greater than that of the adherent 
cells (p < 0.01). The adherent and detached cell populations each showed an approximately 40 % 
change in radiation survival relative to that of the total population irradiated in the presence of 
Mdivi-1. The reductions in radiation survival, relative to that of 5 Gy alone, were 81 and 55 %, for 























Figure 6.5. Mdivi-1-induced radiosensitisation in A549 cells. A) Clonogenic survival following 
Mdivi-1 and radiation treatments for the total cell complement. The surviving fractions for Mdivi-
1 (30 µM for 16 h), 5 Gy, 5 Gy combined with Mdivi-1 [5 Gy + Mdivi-1] and 5 Gy corrected for 
Mdivi-1 toxicity [5 Gy (Mdivi-1)] are shown. B) Reduced clonogenic survival following Mdivi-1 
treatment combined with 5 Gy for the separated cell populations. This graph presents the 
combined toxicity of 5 Gy and Mdivi-1. C) Clonogenic survival as shown in (B) but corrected for 
Mdivi-1 toxicity reflecting radiosensitisation.  Data are shown as mean ± SEM and represent 4 
replicate samples from 2 independent experiments.  
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6.3.1.2. Proportion of cells in mitosis after Mdivi-1 treatment 
Mdivi-1 (30 µM) treatment induced an increase in the mitotic index of cells relative to control 
samples for exposure times up to 24 h (Figure 6.6A). The greatest increase, which was 11-fold that  
of the control, was observed following 16 h continuous Mdivi-1 treatment (p < 0.001). Mitoses were 
subsequently reduced to 5-fold that of the control sample when treatment was extended to  
24 h (p < 0.001), representing an approximately 30 % decrease relative to the 16 h treatment.  
Mdivi-1 treatment for 48 and 72 h did not show a significant difference in the mitotic index relative 
to control samples. Similar results to those obtained for 30 µM Mdivi-1 were obtained for 20 and  
50 µM Mdivi-1 concentrations (Figure 6.6B). However, 20 µM induced approximately 50 % less of  
an increase in mitoses than either the 30 or the 50 µM treatments. The mitotic index for the 20 and  
50 µM treatments were significantly greater than that of the control samples for both the 16 and  








Figure 6.6. Changes in the mitotic index of A549 cells following Mdivi-1 treatment. A) Time course 
showing an increase in mitotic cells up to 16 h. B) The mitotic index following 20, 30 and 50 µM 







6.3.1.3. Metaphase analysis after Mdivi-1 treatment 







Figure 6.7. Mdivi-1 induced a significant increase in A549 metaphase cells after a 16 h treatment. 
Representative images from metaphase spreads for A) a control sample and B) an Mdivi-1-treated 
sample showing the higher proportion of cells in metaphase compared to those in interphase. 400x 
magnification. 
 
6.3.1.4. Immunohistochemical assessment of mitotic cells 
The increase in mitotic cells observed following Mdivi-1 treatment, as indicated above, was also 
visualised using phospho-histone 3 staining (p-H3). Cells were labelled with both DAPI and p-H3, 
which is specific for G2/M phase cells. DAPI stained both mitotic and interphase cells (Figure 6.8A). 
The brightly stained (condensed) chromatin of the mitotic cell in Figure 6.8B is contrasted with the 







Figure 6.8.  High magnification (1000x) example of differential p-H3 staining in 
mitotic and interphase cells. A) Mitotic and interphase nuclei stained with DAPI. 





An example illustrating the higher mitotic index induced by Mdivi-1, as indicated by an increased 
number of p-H3 stained cells, is shown in Figure 6.9. The proportion of p-H3 stained cells for each of 
the fields is 5, 60 and 25 % for the untreated control, Nocodazole positive control and Mdivi-1-















Figure 6.9. Mitotic cells identified by phospho-Histone 3 immunofluorescence. Representative 
images for an untreated control, nocodazole positive control and Mdivi-1-treated sample are shown 
(100x magnification). Phospho-Histone 3 staining of mitotic nuclei (centre). Bright staining typically 
identifies cells in metaphase while G2- and early M-phase cells are more faintly labelled. Cells were 
counterstained with DAPI. The percentage of cells that showed Phospho-Histone 3 positivity is given 














6.3.1.5. Cell cycle analysis 
Representative cell cycle analysis profiles for the Mdivi-1 and 5 Gy treatments are shown in  
Figure 6.10. Graphical representations of the cell cycle analysis results incorporating multiple 













Figure 6.10.  Representative A549 cell cycle analysis profiles for Mdivi-1 treatments and 5 Gy 
irradiated samples. A comparison of the G2/M arrest induced by each treatment is shown. The 
maximum G2/M arrest was observed at 16 h for the Mdivi-1 treatment and at 12 h for the 5 Gy 
treatment. The blue pre-G1 peak represents the level of cellular fragmentation (apoptosis) in 
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Cell cycle analysis after Mdivi-1 treatment 
For the Mdivi-1 treatment, the proportion of cells in G2/M phase was increased for all exposure 
times analysed relative to that of the control samples (p < 0.01). A G2/M cell cycle arrest was 
observed at 6 h, reflected as a 4-fold increase in G2/M to 16 % (Figure 6.11). At 16 and  
24 h the G2/M proportion was increased further to 56 and 51 %, respectively. At 48 h, the 
proportion of G2/M cells was reduced, relative to the 24 h treatment, to 32 %. 
A significant reduction of cells in G1 (68 %), relative to control samples, was observed after 6 h 
Mdivi-1 treatment (p < 0.01) with an 85 % reduction in G1 (p < 0.01) at 16 h. For the 24 and 48 h 
Mdivi-1 exposures, the proportion of G1 cells was reduced by 70 and 55 %, respectively.  
In addition, a 70 % increase in the proportion of cells in S-phase, relative to the control samples, was 




Figure 6.11.  A549 cell cycle dynamics following Mdivi-1 treatment. Notably, an increase in the 
proportion of cells in G2/M was observed at 16 h. Data are shown as mean ± SEM and represent 
4 replicate samples. 
6 h 16 h 
24 h 48 h 
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Cell cycle analysis after 5 Gy 
While representative cell cycle profiles for irradiated samples were included in Figure 6.10, a 
summary of the results is given in Figure 6.12. A radiation-induced cell cycle arrest, as shown 
previously in Chapter 5, was demonstrated at 12 h. Consistent with previous results, the proportion 
of cells in G2/M at 12 h post-irradiation was 57 %. The 18 and 24 h treatments displayed a similar 
increase in the proportion of cells in G2/M, namely 32 and 27 %, respectively. The arrest was still 










Figure 6.12. A549 cell cycle dynamics following 5 Gy irradiation. The radiation-induced G2/M 
cell cycle arrest was demonstrated at 12 h. A representative control profile at 0 h is included 






6.3.1.6. The effect of Mdivi-1 treatment on radiation-induced cytogenetic damage  
Micronuclei were assessed after irradiation, 16 h Mdivi-1 exposure or Mdivi-1 for 16 h followed by  
5 Gy (Figure 6.13). Irradiation induced the highest level of cytogenetic damage, which was 8-fold 
higher than that of the control samples (p < 0.001). In addition, Mdivi-1 significantly induced a level 
of micronuclei that was 4-fold higher than the control samples (p < 0.01). Mdivi-1 in combination 
with 5 Gy, however, induced similar levels of cytogenetic damage as that observed after 5 Gy alone. 
This combined treatment yielded an approximately 30 % increase in micronucleus-containing cells 








Figure 6.13. Radiation- and Mdivi-1-induced micronuclei (MN) in A549 





6.3.1.7. Mdivi-1-induced apoptosis 
Mdivi-1 induced an increase in the apoptotic index for treatments of 16 h and longer (Figure 6.14). 
However, the apoptotic index at 6 h was not significantly different from the control samples. 
Specifically, at 24 h a 3-fold increase was observed for 30 µM Mdivi-1 (p < 0.001) while 50 µM  
Mdivi-1 induced a 4-fold increase in apoptosis (p = 0.001). The greatest increase in apoptotic index 
was observed at 48 and 72 h for 30 and 50 µM Mdivi-1, respectively. Both treatments, however, 








Figure 6.14. Mdivi-1 induced a time- and dose-dependent increase in apoptosis in 
A549 cells with 30 and 50 µM treatments. Data are shown as mean ± SEM and 
represent at least 3 replicate samples. 
 
The apoptotic index at 72 h for 30 µM Mdivi-1 was significantly lower than that observed with the  
50 µM treatment (p < 0.001) and was not significantly different from that of the control samples. 
Using 20 µM Mdivi-1, no significant difference in apoptosis could be demonstrated.  
Cell cycle analysis profiles shown in Figure 6.10 include the sub-G1 peaks, which indicate the 
proportion of fragmented cells in each sample and include apoptotic cells. A summary for each 
treatment is shown in Figure 6.15. In general, a lower proportion of apoptotic cells was observed 
using the Hoechst assay for the same Mdivi-1 treatment. After 16 h Mdivi-1 exposure, 8 % of the 
cells showed fragmented nuclei, a 20-fold increase relative to control samples. Longer exposure 










Figure 6.15. Cell cycle analysis showed an increasing proportion of fragmented  
cells induced by 50 µM Mdivi-1 treatment. Data are shown as mean ± SEM and 
represent 4 replicate samples. 
 
6.3.1.8. Mdivi-1-induced apoptosis post Mdivi-1 removal  
The potential for Mdivi-1 to induce apoptosis after removal of the drug was also investigated.  
A 6 h Mdivi-1 (50 µM) did not result in an increase in apoptosis when measured directly after 
exposure (Figure 6.16). Incubation in Mdivi-1-free medium for up to four days after treatment 
resulted in a slightly higher apoptotic index (1.5-fold increase) relative to the control samples, 







Figure 6.16. A549 relative apoptosis with time after removal of Mdivi-1 following a 6 h 





6.3.1.9. Mdivi-1-induced modulation of radiation-induced apoptosis  
Radiation-induced apoptosis was investigated for the 16 h Mdivi-1 (30 µM) pre-treatment, which 
previously showed radiosensitisation using the clonogenic assay (Chapter 5). Apoptosis was assessed 
at 30 h after treatment to allow opportunity for apoptosis development (Figure 6.17). At 30 h post-
irradiation, 5 Gy increased the apoptotic index to approximately 8-fold that of the control samples  
(p < 0.001). Mdivi-1 induced an approximately 5-fold increase in apoptosis relative to control 
samples (p = 0.01) at 30 h post-treatment. The absolute percentages were only 1.4 and 2 % for 
Mdivi-1 and 5 Gy, respectively. The combined effect of Mdivi-1 and radiation resulted in a slightly 
higher apoptotic index relative to Mdivi-1 alone (p < 0.01) however, it was not significantly different 








Figure 6.17. Modulation of radiation-induced apoptosis and development of apoptosis 
after Mdivi-1 removal. Apoptosis was quantified at 30 h post-treatment in A549 cells. 
Data are shown as mean ± SEM and represent 3 replicate samples. 
 
For comparison, an alternative Mdivi-1 and radiation treatment schedule was assessed. A 24 h 
continuous Mdivi-1 (10 µM) exposure did not induce significant apoptosis relative to the control 
samples (Figure 6.18). However, when combined with radiation, the apoptotic index was 40 % lower 














Figure 6.18. Mdivi-1 treatment at a concentration unable to induce apoptosis 
inhibited radiation-induced apoptosis in A549 cells. Data are shown as 
mean ± SEM and represent at least 3 replicate samples. 
 
6.3.1.10. Effect of radiation on Mdivi-1-induced increase in mitochondrial fusion 
Small-fragment analysis to demonstrate the effect of radiation on Mdivi-1-induced changes in 
fragmentation index is shown in Figure 6.19. Radiation was not shown to influence mitochondrial 
fragmentation. An increase in the proportion of cells containing ≤ 10 small fragments, i.e. increased 
fusion, was observed for the 6 h Mdivi-1 treatment (p < 0.01). However, the effect of the combined 







Figure 6.19. Inhibition of Mdivi-1-induced mitochondrial fusion by radiation. 






































6.3.2. Mdivi-1 effects in U937 cells 
6.3.2.1. Mdivi-1-induced apoptosis  
A time-dependent increase in apoptosis was observed after Mdivi-1 exposure (Figure 6.20), with an 
approximately 10-fold increase in apoptosis relative to control samples for 10 µM Mdivi-1 exposures 
longer than 20 h. All exposure times assessed, with the exception of the 5 h treatment, showed 








6.3.2.2. Mdivi-1-induced apoptosis post Mdivi-1 removal  
A decrease in the apoptotic index over time was observed after Mdivi-1 removal. At 24 h after 
removal a 25 % reduction in apoptosis, relative to that of the 24 h time-point (p = 0.02), was 
determined (Figure 6.21). The apoptotic index was similar to the control samples at four days after 








Figure 6.21. Mdivi-1-induced apoptosis with 
increasing incubation times in Mdivi-1-free 
medium following a 24 h exposure in U937 
cells. The relative apoptosis is presented 
normalised to the respective control 
samples. Data are shown as mean ± SEM  
and represent 3 replicate samples. 
 
 
Figure 6.20. Mdivi-1-induced apoptosis 
in U937 cells with time. The relative 
apoptosis is presented normalised to 
the respective control samples. Data 
are shown as mean ± SEM and 




6.3.2.3. Mdivi-1-induced modulation of radiation-induced apoptosis 
For the U937 cell line, the apoptotic index was quantified for radiation and Mdivi-1 treatments 














Figure 6.22. Mdivi-1-induced modulation of radiation-induced apoptosis in U937 cells.  
A) After 3 Gy. B) After 30 Gy. Apoptosis is expressed relative to a control value determined  
at each time-point. Data are shown as mean ± SEM and represent 3 replicate samples. 
 
Temporal changes in apoptosis 
The effect of Mdivi-1 on apoptosis induced by 3 Gy is shown in Figure 6.22A. In general, the 
apoptotic index increased over time with all treatments up to 72 h. Mdivi-1 and radiation applied 
independently induced approximately 10- and 3-fold increases in the apoptotic index, respectively, 
at 72 h relative to control samples (p = < 0.001). The combined effect of Mdivi-1 and radiation at  
72 h also yielded an approximate 10-fold increase in the apoptotic index relative to control samples 





The effect of Mdivi-1 on apoptosis induced by 30 Gy is shown in Figure 6.22B. All groups displayed 
an increase in apoptosis after treatment relative to control samples. Apoptosis was substantially 
enhanced for Mdivi-1 treatments of 24 h or longer and 48 h induced an approximately 15-fold 
increase relative to control samples (p < 0.001). The combination of radiation and Mdivi-1 induced 
an approximately 11-fold increase in apoptosis after 48 h relative to control samples (p < 0.001). 
However, the combination did not induce a higher apoptotic index than Mdivi-1 alone. The absolute 
apoptosis induced by each treatment was approximately 50, 30 and 40 % for Mdivi-1, 30 Gy, and 












Figure 6.23. Mdivi-1-induced modulation of radiation-induced apoptosis in U937 cells. 
Comparison of the apoptosis induced by 3, 20 and 30 Gy at 5 and 24 h when combined with 
Mdivi-1. The relative apoptosis is presented normalised to the respective control samples. 
Data are shown as mean ± SEM and represent 3 replicate samples. 
Two Mdivi-1 exposure times for all radiation doses used are compared in Figure 6.23. As noted 
previously, 5 h Mdivi-1 exposure induced minimal apoptosis. Significant increases, relative to the 
control samples, were observed at 5 h for 20 and 30 Gy alone (approximately 4- and 8-fold, 
respectively) and in combination with Mdivi-1. However, no significant increase in apoptosis at  
5 h was observed for 3 Gy treatments.  
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At 24 h, Mdivi-1 induced an 8- to 15-fold increase in apoptosis relative to the control samples.  
For 30 Gy, the apoptotic index was approximately 4-fold that of the control samples at 24 h  
(p < 0.001), notably less than observed at 5 h. In contrast, the lower doses of radiation examined 
induced a higher apoptotic index at 24 h than at 5 h, yielding values of 1.7- and 3-fold higher than 
control samples for 3 and 20 Gy, respectively. The combination of Mdivi-1 and radiation for both 20 
and 30 Gy did not induce higher levels of apoptosis than radiation alone. However, 3 Gy combined 
with Mdivi-1 induced an approximate 5-fold increase in apoptosis at 24 h (p < 0.001). The combined 
effect at 24 h was 1.5-fold less than that induced by Mdivi-1 alone. 
6.3.2.4. Effect of post-irradiation Mdivi-1 scheduling on apoptosis-induction 
As established above, the combined effect of Mdivi-1 and radiation was reduced relative to that of 
Mdivi-1 alone when combined with radiation. Changes to the scheduling of Mdivi-1 treatment 
following irradiation may provide insight into the interaction between Mdivi-1 and radiation. 
Therefore, experiments were performed in which Mdivi-1 was applied at various times after 
irradiation to determine whether any enhancement of apoptosis over that induced by Mdivi-1 alone 
could be induced when Mdivi-1 was scheduled differently to the concurrent application used 
previously. The results are presented in Figure 6.24. 
No change in the apoptotic index was observed relative to Mdivi-1 treatment alone for the addition 
of Mdivi-1 at 6 h after irradiation. The combined treatment, although scheduled differently, induced 
similar levels of apoptosis to those shown in previous investigations where Mdivi-1 was applied 
concurrently with radiation (data not shown).  
For an interval of 24 h between irradiation and Mdivi-1, the 48 h Mdivi-1 exposure induced a slight 
but significantly different apoptotic index relative to Mdivi-1 alone (p = 0.0124) (Figure 6.24A).  
A similar level of radiation-induced apoptosis, of approximately 4-fold that of the control samples, 
























Figure 6.24. Differences in the scheduling of radiation and Mdivi-1 treatments alters the 
apoptotic index in U937 cells. A) Comparison of the combined effect of radiation and 
either 24 or 48 h Mdivi-1 exposure following a 24 h interval after 3 Gy. B) Comparison of 
the combined effect of radiation and a 24 h Mdivi-1 exposure following either a 24 or 48 h 
interval after 3 Gy. Data are shown as mean ± SEM and represent 3 replicate samples. 
Figure 6.24B depicts the results for a constant 24 h Mdivi-1 exposure and either a 24 or 48 h gap 
after irradiation. The combined treatment with a 48 h interval showed an increase in apoptosis 
relative to Mdivi-1 alone. At 72 h, corresponding to an interval of 48 h, a 43 % increase in the 
apoptotic index relative to Mdivi-1 alone was observed (p < 0.01). A similar increase in apoptosis to 
that observed with Mdivi-1 alone was observed when cells were treated 48 h after irradiation 
relative to those that received treatment 24 h after irradiation. Importantly, the apoptotic index 




24 h interval 
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6.3.2.5. Proportion of mitotic cells after Mdivi-1 treatment 
U937 mitoses were increased after incubation in Mdivi-1 for up to 72 h and in combination with 
radiation (Figure 6.25A and B). The highest mitotic index, a 5-fold increase relative to control 
samples, was observed at 48 h, however this increase was not significantly different from those 
observed at 5 and 24 h, which were approximately 3- and 2-fold, respectively. At 72 h, the Mdivi-1  



















Figure 6.25. Mitosis-associated alterations induced by 3 Gy and Mdivi-1 in U937 
cells. A) Time dependent alterations in the mitotic index. Data are shown as 
mean ± SEM and represent at least 3 replicate samples. B) Metaphases induced by 
a 48 h Mdivi-1 exposure. Data are shown as mean ± SEM and represent at least 






A decrease in mitotic index of 30 and 20 % at 5 and 24 h, respectively was observed following 3 Gy. 
There was no difference between the irradiated and control samples at 48 h. At 5 h, the combined 
Mdivi-1 and 3 Gy treatment showed a reduced (6-fold) mitotic index relative to Mdivi-1 alone. 
However, by 48 h, the combination of Mdivi-1 and 3 Gy gave a 5-fold increase in mitotic index, which 
was similar to the Mdivi-1 treatment (p < 0.001). At 72 h, the combined treatment increased the 
mitotic index approximately 2-fold relative to that of the control samples. 
Assessment of the proportion of cells in metaphase (Figure 6.25B) for a 48 h treatment with  
Mdivi-1 (10 µM), using the Metafer Msearch automated metaphase finder showed an approximately 
5-fold increase in the number of metaphases (4 %) which is consistent with an increase in mitotic 
cells at 48 h (Figure 6.25A). 
6.3.2.6. Reversibility of Mdivi-1-induced cell cycle effects 
The Mdivi-1 induced increase in mitoses was reduced to background levels within 24 h after Mdivi-1 








Figure 6.26. Reduction in U937 mitotic index after Mdivi-1 removal. Mdivi-1 induced 
an increase in mitotic cells during the initial 24 h incubation period however the 
increase was not maintained after removal of Mdivi-1. Data are shown as mean ± SEM 







6.3.2.7. Mdivi-1 induction of cytogenetic damage 
Mdivi-1 induced cytogenetic damage in the U937 cells indicated by an increase in the frequency of 
micronucleus-containing cells (p < 0.01). The absolute percentage of micronucleus positive cells 
induced by a 24 h Mdivi-1 treatment was less than 10 % (Figure 6.27). Radiation induced a 13-fold 
increase in micronucleus-containing cells relative to control samples (p < 0.001). Notably, the 
proportion of cells containing micronuclei for the combined treatment was 20 % lower than 







Figure 6.27. Induction of micronuclei (MN) by Mdivi-1 and irradiation in U937 cells. 
The combined additive effects of Mdivi-1 and radiation are illustrated in the right-hand 





We described novel findings in Chapter 5 in which Mdivi-1 was shown to significantly enhance 
radiosensitivity. While such findings may have therapeutic potential, further studies are required to 
contribute to an understanding of the mechanisms involved. In this chapter we present our 
investigations into the effects of Mdivi-1 that have the potential to influence radiation response.  
Current understanding of the actions of Mdivi-1 suggests that this agent is able to induce 
cytogenetic damage, cell cycle arrest and cell death in a variety of model systems, as well as to 
modulate the cytotoxicity of other agents. In this chapter, we investigated similar end-points after 
Mdivi-1 treatment for their potential role in the radiosensitising effect of Mdivi-1. 
In addition to effects on survival, we found that Mdivi-1 caused rounding and detachment of 
adherent cells, which suggests that other drug-induced changes, may occur. Adherent cells can 
detach from culture plates as a result of cell death but may also detach during division as mitotic 
cells round up and become loosely attached. The initial experiments described in this chapter were 
conducted to interrogate the viability of the detached cells in order to determine the contribution of 
this population of cells to the decrease in survival observed following Mdivi-1 treatment. Further 
investigations aimed to determine the contribution of apoptosis and cytogenetic damage to Mdivi-1-
induced cell death. In addition, the ability of Mdivi-1 to affect cellular response to radiation-induced 
damage by influencing the passage of cells through the cell cycle was investigated.  
6.4.1. Viability of detached Mdivi-1-treated cells  
Mdivi-1 may induce complex changes in cultured cells including growth arrest and cell death.  
It was observed that treated cells were differentially affected by Mdivi-1 with a proportion of the 
cells becoming detached while the majority remained adherent. The appearance of floating cells  
in culture may indicate cell death. However, rounding up of cultured cells is also characteristic of 
mitotic cells which generally remain loosely adherent to the surface of the culture plate710, 711. 
Typically, after such de-adhesion, cells progress through mitosis and re-attach712-714. Complete 
detachment may occur when mechanically agitated. Thus, both cytotoxic treatment and potentially 
prolonged mitotic arrest may result in the accumulation of floating cells. However, it is common to 




It has been reported that cells becoming detached following cytotoxic treatment may later  
re-adhere718, suggesting that survival after drug-induced detachment is possible. In this study, 
clonogenic assays were modified to assess the survival of the adherent and detached populations  
of cells separately. 
Effect of Mdivi-1 in adherent and detached cells 
Cell survival following the Mdivi-1 treatment alone was initially investigated. Overall, Mdivi-1 was 
confirmed to reduce A549 cell survival significantly. A large proportion of the detached cells died, 
however, approximately 10 % were observed to survive, demonstrating that detachment of cells was 
not only as a result of cell death. In addition, more than half of the adherent cells did not survive 
Mdivi-1 treatment. The differential influence of Mdivi-1 treatment on the two cell fractions provides 
insight into the mechanism of Mdivi-1-induced cell death in that cell detachment, although a 
consequence of Mdivi-1 exposure, is not entirely related to cell death. This finding prompted the 
assessment of mitoses in Mdivi-1-treated cells which will be discussed below.  
Importantly, in an experiment of this nature, where treatment results in detachment of cells, 
collection of these non-adherent cells is essential so as not to underestimate the effect of the 
treatment. Visual inspection of cells during potentially cytotoxic treatments, as well as the  
collection of detached cells, is critical as discarding these cells may lead to spurious results. 
To confirm that cells had not been lost during separation of the adherent and detached populations, 
the surviving fractions for each group were also calculated as a proportion of the total cell 
complement. It was confirmed that the effect of Mdivi-1 on survival of the separated populations, 
when summed, yielded a surviving fraction similar to that obtained for the unseparated population.  
Combined effect of Mdivi-1 and radiation in adherent and detached cells 
Initial experiments indicated that Mdivi-1 could induce radiosensitisation. Subsequently, in 
experiments using separated populations of adherent and detached cells, it was shown that both 
sub-populations were radiosensitised by Mdivi-1. In addition, the detached cells exposed to Mdivi-1 
appeared to be more radiosensitive than the adherent cells. Through necessity, certain assumptions 
were made in evaluating the effect of radiation in the presence of Mdivi-1. Given that cells do not 
detach early after irradiation, as they do with Mdivi-1, it was assumed, that after 5 Gy, the surviving 
fractions of the separated populations would be the same as that of the unseparated population. 
The radiosensitivity of the sub-populations would ideally have been determined relative to controls 




Similar to our previous results with unseparated cells, Mdivi-1 also added to the cytotoxicity caused 
by radiation in the separated populations. The detached cells were shown to be more susceptible to 
the combined Mdivi-1 and radiation treatment than the adherent cells. Overall, the observations 
that Mdivi-1 treatment adds to the radiation efficacy suggests therapeutic potential. 
6.4.2. Effects of Mdivi-1 on the cell cycle 
Mdivi-1-induced effects on G2 and mitosis 
Mdivi-1 treatment induced an increase in mitotic cells in both the A549 and U937 cell lines.  
Phospho-H3 immunohistochemical analyses that detect cells in late G2 and mitosis provided 
additional evidence for an increase in mitotic index during Mdivi-1 treatment and verified the 
criteria used for manual morphological scoring. 
In A549 cells, an Mdivi-1 exposure of a few hours was shown to result in a small but significant 
increase in the mitotic index relative to control samples. This increase was consistent with the cell 
cycle analysis results reported in Chapter 5. Longer Mdivi-1 exposures (16 hours), however, induced 
a more pronounced cell cycle arrest, with approximately 30 % of the cells in mitosis. It can be 
speculated that the rounded, detached or loosely adherent cells observed in culture after Mdivi-1 
treatment to some extent represented mitoses. While there appeared to be a gradual release of the 
cell cycle arrest from 24 hours, the reduced mitotic index observed at longer time-points may in part 
be as a result of the proliferation of surviving cells.  
The Mdivi-1-induced increase in mitotic index in the A549 cells was confirmed using flow cytometry. 
Mdivi-1-treated cells displayed an initial brief S-phase arrest prior to a G2/M arrest that reached 
maximal levels by approximately 16 hours. Mdivi-1 treatment induced a large proportion, at least  
50 %, of the cells to be arrested in G2/M phase, which was comparable to the cell cycle arrest 
induced by 5 Gy. The increased G2/M proportion after 16 h Mdivi-1 may explain the significant 
radiosensitisation observed as cells in this phase are particularly radiosensitive.  
As shown in Chapter 5, even brief exposure to Mdivi-1 could result in a subsequent increase in 
G2/M, however, this was not sustained. In contrast, the G2/M arrest during more extended 
treatments was maintained while cells were exposed to Mdivi-1 suggesting continued accumulation 




However, some dissipation of the G2/M arrest was observed with continuous Mdivi-1 treatment. 
These results are consistent with the decrease in mitoses reported above for longer exposures.  
The increases in both the G1- and the sub-G1 peaks as G2/M decreased suggest that a proportion  
of cells exiting the Mdivi-1-induced arrest undergo cell death while the rest continue to cycle.  
In U937 cells, the mitoses were similarly increased after Mdivi-1 treatment although the increase 
was earlier and less pronounced than that observed for the A549 cells. The proportion of mitotic 
cells also remained constant for an extended period up to 48 hours. This sustained level of mitoses, 
despite continued Mdivi-1 exposure, may suggest stabilisation of the mitotic fraction. Alternatively, 
mitotic cells may undergo apoptosis, thus eliminating them from the evaluable mitotic proportion. 
As mentioned previously, another factor expected to influence the quantitation of mitoses is the 
proliferation of cells surviving Mdivi-1 treatment. Therefore, the mitotic index determined will be 
the net effect of all competing processes. Taken together, the kinetics of response to Mdivi-1 
appears to differ in the U937 apoptosis-responsive cells compared to that of the A549 cells. 
Previously reported Mdivi-1-induced cell cycle effects  
Mitochondrial dynamics are carefully regulated during the cell cycle503 and modulation, using 
inhibitors of fission such as Mdivi-1, has the potential to control cell cycle progression. Extensive 
fission occurs prior to mitosis in order to allow equal distribution of mitochondria between daughter 
cells443, 504. Mdivi-1-induced cell cycle arrest in our cell models was proposed to result from reduced 
mitochondrial fragmentation prior to mitosis. 
The results presented are supported by a number of researchers, who have similarly reported an 
Mdivi-1-induced G2/M cell cycle arrest88, 571, 573, 696. Further evidence of Mdivi-1 effects on the cell 
cycle came from synchronisation experiments in which cells specifically arrested in mitosis, were 
prevented from progressing through the cell cycle21, 572. Although, specific interactions of Mdivi-1 
with the cell cycle are not well described, Marsboom et al. (2012)571 determined that the Mdivi-1-
induced arrest occurred at prometaphase. They showed that Mdivi-1 prevented a decrease in cyclin 
B1 levels that would normally be associated with later stages of mitosis. Degradation of cyclin B1 
occurs via Cdh1 and leads to inactivation of the mitosis promoting factor and mitotic exit719 






Mechanistic aspects of the Mdivi-1-induced mitotic arrest 
A few studies have investigated further potential mechanisms related to the Mdivi-1-induced cell 
cycle arrest. Given the role of Mdivi-1 as a fission inhibitor, the Mdivi-1-induced mitotic or G2/M-
phase arrest has been ascribed to mitochondrial hyperfusion88, 696. Such hyperfusion was associated 
with decreased phosphorylation and inactivation of DRP1571, 696. In addition, siRNA knockdown of 
DRP1-induced hyperfusion and caused an arrest similar to that observed using Mdivi-188, 572. Such 
alterations in DRP1 expression have been reported to influence cell cycle progression by regulating 
cyclin levels. For example, DRP1 deficient breast cancer cells that were synchronised at mitosis did 
not show an expected cyclin B1 increase or cdc2 dephosphorylation initially572, both of which have 
been associated with entry into mitosis in normal cells720. Release from the arrest in these DRP1-
deficient cells, however, was shown to slowly initiate dephosphorylation of cdc2 resulting in gradual 
progression through the cell cycle572. Thus, alterations in DRP1 expression may modulate G2 to M 
transition directly or indirectly.  
There is some controversy concerning whether the Mdivi-1-induced cell cycle arrest is exclusively 
related to its role as an inhibitor of DRP1. In two studies, downregulation of DRP1 in breast cancer 
cells593 and DRP1 knock-out in mouse embryonic fibroblast cells466 did not have an effect on the cell 
cycle. However, one investigator indicated that DRP1 knockdown was only 85 % and residual protein 
may have been sufficient to prevent cell cycle changes593. In addition, Qian et al. (2012)572, who 
showed a G2/M arrest in breast cancer cells treated with Mdivi-1, suggested that, although 
hyperfusion was deemed necessary for cell cycle arrest, the effect may partly be non-mitochondrial. 
Restoration of an induced fragmented mitochondrial status by double knockdown of DRP1 and 
OPA1, a fusion protein, did not completely prevent the cell cycle arrest. Additional evidence 
suggesting that the arrest is partly non-mitochondrial came from the use of Rho0 cells, which lack 
mitochondrial DNA. These cells still arrested at G2/M and underwent hyperfusion upon knockdown 
of DRP1572.  
Mdivi-1-induced effects on G1 and S-phase 
In the current work, when cell cycle profiles for Mdivi-1 treatment and 5 Gy were compared, it was 
apparent that, although a similar G2/M arrest was induced by each agent, the G1 populations were 
differentially affected. The proportion of G1 cells accumulated to a greater extent after irradiation 
than after Mdivi-1 treatment. This may be consistent with reports of time-dependent increases in 
the movement of cells into S-phase144 and into G1507, respectively, after Mdivi-1 exposure. However, 
it may also suggest that, in contrast to radiation, Mdivi-1 does not induce G1-checkpoint activation.  
161 
 
The Mdivi-1-induced S-phase arrest was previously demonstrated and discussed in Chapter 5.  
Mdivi-1-induced hyperfusion in serum-starved G0 cells has been shown to increase cyclin E levels 
which initiate the movement of cells into S-phase144. The investigators suggested that mitochondrial 
hyperfusion is sufficient to induce entry into S-phase in the absence of growth factor stimulation.  
The S-phase arrest demonstrated after a few hours of Mdivi-1 exposure in our study, may be a 
similar response, possibly related to increased cyclin E. Overexpression of cyclin E has been 
associated with DNA damage and increased initiation or stalling of DNA replication721, 722.  
Qian et al. (2014)582 identified similar replication stress induced by Mdivi-1, although the S-phase 
proportion was reduced. Although our analysis showed that S-phase was increased after a short 
Mdivi-1 treatment, our results were consistent with those of Qian et al. (2014)582 in that S-phase  
was reduced with a 24 h treatment, which was a similar exposure time.  
In addition, an intra- S-phase arrest, in response to DNA damage, has been reported previously115, 117. 
Mdivi-1-induced DNA damage during S-phase is plausible, as aberrant mitochondrial fusion may lead 
to increased ROS production435 that can cause DNA breaks723, 724. DNA damage induced during 
replication or as a result of increased ROS may immediately interfere with cell cycle progression or 
enhance a later arrest. Alternatively, a short G1 arrest followed by a semi-synchronised movement 
of cells may account for the increase in S-phase. An Mdivi-1-associated early S-phase arrest, which 
was attributed to a transient G1 arrest, was similarly observed for the irradiated cells. Mdivi-1 may, 
thus, likewise have the potential to initiate a transient G1-arrest prior to the G2/M arrest. 
Differential Mdivi-1 effects in cancer and normal cells 
Importantly, it has been demonstrated that Mdivi-1 induced a cell cycle arrest in a number of cancer 
cell lines but not in normal fibroblasts or epithelial cells573. In contrast, cell cycle arrest was observed 
in vascular and pulmonary artery smooth muscle cells treated with Mdivi-1569-571. The latter 
experiments, however, were conducted under conditions of serum starvation, high glucose and 
hyperproliferation that represent aberrant or stressful environments. The observation that Mdivi-1 
may affect normal tissue less holds promise for this drug as a cancer therapeutic. Further 
experimental work is required to elucidate Mdivi-1 effects in normal tissue.   
In general, in the current work, the observed Mdivi-1-induced increase in mitotic index was 
consistent with the hypothesis that an Mdivi-1-induced cell cycle arrest is associated with aberrant 
mitotic transition. Mechanistically, Mdivi-1 may induce an arrest either by acting directly as a mitotic 




Overall, results suggest that there is significant variation in the kinetics of cell cycle arrest after 
Mdivi-1 treatment in the models examined. Differential responses may be related to their individual 
sensitivities to apoptosis or checkpoint activation. 
6.4.3. Mdivi-1 effects on the radiation-induced cell cycle arrest 
As mentioned above, Mdivi-1 treatments in U937 cells induced a mitotic arrest earlier than in the 
A549 cells. However, when Mdivi-1 was combined with radiation, this early increase in mitotic index 
was not observed. A radiation-induced G2/M arrest has been shown to occur and may preclude 
Mdivi-1 effects related to mitosis as cycling cells may be susceptible to interaction with Mdivi-1.  
An increased mitotic index was subsequently observed and was comparable to that induced by 
Mdivi-1 alone. The mitotic index of the irradiated samples was increased at 24 h (Figure 6.25) 
suggesting release from the radiation-induced G2/M arrest. The delayed Mdivi-1 effects may thus 
have been influenced by the arrest. 
In addition, Mdivi-1 was reported to augment the radiation-induced G2/M arrest (Chapter 5,  
Figure 5.15). Cell cycle analysis based on DNA content alone does not distinguish between G2- and 
M- phase cells, therefore, any G2/M arrest observed may represent both cells arrested in mitosis 
and/or activation of the G2/M checkpoint. In this work, Mdivi-1 was found to induce an increase in 
mitotic index, however, this does not rule out accumulation of cells in G2, which would be expected 
to occur in response to DNA damage. Cytogenetic damage, as discussed below, was previously 
shown to be a consequence of Mdivi-1 treatment. Therefore, additional Mdivi-1-induced DNA 
damage may arrest cells prior to mitosis. Mdivi-1, like radiation, may induce activation of the G2/M 
checkpoint, with the result that a lower level of mitoses is observed with the combined treatment. 
Taken together, the delayed increase in mitoses induced by Mdivi-1 in the context of radiation 
treatment is likely a result of the inability of G2/M arrested cells to move into mitosis which is 
proposed to be a requirement for Mdivi-1-induced cell cycle arrest. Overall, the results suggest that 
Mdivi-1 effects interact with radiation effects to influence the radiation-induced arrest. 
While not specifically examined in this study, oxidative stress associated with mitochondrial 
dysfunction may have a potential role in the Mdivi-1 effect on the radiation-induced cell cycle arrest. 
Cell cycle arrest occurs in response to DNA damage725, nutrient deprivation726 or cellular stress126, 140. 
Specifically, ROS- and stress-activated protein kinases that signal cell death or growth arrest, are 
often increased in response to stress727, 728.  
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Mdivi-1 inhibition of mitochondrial division may result in the aberrant release of ROS due to its 
effects on mitochondrial function. A G2/M arrest induced by increased oxidative stress as a 
consequence of Mdivi-1 treatment may alternatively be a result of secondary nuclear damage38, 154.  
Potential therapeutic application of Mdivi-1 as a mitotic inhibitor and radiosensitiser 
The observation that Mdivi-1 induced a cell cycle arrest in cancer cells may be important 
therapeutically both for the potential use of Mdivi-1 alone and in combination with radiation as  
anti-cancer therapy. Mitotic inhibitors such as taxanes729 or vinca alkaloids730 interfere with 
microtubule formation and induce both mitotic arrest and cell death that restrict tumour growth731. 
Mdivi-1 may similarly have potential as a mitotic inhibitor that may be exploited to enhance 
radiation effects. Mitotic inhibitors that inhibit tubulin and prevent the formation of spindle fibres 
are not tumour-specific and these agents are therefore also toxic to normal dividing tissue. As 
mentioned previously, Mdivi-1 was shown to have no effect on mitosis in fibroblasts and 
untransformed cell lines573 suggesting that Mdivi-1 toxicity may be largely tumour-specific and may 
therefore, have future clinical utility. As cells in mitosis are particularly sensitive to radiation, Mdivi-1 
may be a promising agent for modulation of radiation therapy of tumours due to the accumulation 
of cells in mitosis.  
6.4.4. Assessment of Mdivi-1-induced cell death 
Mdivi-1 reduced survival of A549 cells as assessed by clonogenic assays (Chapter 5). Here, we 
reported that Mdivi-1 induced a significant but limited amount of apoptosis (less than 10 %) in A549 
cells. In contrast, significant apoptosis was observed when Mdivi-1 treatments were investigated in 
the U937 cell line. Approximately 40 % apoptosis was induced by 24 h Mdivi-1 exposure and a similar 
level was maintained with treatments up to 72 h. The U937 cells are generally considered to be 
more sensitive to apoptosis induction than the A549 cells suggesting that Mdivi-1 can induce 
apoptosis in cells that are susceptible to this mechanism of cell death.  
In Chapter 5, we established that A549 clonogenic survival after 16 h Mdivi-1 treatment was reduced 
to 30 % (Figure 5.8). The minimal apoptosis observed suggests that alternative modes of cell death 
e.g. necrosis may be important in Mdivi-1 related cytotoxicity. Similar phenomena have been 





For example, a study involving the administration of Mdivi-1 at the time of re-oxygenation found 
that, although Mdivi-1 inhibited apoptosis, overall cell death was exacerbated. In this case, 
necroptosis (programmed necrosis) was postulated to be the mode of cell death, as the necrosis 
inhibitor Necrostatin was demonstrated to reduce overall cell death732.  
In spite of U937 cells being functionally p53-deficient as a consequence of a large deletion in the p53 
gene733 they are relatively apoptosis-sensitive. A549 cells have a wildtype p53 expression but express 
high levels of MDM2 and, as a result, are more resistant to apoptosis734.  
In our study, lower Mdivi-1 concentrations, namely, 10 and 20 µM and short, 6 h exposures did not 
result in a significant increase in apoptosis or reduced survival in A549 cells. However, apoptosis was 
significantly increased using longer exposure times up to 72 h and higher concentrations of Mdivi-1, 
which is consistent with the general trend reported in previous studies23, 441, 582, 585. In general, 
apoptosis has been observed when the dose is increased above a certain threshold, usually 
concentrations greater than 20 µM and exposures of more than 6 h22, 469, 585. In particular, a study by 
Rehman et al. (2012)21, showed that a minimum of 16 h Mdivi-1 treatment yielded apoptosis.  
Despite initial increases in apoptosis for both 30 and 50 µM Mdivi-1 treatments in A549 cells, the 
level of apoptosis was greatest at 72 h using 50 µM Mdivi-1 while apoptosis was significantly 
reduced at 72 h using 30 µM Mdivi-1. It was speculated that the higher concentration prevented 
proliferation of cells, perhaps by inducing a more efficient cell cycle arrest resulting in an apparently 
higher level of apoptosis with longer treatments. Uninhibited proliferation of surviving cells in the 
sample exposed to the lower concentration may have led to an apparently lower level of apoptosis. 
It is acknowledged that the amount of apoptosis observed is dependent on the assessment time. 
Continued development of drug-induced cell death and the proliferation of unaffected cells will 
influence the value determined at a given time. 
Cell cycle analysis showed that, as the number of mitotic cells induced by Mdivi-1 treatment 
decreased, the proportion of fragmented cells, represented by the sub-G1 peak, increased 
suggesting apoptosis may be a consequence of prolonged arrest in these cells. The sub-G1 peaks,  
an additional estimation of the level of apoptosis induced by Mdivi-1 treatments, suggested 
significantly more apoptosis than that obtained by microscopic evaluation. Although the sub-G1 
peak in flow cytometry, representing dead or fragmented cells, primarily detects apoptosis as a 
result of DNA fragmentation, necrosis may also increase the sub-G1 peak735. This may explain the 
higher apparent apoptotic index observed with cell cycle analysis compared to morphological 
assessment of apoptosis.  
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Reported effects of Mdivi-1 on apoptosis 
Mdivi-1, which inhibits mitochondrial fragmentation, might be expected to prevent apoptosis, a 
process associated with fragmentation. Mdivi-1 has been shown to protect against STS-induced 
apoptosis and the associated mitochondrial fission559.  
The limited induction of apoptosis we observed after Mdivi-1 treatment, in spite of a significant 
reduction in survival, is consistent with a protective role for Mdivi-1 but suggests stimulation of 
other forms of cell death. In a similar study, Qian et al. (2014)582 reported minimal apoptosis  
but significantly decreased survival of breast cancer cells following Mdivi-1 treatment. Despite  
this evidence, the extensive apoptosis observed in U937 cells suggests that the balance of apoptosis 
induction exceeds any apoptosis inhibition. 
The above experiments assessed apoptosis immediately following exposure to the drug. It was 
thought that continuous exposure to a cytotoxic agent such as Mdivi-1 may prevent expression of 
cell death. Hence, apoptosis was also assessed by incubating cells in drug-free medium for a period 
after exposure. Both cell lines, however, showed a progressively reduced level of apoptosis with 
increasing time after exposure indicating no further increase in apoptosis. The presence of Mdivi-1 
may therefore be required for the accumulation of apoptotic cells. However, the gradual reduction 
in apoptosis may also partly be a result of the proliferation of unaffected cells over time. 
From the results it is clear that there is considerable variation in the response of different models to 
Mdivi-1.  
6.4.5. Modulation of radiation-induced apoptosis by Mdivi-1 
Mdivi-1-induced modulation of radiation-induced apoptosis was initially investigated using the 
Mdivi-1 treatment shown by us to induce radiosensitisation in the A549 cell line. Apoptosis was 
quantified at 30 h after irradiation to allow for the release of the G2/M arrest which is required for 
cells to enter mitosis and which usually occurs by 48 h. Although apoptosis was low, samples  
treated with Mdivi-1 showed significantly increased apoptosis relative to that of the control samples. 
The combined effect of Mdivi-1 and radiation did not increase the level of apoptosis significantly 
above that induced by irradiation alone. This sub-additive response when Mdivi-1 was combined 
with radiation may be attributed to an extended cell cycle arrest induced by Mdivi-1. In Chapter 5, it 
was reported that the combination of radiation and Mdivi-1 significantly increased the G2/M arrest 
within a few hours. Mdivi-1 treatment alone yielded a G2/M arrest of more than 50 % of the cells, 
with 30 % of the cells being mitotic at the time of irradiation.  
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A greater proportion of the cells may be affected by radiation, as they are in the radiosensitive M-
phase, and may more effectively undergo mitotic catastrophe. The sub-additive apoptotic response 
could therefore manifest as a result of cells undergoing mitotic catastrophe instead of apoptosis 
when Mdivi-1 is combined with radiation. In addition, many of the cells affected by radiation may 
have already been lethally targeted by Mdivi-1, i.e. overlapping intracellular targets. 
In general, minimal apoptosis could be demonstrated in the A549 cells, which is consistent with the 
notion that many solid tumours are resistant to apoptosis. In addition, early apoptosis after radiation 
does not occur readily in epithelial cells, as cell death generally occurs later once mitosis has 
occurred736. Consequently, we examined radiation-induced apoptosis in U937 leukaemia cells, which 
undergo both early and post-mitotic apoptosis.  
In U937 cells, Mdivi-1 was shown to significantly increase apoptosis when applied on its own. 
However, results suggest that high doses of 20 or 30 Gy interfered with the expression of Mdivi-1  
-induced apoptosis, as evidenced by a reduced apoptotic index for the combined treatment relative 
to Mdivi-1 alone. Such high doses given in a single fraction may induce strong, often permanent 
G2/M arrest as a result of increased damage737, 738. The demonstration of the effects of Mdivi-1 on 
the passage of cells through mitosis suggests that Mdivi-1-induced damage may, in part, be related 
to aberrant mitosis. Radiation-induced G2/M arrest prevents cells from entering mitosis possibly 
preventing the Mdivi-1-induced damage necessary for apoptosis. The Mdivi-1-induced apoptosis 
appeared to be suppressed in irradiated samples up to approximately 40 h post-irradiation. By 48 h, 
the apoptotic index from the combined Mdivi-1 and radiation treatment had started to rise, 
however, the level failed to reach that of Mdivi-1 alone. This may suggest partial release of the 
radiation arrest. 
In contrast, the combination of a lower (3 Gy) radiation dose with Mdivi-1 induced a similar 
apoptotic index compared to Mdivi-1 alone from 48 h. As cycling of cells was able to occur from 24 h 
after 3 Gy, the comparable level of apoptosis suggests that a higher proportion of cells may have 
been available for interaction with Mdivi-1 following release from the arrest.  
Although the apoptosis increased with time for the combined treatment, no increase above the  
level induced by Mdivi-1 alone was observed. As discussed for the A549 cells, such a sub-additive 
response may be attributed to overlapping of intracellular targets. Alternatively, Mdivi-1 itself can 
enhance the radiation-induced G2/M arrest of cells, further preventing expression of radiation or 
Mdivi-1-induced damage. Cell cycling therefore appears to be required for expression of Mdivi-1-
induced apoptosis.  
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A recent experiment that combined the use of radiation and Mdivi-1, reported that Mdivi-1 
protected against radiation-induced damage in normal mouse embryonic fibroblasts466. Mdivi-1 
reduced mitotic catastrophe and suppressed the increase in centrosome number induced by 
radiation. The protection against radiation-induced mitotic catastrophe was replicated using DRP1-
knock-out and mutant models466. While not specifically implicated, it is possible that cell cycle arrest 
may have played a role in the reduced cellular effects. 
Overall, as expected, less apoptosis was induced by 3 Gy compared to 30 Gy. High and low dose 
responses also differed with respective to the latent period before significant apoptosis occurred.  
Negligible apoptosis was observed a few hours after a low dose compared to a significant increase 
relative to control samples for a high dose. This is consistent with higher radiation doses being able 
to induce early, interphase cell death while lower doses induce primarily mitosis-related cell death in 
this cell line204. While the relevance of using high or single doses of 20 or 30 Gy may be questioned in 
the context of therapeutic utility, it may nevertheless be mechanistically informative. It is however 
possible that stimulation of cell death after such high doses may be mechanistically different from 
that induced by lower doses.  
6.4.6. Effects of delaying Mdivi-1 application after irradiation  
To allow for maximal expression of apoptosis induced by the combined Mdivi-1 and radiation 
treatments, we altered the scheduling of the two agents by delaying the addition of Mdivi-1 for an 
interval sufficient for at least partial release of the G2/M arrest. Despite a constant exposure to 
Mdivi-1, by leaving a longer interval the apoptosis was significantly increased. In addition, the 
combined effect was greater than that observed for Mdivi-1 alone. While an interval up to 24 h did 
not change the previous outcome, a 48 h interval was effective in increasing the proportion above 
the level induced by Mdivi-1 alone. The additional apoptosis achieved by delayed application of 
Mdivi-1, is consistent with a requirement of mitosis for expression of both Mdivi-1- and radiation-
induced apoptosis in these cells. As radiation-induced apoptosis remained constant, the increased 
apoptosis observed with the longer interval was not ascribed to increased radiation-induced effects 






6.4.7. Effect of Mdivi-1 on radiation-induced cytogenetic damage 
Mdivi-1, an inhibitor of mitochondrial fission, induced a significant increase in the amount of 
cytogenetic damage, as assessed by micronuclei, in both cell lines tested (Figures 6.13 and 6.27).  
Cytogenetic damage induced following Mdivi-1 treatment was less in the U937 than in the A549 cell 
line. This may be due to a reduced inherent susceptibility of U937 cells or competing processes such 
as apoptosis, which may result in lower detection. In this cell line, chromosomal damage, which has 
been associated with Mdivi-1 exposure, may efficiently induce apoptosis and thus may render 
damage undetectable. For micronuclei assessment cells are required to undergo karyokinesis 
without cytokinesis for the formation of bi-nucleate cells. As Mdivi-1 effects are related to mitotic 
arrest, differences in the response of cells to aberrant mitosis may affect detection of micronuclei.  
In contrast, similar responses in the two cell lines were observed when Mdivi-1 was combined with 
radiation. Mdivi-1 pre-treatment, prior to irradiation, inhibited the induction of cytogenetic damage. 
For reasons described above, this may also be related to mitotic arrest, which may prevent 
expression of Mdivi-1-induced damage in the absence of karyokinesis. In addition, mitotic cells are 
known to be more sensitive to radiation and therefore, an Mdivi-1-induced mitotic arrest may result 
in increased radiation-induced cell death thereby reducing the proportion of evaluable cells. 
Similar to our results, DRP1-deficiency572 and Mdivi-1 treatment573 was previously associated with 
micronuclei, however, Mdivi-1 has also been shown to protect against radiation-induced micronuclei 
formation 466.  
6.4.8. Mechanisms of Mdivi-1-induced micronuclei formation 
The mechanisms of Mdivi-1 induction of micronuclei are not well-established. In general, 
micronuclei may occur as a result of improper attachment of chromosomes to the spindle or  
direct damage leading to broken chromosomal fragments247, 248. Mdivi-1 or reduced DRP1 expression 
has been associated with DNA replication errors582 and aberrant centrosome duplication with 
improper spindle attachment to kinetochores of chromatids573. Cytogenetic aberrations are 
commonly associated with mitotic arrest and slippage739, 740. Arrested cells may divide, potentially 
displaying cytogenetic damage or aneuploidy. Mitotic slippage, whereby cells exit mitosis without 
dividing, leading to polyploidy126, occurs following prolonged mitotic arrest as a result of degradation 
of cyclin B132 and securin 741. An increase in the number of polyploid cells after Mdivi-1 treatment has 
been described previously572, 573. In addition, early progression to anaphase without prolonged 
mitotic arrest has been shown to cause micronuclei formation742.  
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Since Mdivi-1 is cytotoxic, it may be expected to induce DNA damage, either directly or indirectly. 
Mdivi-1 was able to enhance a cisplatin -induced -H2AX signal, indicative of an increased number of 
DNA double-strand breaks although it did not induce double-strand breaks itself582. Whether this is a 
general phenomenon needs to be evaluated further, particularly at increased Mdivi-1 doses and in 
combination with radiation.  
DRP1-deficient cancer cells have been shown to display abnormal nuclear morphology and 
micronuclei, indicating chromosomal instability572. Micronuclei were observed within regions of 
aggregated mitochondria which may represent areas of increased fusion572. Misalignment of mitotic 
chromosomes has been reported following Mdivi-1 treatment144, 573. Wang et al. (2015)573 specifically 
demonstrated the presence of acentrosomal multipolar spindles in Mdivi-1-treated cells with 
consequent mis-segregation of chromosomes and mitotic catastrophe. Defective spindle attachment 
to chromosomes was associated with dysregulation of centrosome replication and abnormal 
karyokinesis573. It can be speculated that abnormal mitochondrial dynamics including localisation 
may provide a physical barrier to spindle development.  
Of interest, chromosome misalignment could be demonstrated in HCT-116 colorectal cancer cells 
expressing mutant DRP1 and hyperfusion but was not observed in equivalent p53-null cells. The 
damage response pathway whereby cells either undergo apoptosis or arrest has been shown to be 
influenced partly by p53 status743. p53 has been associated with both G1 and G2-checkpoint arrest744 
that prevent cells containing chromosomal aberrations from continuing to cycle. p53-deficient cells, 
however, may bypass such checkpoints and maintain misaligned chromosomes.  
Oxidative stress may lead to double-strand breaks and the occurrence of micronuclei. Mitochondrial 
fission is associated with mitochondrial quality control mechanisms including mitophagy511, which is 
necessary for the elimination of dysfunctional mitochondria745, 746. The inability to remove 
dysfunctional mitochondria leads to increased oxidative stress435 and consequently DNA damage723. 
It is possible that inhibition of fission by Mdivi-1 may thus result in oxidative stress and provide an 








6.4.9. Potential kinetics of Mdivi-1 interaction with radiation 
A paradox exists in that Mdivi-1 enhances radiation-induced cell kill, yet apparently inhibits 
expression of certain radiation-induced cellular consequences, such as micronuclei. Further, as a 
recurring theme, the combined effects of Mdivi-1 and radiation were frequently reduced compared 
to those of the individual agents. In each case, the previously observed Mdivi-1-enhanced radiation 
arrest may have been a contributory factor. 
With respect to the reduced induction of micronuclei with the combined treatment, delayed cycling 
of cells may result in lower micronuclei expression as chromosomal fragments become excluded 
during anaphase. In addition, the longer arrest may increase the opportunity for repair prior to 
division. The apparent reduction in cytogenetic damage may in fact reflect the increase in cell death 
from combined treatment due to M-phase radiosensitivity of Mdivi-1 arrested cells. Hence mitotic 
catastrophe and subsequent cell death may outweigh demonstrable cytogenetic damage. 
The previously identified Mdivi-1-induced increase in fusion was reduced when Mdivi-1 was 
combined with radiation. However, no change in mitochondrial morphology after irradiation  
was found using Small-fragment analysis. Mitochondrial fragmentation has previously been 
demonstrated after irradiation57, 466 which may counteract the increased fusion observed with  
Mdivi-1. Alternatively, it is possible that the level of fragmentation induced by irradiation in our  





• Mdivi-1 reduced survival in both detached and adherent A549 cell populations. 
• Both populations were radiosensitised by Mdivi-1, however, the detached cells were 
significantly more affected.  
• Mdivi-1 induced a G2/M arrest. 
• Survival of a proportion of the detached cells suggested that detachment was not solely 
related to cell death. Since cells in G2/M round up and detach, it is likely that some of the 
detached cells represent an arrested population. 
• Mdivi-1 modulated the radiation-induced cell cycle arrest but differential kinetics were 
apparent for the cell lines examined. Since radiation-induced cell cycle arrest influenced the 
Mdivi-1 response, cell division may be necessary for expression of Mdivi-1 effects including 
apoptosis and cytogenetic damage.  
• Mdivi-1 induced apoptosis in both cell lines examined. U937 cells, which are considered to 
be apoptosis-responsive, were particularly sensitive to Mdivi-1. Radiosensitisation, reported 
previously, was not due to apoptosis.  
• Mdivi-1 induced cytogenetic damage expressed as micronuclei. In addition, Mdivi-1 
interfered with the development of cytogenetic damage after irradiation.  
• A sub-additive response for the drug-radiation combination was consistently found for all 
end-points examined except where an interval between treatments was allowed, which 
yielded an approximately additive response.  







FINAL DISCUSSION AND CONCLUSIONS 
 
This study initially characterised a group of cancer cell lines in terms of radiosensitivity, cellular 
respiration, mitochondrial morphology and ΔΨm and investigated potential correlations between 
inherent radiation-responsiveness and mitochondrial status. In addition, modulation of 
mitochondrial dynamics was shown to influence radiation response in two of the characterised 
cancer cell lines. Further, the effects of Mdivi-1 on cell cycle dynamics, apoptosis and cytogenetic 
damage were examined.  
The current chapter presents a brief summary of the findings as they relate to the original research 
questions that prompted these investigations. 
 
7.1. Is the radiation responsiveness of cancer cells associated with 
mitochondrial morphology or function? 
Investigations into the relationship between radiation response and mitochondrial status, including 
morphological and functional characteristics, demonstrated some correlation. Increased 
mitochondrial fusion was strongly correlated with decreased radiation response, however, statistical 
significance was not reached. In addition, ΔΨm was correlated with measures of the intrinsic 
radiosensitivity of the cell lines, but also did not reach significance. In general, indicators of 
mitochondrial function, namely respiratory indices and ΔΨm correlated strongly and significantly. 








7.2. Does modulation of mitochondrial dynamics influence cellular integrity 
or response to radiation? 
We initially postulated that Mdivi-1, a mitochondrial fission inhibitor, would protect against 
radiation-induced cell death. However, no protective effect was observed. In contrast, Mdivi-1 
significantly increased the sensitivity of cancer cells to radiation treatment.  
7.2.1. Does Mdivi-1 induce mitochondrial fusion?  
Mdivi-1 was shown to alter mitochondrial morphology resulting in a shift towards increased fusion. 
A wide range of Mdivi-1 concentrations induced a rapid increase in the number of cells displaying 
predominantly fused mitochondria. However, a dose dependence was observed, with lower Mdivi-1 
concentrations failing to induce a shift towards fusion. 
7.2.2. Does inhibition of mitochondrial fission alter survival of cancer cells? 
Mdivi-1 was demonstrated to significantly reduce survival in the cell lines tested. In general, Mdivi-1 
treatments in excess of 6 h were required to influence the survival and the toxicity was cell line 
dependent. A higher Mdivi-1 concentration was required to induce toxicity in the A549 lung cancer 
cell line compared to the U937 monocytic leukaemia cell line. Differential effects may potentially be 
related to the inherent capacity of the cell lines for programmed cell death. 
7.2.3. Does inhibition of mitochondrial fission influence radiation survival of cancer cells? 
Mdivi-1 was demonstrated to significantly sensitise A549 lung cancer cells to radiation. Overall, 
Mdivi-1 was found to augment radiation sensitivity by approximately 20 %. In general, for such 
modulation, doses at which a degree of Mdivi-1-induced toxicity was evident were required.  
7.2.4. Does inhibition of mitochondrial fission influence repair of radiation-induced 
damage?  
Mdivi-1 was not shown to modulate sub-lethal- or potentially-lethal damage repair as  




7.2.5. Does inhibition of mitochondrial fission influence cell cycle dynamics and/or 
radiation-induced cell cycle arrest?  
While both Mdivi-1 and radiation were found to induce a cell cycle arrest independently,  
Mdivi-1 also enhanced the radiation-induced G2/M cell cycle arrest in A549 cells.  
7.3. How does Mdivi-1 alter radiation response? 
The effects of Mdivi-1 treatment on two cancer cell lines were shown to influence processes known 
to be involved in radiation response. Mdivi-1 was shown to induce apoptosis, cell cycle arrest and 
cytogenetic damage in both cell lines investigated. Mdivi-1 was shown to modulate the radiation-
induced effects on these processes, however, in general, responses were sub-additive. 
7.3.1. Does Mdivi-1 delay cells in mitosis?  
In both cell lines investigated, Mdivi-1 induced a significant G2/M cell cycle arrest, and an increase in 
both mitotic index and metaphase cells specifically, which may indicate a mitotic delay. The 
accumulation of cells in mitosis and subsequent apoptosis suggests that the mitotic arrest may be 
required for Mdivi-1-induced cytotoxicity.  
7.3.2. Does Mdivi-1 influence the level of mitosis after irradiation? 
In the U937 cell line, Mdivi-1 caused a notable increase in mitoses with exposure. However, when 
combined with radiation, which also increased the mitotic index, a sub-additive response was 
obtained. It is likely that a radiation-induced cell cycle arrest prevented entry of cells into mitosis and 
thus, the Mdivi-1 induced accumulation of mitotic cells.  
7.3.3. Does Mdivi-1 cause apoptosis in cancer cells?  
Mdivi-1 induced significant apoptosis. The U937 cells were more sensitive to Mdivi-1-induced 
apoptosis than the A549 cells with up to 40 % of the cells undergoing apoptosis after 24 h of 
treatment. As the apoptotic index decreased after the removal of Mdivi-1, it can be speculated that 
expression of Mdivi-1-induced damage requires continuous exposure.  
Mdivi-1 would appear to be capable of inducing apoptosis in apoptosis-responsive cells, such as the 
U937 cells. However, the lack of correlation between clonogenic survival and apoptosis in the A549 
cell line suggests that Mdivi-1 may induce other modes of cell death in more resistant cells.  
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7.3.4. Does Mdivi-1 modulate radiation-induced apoptosis in cancer cells?  
It was consistently observed that Mdivi-1 combined with radiation did not increase the apoptotic 
index above that observed for Mdivi-1 alone. However, in U937 cells, once irradiation and Mdivi-1 
treatment were separated by a time interval, equivalent to the time required for release of the 
radiation-induced G2/M arrest, the apoptotic index was increased relative to Mdivi-1 treatment 
alone. Our results thus suggest that the passage through mitosis may be required for the expression 
of Mdivi-1-induced effects.  
7.3.5. Does Mdivi-1 induce cytogenetic damage? 
Mdivi-1 was shown to induce cytogenetic damage in both cell lines but to a lesser extent in the U937 
cell line. It can be speculated that cells that are resistant to apoptosis, such as the A549 cells, are 
more likely to survive and express cytogenetic damage. Apoptosis-sensitive cells, however, are likely 
to be eliminated early, thus reducing the number of evaluable cells displaying cytogenetic damage.  
7.3.6. Does Mdivi-1 modulate the induction of radiation-induced cytogenetic damage? 
Radiation induced high levels of cytogenetic damage in both cell lines. The combined treatment of 
Mdivi-1 and radiation resulted in fewer cells displaying cytogenetic damage than induced by 
radiation alone. This may suggest that Mdivi-1 protects against radiation-induced cytogenetic 
damage. However, the reduced effect may be attributed to an Mdivi-1-induced accumulation of cells 
in mitosis prior to irradiation. Increased radiosensitivity of these cells may increase the probability of 
mitotic cell death and selective reduction of the population evaluable for assessment of cytogenetic 
damage. 
Study limitations 
Studies were conducted in an in vitro system and would need to be replicated in vivo for further pre-
clinical testing. In addition, a limited number of cell lines were included for analysis, particularly the 
radiomodulation experiments, thus restricting generalisability. Cancer type-specific effects could 
also not be fully elucidated, however distinct differences in the responses of cells from malignancies 
of solid- and haematological origin were suggested. The lack of inclusion of normal cells prevented 
the evaluation of potential differential effects. Further, evidence of changes at a protein level, e.g. 
DRP1 expression, after mitochondrial modulation would strengthen conclusions regarding Mdivi-1 
effects. Finally, single radiation doses were used for most investigations and the effect of 
combination with fractionation remains unclear. 
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Clinical prospects and future work 
Having demonstrated a proof of principle, it is envisaged that drugs like Mdivi-1 may be developed 
further for clinical use. Provision of mitochondrial modulating agents to patients prior to 
radiotherapy treatments could possibly enhance tumour response. However, extensive clinical 
development would be required before this goal could be realised. Investment in the design of 
specific drugs that can regulate mitochondrial dynamics precisely and with minimal toxicity may also 
be worthwhile. As a therapeutic strategy, manipulating mitochondrial dynamics may offer a 
favourable therapeutic ratio as Mdivi-1 has been shown to be relatively well-tolerated in normal 
tissue models.  
Screening for tumour mitochondrial function may be useful in predicting sensitivity to treatment. 
Currently, techniques exist for the diagnosis of mitochondrial diseases through clinical, 
histopathological, biochemical and molecular examinations. The development of markers that can 
act as a proxy for tumour mitochondrial status is an important future consideration. Such a tool may 
be useful to inform treatment and may also have prognostic application. 
Further avenues for investigation may include mechanistic studies, and the inclusion of additional 
models and fractionation schemes. It would be important to replicate the radiation experiments 
with Mdivi-1 in additional models to determine if the radiosensitisation demonstrated is 
generalisable. In addition, the assessment of DRP1 and other associated proteins in response to 
modulation of mitochondrial dynamics would yield a more holistic interpretation. Other approaches 
to modulate mitochondrial dynamics, including siRNA knock-down of relevant proteins would 
provide additional evidence for construction of a universal theory. The investigation of such effects 
in additional cell lines, including normal cells, other types of cancer and in in vivo models, will 







Radiation response is influenced by changes in mitochondrial dynamics. Although measures of 
cellular radiosensitivity did not correlate significantly with inherent mitochondrial membrane 
potential, respiration or morphology, Mdivi-1 treatment, which resulted in increased mitochondrial 
fusion, significantly radiosensitised lung cancer cells. In addition, Mdivi-1 reduced clonogenic 
survival, increased apoptotic cell death and induced cytogenetic damage in two cancer models. 
Mdivi-1, induced an increase in mitotic cells and a G2/M arrest, and enhanced the radiation-induced 
cell cycle arrest. However, combined Mdivi-1 and radiation treatments frequently yielded sub-
additive responses for measures other than clonogenic survival, and did not influence radiation-
induced damage repair.  
Overall, the evidence presented demonstrates the potential for the modulation of mitochondrial 
dynamics to induce cytotoxic effects in tumours and to enhance the effectiveness of radiation 















CELL LINES AND CULTURE TECHNIQUES 
1. Cell lines  
The cell lines obtained for this study are listed in Table 4.1, p. 58). A549 (cat. 86012804),  
T47D (cat. 85102201) and U937 cells (cat. 85011440) were obtained from the European Collection of 
Authenticated Cell Cultures (ECACC) (Porton Down, Salisbury, UK). DU145 cells were obtained from the 
International Centre for Genetic Engineering and Biotechnology (ICGEB), University of Cape Town 
(UCT) and the MDA-MB-231 and HeLa cells were received from the Department of Medicine, UCT. 
Cells within 5 passages were used in experiments. Mycoplasma testing was performed bi-monthly.  
2. Cell culture 
Cell lines were incubated at 37°C with 100 % humidity and 5% CO2 /95% O2. A549, T47D, U937,  
MDA-MB-231 and HeLa cells were grown in RPMI (Roswell Park Memorial Institute) 1640 culture 
medium (Sigma-Aldrich, St. Louis, MO, USA) while DU145 cells were grown in Dulbecco's Modified 
Eagle's medium (DMEM) cell culture medium (Sigma-Aldrich) (Appendix A2.1). Cell culture medium 
was supplemented with 10 % heat inactivated fetal calf serum (FCS) (Highveld Biological, Johannesburg, 
SA) and 1 % antibiotics (AB) (penicillin and streptomycin) (Highveld Biological) unless otherwise 
indicated.  
2.1. Cell culture media 
RPMI/DMEM      10.4/13.4 g 
NaHCO3 (Sigma-Aldrich)      2/3.7 g 
Made up to 1L with ddH2O      
Filtered using a sterile 0.22 µm Corning® bottle-top vacuum filter system (Sigma-Aldrich)  
and stored at 4°C. 
2.2. Sub-culture of cells 
Cells were passaged every 2-3 days as required. Adherent cell lines were sub-cultured by 
trypsinisation as follows; the cell culture medium was removed and cells were washed with 1 ml 
phosphate buffered saline (PBS) (Appendix A 2.2.1).  
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A volume of 1 ml trypsin (Highveld Biological) (Appendix A2.2.2) was added and cells were incubated 
for 10 minutes at 37°C. The trypsin was inactivated with culture medium and then removed by 
centrifugation for 5 minutes at 100 RCF. The cells were resuspended in fresh medium and the cell 
number determined using a haemocytometer. An appropriate number of cells was then seeded into 
a 25 cm2 CELLSTAR® sterile cell culture flask (Greiner Bio-One GmbH, Frickenhausen, Germany) and 
incubated as described previously.  
The U937 suspension culture does not require enzymatic treatment for sub-culturing. Cells were 
cultured in 75 cm2 CELLSTAR® sterile suspension culture flasks (Greiner Bio-One). For sub-culture, a 
sample of cells was diluted to the appropriate seeding density in fresh medium.  
2.2.1. 1x PBS (0.01 M) 
100 mM NaCl (Sigma-Aldrich)      5.84 g 
20 mM NaH2PO4 (Sigma-Aldrich)      2.4 g 
80 mM Na2HPO4 (Sigma-Aldrich)      11.36 g 
Made up to 1L with ddH2O (pH = 7.4) 
2.2.2. Trypsin (0.05 %) 
Trypsin powder (Difco Laboratories, MI, USA)   0.5 g 
NaCl        11.24 g 
KCl        0.4 g 
NaHCO3       0.58 g 
Di sodium EDTA (BDH Laboratory supplies, Poole, UK)   0.2 g 
Made up to 1L with ddH2O 
Filtered using a sterile 0.22 µm Corning® bottle-top vacuum filter system and stored at 4°C. 
 
2.3. Trypan blue cell viability assay 
The viability of cells was assessed using trypan blue solution (0.4 %) (Gibco, Massachusetts, USA). This 
dye stains cells only if the cell membrane has been compromised. A small volume (100 µl) of cells in 
suspension was transferred to a 0.5 ml Eppendorf tube (Greiner Bio-One) containing an equal volume 
of trypan blue solution (1:1). Cells were visualised on a WILD M12 phase contrast microscope (Wild, 
Heerbrugg, Switzerland) at 100x magnification and quantified using a haemocytometer. Cells were 




CELL SURVIVAL ASSAYS AND RADIATION SETUP 
1. Clonogenic cell survival assays 
1.1. Pre-plated clonogenic survival assay: Adherent cells 
A suitable number of exponentially growing cells were plated into 60 mm CELLSTAR® cell culture 
dishes (Greiner Bio-One) for a yield of at least 100 colonies after treatment. Culture dishes were 
incubated overnight at 37°C for cells to adhere before irradiation.  
Cells were -irradiated in quadruplicate using a 60Co source with a dose rate of approximately  
1 Gy/min at a source to surface distance (SSD) of 80 cm. Please refer to Appendix B2 for the 
irradiation setup. Unirradiated control samples were mock treated. Culture dishes were incubated at 
37°C for up to three weeks depending on the cellular doubling time and period to form colonies for 
each cell line. When colonies of at least 50 cells were observed, the culture medium was removed 
and the cells were rinsed with 1 ml PBS. Colonies were then stained with 2 ml crystal violet solution 
[0.2 %] (Appendix B1.1.1) for five minutes. Following a rinse with water to remove excess dye, 
culture dishes were air dried and colony number was determined manually. Colonies of at least  
50 cells were counted and cell number was confirmed microscopically using a WILD M40 inverted 
microscope (Wild) fitted with a Fluotar 10x Ph0.4 objective lens. 
1.1.1. Crystal violet solution (0.2 %)  
Crystal violet (Sigma-Aldrich)      200 mg 
Methanol (Merck, NJ, USA)      10 ml 
ddH2O        90 ml 
Clarified using No 1. Whatman filter paper (Sigma-Aldrich). 
1.2. Pre-plated clonogenic survival assay: Suspension cells 
The clonogenic assay was adapted for the U937 non-adherent cell line to facilitate formation of 
colonies within an agarose-based culture medium that prevented the cells from separating after 
division. The modified medium (Appendix B1.2.3.) consisted of 0.6 % low melting point agarose 
(Appendix B1.2.1), 2x RPMI culture medium (Appendix B1.2.2) and FCS in the ratio 5:4:1.  
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U937 cell number was determined in 1x RPMI culture medium and calculated volumes of cells were 
added to give a final volume of 2 ml. After careful mixing, cells were transferred to 35 x 10 mm 
CELLSTAR® cell culture dishes (Greiner Bio-One) and incubated at room temperature for 1 h. A short 
incubation of 10 minutes at 4°C facilitated setting of the agarose prior to irradiation. Cells were 
irradiated as described above and incubated at 37°C for 1 week until visible colonies had formed. 
1.2.1. Agarose (0.6 %) 
Low melting point agarose (Sigma-Aldrich)   0.6 g 
ddH2O       100 ml 
Heated to dissolve and autoclaved to sterilise. 
1.2.2. 2x RPMI culture medium 
RPMI 1640      1.04 g 
NaHCO3      0.2 g 
Made up to 50 ml with ddH2O 
Filter sterilised with a 0.2 µm Supelco minisart syringe filter (Sigma-Aldrich) and heated to 45°C in a 
water bath (FMH Instruments, Labotec, Midrand, SA). 
1.2.3. Semi-solid culture medium 
0.6 % Agarose (cooled to 45°C)    50 ml 
2x RPMI medium (Appendix B1.2.2.)    40 ml 
FCS       10 ml 
1.3. Post-plated clonogenic survival assay 
Mdivi-1 (Sigma-Aldrich) was found to cause mitotic arrest of > 10 % of cells after 6 h treatment.  
As cells in mitosis become round and easily detached, pre-plated experiments may result in loss of 
cells during wash steps. Post-plated experiments however circumvent this problem by plating cells 
for colony formation after treatment.  
For post-plated clonogenic assays, an equal number of cells were plated into 25 cm2 CELLSTAR® 
sterile cell culture flasks (Greiner Bio-One) at a low density (100 000 cells/ml) and incubated overnight 
at 37°C. Up to 4 flasks per treatment group, as detailed in the relevant methodology sections were 
included for analysis. Replicates were processed in separate experiments. After treatment the 
medium containing any detached cells, and PBS washes were collected in 12 ml CELLSTAR® cell 
culture tubes (Greiner Bio-One).  
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The remaining cells were trypsinised for 10 minutes and added to the respective tube. Samples were 
washed 3x with 3 ml of medium and cells were collected by centrifugation at 100 RCF. A cell count 
was performed for each test group using a haemocytometer. From this, dilutions were made and 
cells were plated into 60 mm CELLSTAR® cell culture dishes (Greiner Bio-One) for a yield of at least 100 
colonies. Culture dishes, in triplicate, were incubated for up to 10 days at 37°C for colony formation. 
Colonies were stained with crystal violet as was described previously. 
1.4. Clonogenic assay for separated adherent and detached cell populations 
Cells at a density of 150 000 cells/ml were plated into 35 x 10 mm CELLSTAR® cell culture dishes 
(Greiner Bio-One) and incubated in 2 ml RPMI (with FCS and AB) at 37°C overnight to adhere.  
Two plates per sample were used where adherent and detached cells were to be separated.  
The cells from both dishes were pooled to ensure an adequate number could be collected for 
plating. The incubation medium was replaced with 1 ml RPMI containing 30 µM Mdivi-1  
(Chapter 6, section 6.2.1) or the vehicle and cells were irradiated, if required, and incubated  
at 37°C for 16 h.  
For the unseparated samples, collection of cells was as described previously for post-plated 
experiments. For samples to be separated, cells were collected by transferring the incubation 
medium from the dishes to a 12 ml CELLSTAR® cell culture tube (Greiner Bio-One). Each plate was 
washed multiple times with 1 ml PBS to ensure all detached cells had been collected. The remaining 
adherent cells were trypsinised and cells were collected in a separate 12 ml CELLSTAR® cell culture 
tube (Greiner Bio-One). All samples were centrifuged at 100 RCF for 15 minutes to pellet cells and 
washed twice with 4 ml RPMI (with FCS and AB) to remove Mdivi-1.  
Cell pellets were resuspended in an appropriate volume of RPMI (with FCS and AB) for a cell count 
and the required numbers of cells were plated out for each sample to give at least 100 colonies for 
analysis. Five replicate plates were incubated at 37°C for 7-10 days to allow colony formation and 
then stained with crystal violet as described previously. In addition, the total number of cells in each 




2. Radiation setup  
An Eldorado 8 Cobalt teletherapy unit (Atomic Energy of Canada Ltd, Ottawa, Canada) with a fixed head 
was used for -irradiation of cells. Photographs of the irradiation setup are shown in Figure B1. The 
60Co source produces a beam of -rays of 1.17 and 1.33 MeV energies. This unit provides an 
irradiation field size of 10 x 10 cm2 (within 95 % isodose) at an SSD of 80 cm. Samples were irradiated 












Figure B1: Radiation setup. A. The 60Co teletherapy unit used for -irradiation of cells. 
Insert: Two flasks demonstrating placement of build-up for irradiation. B. Schematic 





STAINING OF MITOCHONDRIA 
1. MitoTracker® Red staining protocol 
Adherent A549, T47D and DU145 cells were plated at a density of 100 000 cells per 10 cm2 onto  
22 x 22 mm glass coverslips (Lasec, Cape Town, South Africa) in 35 x 10 mm CELLSTAR® cell culture 
dishes (Greiner Bio-One). Cells were incubated in the appropriate culture medium (with FCS and AB) 
at 37°C for 24 h prior to staining. 
MitoTracker® Red (Molecular Probes® Inc) stock solution (100 µM in DMSO) was diluted to give an 
optimised final working solution (Appendix C, Table C1) in the appropriate pre-warmed culture 
medium (with FCS and AB) for each cell line. Solutions maintained a DMSO concentration of < 0.1 %. 
A volume of 1 ml MitoTracker® Red solution was added and cells were incubated at 37°C for up to  
25 minutes depending on the cell type (Appendix C, Table C1). The cells on the coverslips were 
washed twice with 2 ml of medium. Cells were fixed for 20 minutes at room temperature using 4 % 
paraformaldehyde prepared in medium (Appendix D2.2). The fixative was replaced with PBS and 
samples were stored at 4°C.  
For microscopic visualisation, coverslips were mounted onto 76 x 26 mm glass slides (Lasec) as 
described in Chapter 4. Fluorescence microscopy is detailed in Appendix D. During processing,  







Figure C1: MitoTracker® Red CMXRos (C32H32Cl2N2O). A) Chemical structure. B) Excitation and 





Table C1: MitoTracker® Red concentrations and incubation times  
Cell line [MitoRed] Incubation time  
A549 100 nM 15 minutes 
DU145 100 nM 25 minutes 
T47D 80 nM 15 minutes 
 
2. Comparison of mitochondrial staining techniques 
2.1. Live cell imaging 
Samples from each cell line were stained with MitoTracker® Red (Molecular Probes® Inc.) and assessed 
using live cell imaging as described in Chapter 4 to confirm that the mitochondrial morphology of 
fixed cells was comparable to that observed in live cells. Images of mitochondria from live cells are 
shown in Figure C3 for comparison with the mito-RFP-transfected cells (Figure C4), confocal 


















2.2. Mito-RFP transfection 
The A549 cell line was transfected with a red fluorescent protein construct (mito-RFP) to label 
mitochondria (CellLight® Mitochondria-RFP, BacMam 2.0; Molecular Probes Inc). Briefly, 2 µl of the 
BacMan reagent was added per 10 000 cells in the appropriate culture medium. Cells were 
incubated at 37C for 16 h. Figure C4 shows a collection of transfected cells that represent a 
























2.3. Confocal microscopy 
In order to further evaluate the quality of the images obtained using conventional fluorescence 
microscopy, mitochondria were imaged using confocal microscopy (Figure C5). Cells were stained 
with MitoTracker® Red and the mitochondria were visualised using a Zeiss Axiovert 200M LSM 510 
Meta Confocal Microscope with pulsed infrared laser for 2-photon excitation (UCT Confocal and Light 
Imaging Facility).  Images were collected using a Zeiss AxioCam and analysed using LSM software for 
















3. JC-1 staining protocol for mitochondrial membrane potential assessment 
3.1. Staining of cells  
All cell lines were stained in suspension to determine the relative ΔΨm. U937 cells were seeded into 
60 mm CELLSTAR® cell culture dishes (Greiner Bio-One) at a density of 250 000 cells/ml. Adherent 
A549, T47D, and DU145 cells were cultured in 35 x 10 mm CELLSTAR® cell culture dishes (Greiner Bio-
One) to a density of 500 000 cells/ml. The cell culture medium was replaced 3 h prior to assessment. 
After trypsinisation as required, cells were collected in 12 ml CELLSTAR® cell culture tubes (Greiner Bio-
One) and centrifuged at 100 RCF for 10 minutes. The supernatant was carefully removed and the 
pellet was resuspended directly in JC-1 stain (Appendix C3.1.1). Samples were incubated at 37°C for 
20 minutes and collected by centrifugation at 100 RCF for 5 minutes giving a total JC-1 staining time 
of 25 minutes. Cells were washed once with 2 ml of cell culture medium and were resuspended in a 
final volume of 100 µl of medium. Samples were mounted onto 76 x 26 mm glass slides (Lasec), 
covered with 22 x 22 mm glass coverslips (Lasec). Slides were maintained at 37°C and imaged  
30 minutes after staining to allow for JC-1 aggregation. 
3.1.1. JC-1 stain preparation 
JC-1 (Sigma-Aldrich) was reconstituted in DMSO at a concentration of 3 mM. Solutions were diluted to 
5 µM in the appropriate culture medium (with FCS and AB) giving a final DMSO concentration of  
0.17 %. For dilutions, the JC-1 stock solution and the appropriate cell culture medium were  
pre-warmed and JC-1 was added while vortexing. Solutions were maintained at 37°C until use to 
ensure continued dissolution of JC-1. 
3.2. Quantification of fluorescence images using Image J 
RAW image files (.CR2) were converted to "Tagged Image File Format" (.tiff) using Digital Photo 
Professional v3.4. Images collected using blue light excitation, showing both ‘green’ and ‘orange’ 
fluorescence were used to demarcate specific regions for intensity measurements. Images were 
opened in Image J v1.48 (NIH)634 and were separated into red, green and blue channels. The green 
channel image was converted to 8-bit and a threshold was applied to include all cells in the field  
but exclude background fluorescence. Selected areas were identified as regions of interest (ROI)  




The original combined image was then re-opened and the saved ROI set was applied to the image. 
Quality control of the ROI set was done manually to ensure the entire cell was included in the 
analysis and artifacts were excluded.  
The average grey value per cell was measured using the green channel from this image only. In 
addition, the saved ROI mask was applied to the corresponding image captured using green light 
excitation. This image was also divided into blue, green and red channels and the red channel was 
used to quantify the red fluorescence in each of the corresponding cells. Included in the ROI mask 
were five regions chosen from areas of the image that did not contain cells. The average value from 
these five measurements, namely the average background reading, was subtracted from the ‘red’ or 
‘green’ mean grey values respectively to give a corrected mean grey value. Once red and green 
values were collected for all cells in a field the Red:Green ratio was calculated by dividing the ‘red’ 
mean grey value by the ‘green’ mean grey value. 
3.3. High magnification images of mitochondria stained with JC-1 
3.3.1. JC-1 staining of adherent cells cultured on coverslips 
Adherent A549, T47D, and DU145 cells were plated into 35 x 10 mm CELLSTAR® cell culture dishes 
(Greiner Bio-One) at a density of 100 000 cells per 10 cm2 onto 22 x 22m m glass coverslips. Cells were 
incubated overnight to adhere in the appropriate culture medium (with FCS and AB) at 37°C prior to 
staining. The culture medium was replaced with JC-1 stain (Appendix C3.1.1) and incubated at 37°C 
for 15 minutes. Coverslips were washed once with culture medium and mounted onto 76 x 26 mm 
glass slides (Lasec). Slides were incubated at 37°C for 25 minutes before viewing. A subset of high 
magnification images were collected for each of the cell lines to document differences in JC-1 
aggregate distribution within the mitochondria of individual cells and between cell types. Samples 
were imaged with the UPlanFl 100x/0.75 objective (Olympus) using the WB fluorescence filter block 
(Appendix D, Table D1).  Images were captured using a Moticam Pro 285D monochrome scientific 










1. Fluorescence microscopy and image capture  
Cell culture and staining has been described previously. For adherent cell lines, stained cells on glass 
coverslips (Lasec) were rinsed with PBS and mounted on a 76 x 26 mm glass slide (Lasec) with 15 µl 
mounting solution (Appendix D1.1). Coverslips were sealed with nail varnish where aqueous 
mounting solutions were used and high magnification (1000x) was required. Samples mounted with 
Mowiol and ProLong® Gold did not need to be sealed once mountant had hardened. For cells in 
suspension, 10 µl of sample was mixed with 10 µl mounting solution (Appendix D1.1) on a 76 x 26 
mm glass slide. The sample was covered with a 22 x 22 mm glass coverslip and sealed as required. 
For live cell viewing, cells were mounted immediately with 15 µl of the appropriate cell culture 
medium. Cells were visualised using light or fluorescence microscopy, as required. All preparations 
for fluorescence microscopy were performed under low-light conditions.  
Slides were visualised using a BX41 Olympus fluorescence microscope (Olympus). The UPlanFl 
100x/1.30 oil immersion objective (Olympus) was used for high magnification microscopy and the 
UPlanFl 10x or 40x/0.75 objective for lower magnifications (Olympus). 
The appropriate filter block was selected based on the fluorescent label used in each experiment 
(Appendix D, Table D1). Images were captured using a Moticam Pro 285D monochrome scientific 
CCD camera (Peltier cooled) for Olympus fluorescent microscope (Motic).  
 







Light (Ex/Em)  
nm 
MitoTracker Red WG 579/599 Green/Red 
JC-1 WB & WG 490/520 & 590 Blue/Green & Green/Red 
FITC WB 495/519 Blue/Green 
Acridine Orange WB 502/525 & 460/650 Blue/Green (and orange) 




2. General mounting, fixing and staining solutions for microscopy 
2.1. Mounting solutions 
a) Mowiol:  
Glycerol (Sigma-Aldrich)      6 g 
Mowiol (Sigma-Aldrich)      2.4 g 
ddH2O       6 ml 
The mixture was incubated at room temperature for 2 h followed by the addition of  
12 ml 0.2 M Tris, pH 8.5 (Sigma-Aldrich). After incubation for a further 10 minutes at 60°C,  
the Mowiol was centrifuged at 5000 RCF for 15 minutes to remove undissolved solids.  
Long-term and short-term storage of aliquots was at -20°C at 4°C, respectively. 
b) Glycerol:PBS (8:2) solution combined in a 2 ml cryogenic vial (Greiner Bio-One). 
c) VECTASHIELD Antifade Mounting Medium: DAPI (Vector Laboratories Inc.). 
d) ProLong® Gold Antifade Mountant (Fairland, Johannesburg, SA). 
2.2. Staining solutions 
2.2.1. Hoechst 33342 (1 µg/ml) 
1 mg/ml Hoechst 33342 (Sigma-Aldrich)     10 µl 
PBS        10 ml 
2.2.2. Acridine orange solution (10 µg/ml) 
1 mg/ml Acridine orange stock solution    400 µl 
Gurr’s phosphate buffer     40 ml 
2.2.2.1. Acridine orange stock (1 mg/ml) 
Acridine orange (BDH Laboratory supplies)    0.1 g 
ddH2O        100 ml 
2.2.2.2. Gurr’s phosphate buffer (0.004 M, pH 6.8) 
0.54 M KH2PO4        100 ml 
0.57 M Na2HPO4      50 ml 
Made up to 1L with ddH2O 
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2.3. Fixing solutions and buffers 
2.3.1. Paraformaldehyde (4 %)  
Paraformaldehyde (Sigma-Aldrich)    0.4 g  
PBS or medium as required    10 ml 
The solution was heated to 60°C and the pH was adjusted with 25 µl 1N NaOH to  
obtain a clear solution and ooled to room temperature before application. 
2.3.2. Metaphase fixative solutions A and B 
A = Methanol:acetic acid:Ringers solution (4:1:5) 
B = Methanol:acetic acid (4:1) 
2.3.3. KCl (75 mM) 
KCl        5.6 g  
Made up to 1L with ddH2O and pre-warmed to 37°C before use. 
2.3.4. Ringers solution (75 mM) 
NaCl       6.5 g 
KCl       0.42 g 
CaCl2        0.25 g  
NaHCO3       0.2 g 







MITOCHONDRIAL MORPHOLOGICAL SUBTYPES 
 
1. Morphological classification 
1.1. Image processing 
Mitochondrial images were analysed using Image J software (NIH)634 and were processed using a 






Figure E1: Processing of images for morphological assessment of mitochondria in 
MitoTracker® Red stained cells.  
 
1.2. Quality control 
Slides containing a large proportion of cells that appeared to be rounded and swollen were excluded 
as this morphology has been reported to represent deterioration of cells and/or dysfunctional 






Original image Convolution filter Binarisation 
Figure E2: Representative example of a cell  
containing swollen mitochondria indicating 




1.3. Morphological assessment by categorisation 
1.3.1. Acquisition and documentation of representative images 
Morphological data was acquired manually from direct observation and not from images. However, 
certain images were captured to document morphology. Representative images were captured with 
a Moticam Pro 285D monochrome scientific CCD camera (Motic). Exposure settings were adjusted to 
optimise capture of both brightly-stained perinuclear mitochondria and faint peripheral fragments. 
Image J v1.48 (NIH)634 was used for image processing to enhance the brightness and contrast mainly 




Figure E3: Mitochondrial morphological categories and examples of each for the cell types analysed. 










Figure E4: Diagram illustrating the 
cut-off rule for morphological 
categorisation of cells based on 
mitochondrial fragmentation. 
Copyright: ©2013 Farrand et al. 688 
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APPENDIX F  
HIGH-RESOLUTION RESPIROMETRY  
1. Preparation of cells  
Cells for analysis of oxygen consumption were plated at 200 000 cells/ml in 75 cm2 CELLSTAR®  
sterile cell culture flasks (Greiner Bio-One). Exponentially growing adherent A549, T47D and DU145 
cells were harvested by trypsinisation and, with the U937 non-adherent cells, were centrifuged at 
100 RCF and resuspended in the appropriate culture medium containing FCS and AB. Cells were 
diluted to 800 000 cells/ml and were maintained in 75 cm2 CELLSTAR® sterile cell culture flasks 
(Greiner Bio-One) at 37C and with gentle agitation until analysis. 
2. Respirometry apparatus 
 
Figure G1: The OROBOROS Oxygraph-2k (O2k series C) for high resolution respirometry.  




APPENDIX G  
FLOW CYTOMETRY 
1. Experimental protocol and sample preparation 
A549 cells were seeded into 25 cm2 CELLSTAR® sterile cell culture flasks (Greiner Bio-One) at the 
required density to obtain approximately 500 000 cells/ml for analysis. Specific protocol details are 
provided in the experimental chapters. Following the required treatment time, the medium 
containing any detached cells was collected into a 12 ml CELLSTAR® cell culture tube (Greiner Bio-One). 
Adherent cells were washed with 1 ml PBS, trypsinised for 10 minutes at 37°C and added to the 
medium. After centrifugation at 100 RCF for 10 minutes, cells were washed twice with 2 ml PBS. 
Note: Throughout this protocol the PBS was supplemented with 2 % FCS. Cells were resuspended in 
1 ml PBS and 3 ml ice cold absolute ethanol (Sigma-Aldrich) ([Final] = 75 %) was added dropwise to 
each sample while vortexing. After incubation at 4°C for 1 h, samples were stored at -20°C in 
preparation for staining 24 h prior to analysis.  
1.1. Staining of cells for cell cycle analysis 
Samples were vortexed and centrifuged for 20 minutes at 200 RCF to pellet cells. The supernatant 
was discarded and cells were resuspended in 2 ml PBS. Following an additional wash step, the cells 
were resuspended in 500 µl of 1 mg/ml RNAse A solution [0.025 g RNAse A (Sigma-Aldrich) in 25 ml 
PBS] and were mixed thoroughly. Samples were incubated at 37°C for 30 minutes and 50 µl of  
500 µg/ml propidium iodide [0.001 g propidium iodide (Sigma-Aldrich) in 2 ml PBS] was added directly 
to the RNAse A solution ([Final] = 50 µg/ml). Samples were stored in the dark at 4°C until analysis. 
2. Flow cytometric analysis 
Flow cytometry and cell cycle profile analysis were carried out with the assistance of the UCT Flow 
Cytometry Core Facility (Institute of Infectious Disease and Molecular Medicine). At the time of sample 
acquisition, each sample was filtered using a 5 mL Falcon round bottom polystyrene test tube with 







The presence of DRP1 was demonstrated in A549 cells by means of immunocytochemistry and 
Western blotting (Figure H1A and B). Antibodies for detection included the primary anti-DRP1 
antibody (1/200 dilution, Santa-Cruz Biotechnology, Dallas, Texas, US) and secondary antibodies, anti-
mouse IgG FITC conjugate (Sigma-Aldrich) and anti-mouse IgG peroxidase (Sigma-Aldrich) for 
immunocytochemistry and Western blotting, respectively. 
For immunocytochemistry A549 cells were seeded onto glass coverslips, stained with MitoTracker® 
Red and fixed with paraformaldehyde as described previously. After antibody probing cells were 










Figure H1: A) Visualisation of DRP1 (green) in A549 cells counter-stained with MitoTracker® Red 
(mitochondria) and Hoechst 33342 (nuclei). Yellow regions suggest areas of co-localisation of  
DRP1 with the mitochondrion. 1000x magnification. B) Western blot for the detection of DRP1 in 
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